{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/ort-eila/git_kundaje_annotations/blob/main/step_2_load_dataset.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 84,
      "id": "1d0b51a6-4042-4faa-adde-f3f4c668fa18",
      "metadata": {
        "id": "1d0b51a6-4042-4faa-adde-f3f4c668fa18"
      },
      "outputs": [],
      "source": [
        "# Step 2 - load dataset"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PFmuWx--58vL",
        "outputId": "d00cfa40-eeda-4910-f2f4-5ae84bd66ed1"
      },
      "id": "PFmuWx--58vL",
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "source_file = 'wikipedia_details.tsv'\n",
        "\n",
        "# Define the destination folder in Google Drive\n",
        "destination_folder = '/content/drive/MyDrive/bio-llm/'\n",
        "\n",
        "output_folder = os.path.join(destination_folder,\"output\")"
      ],
      "metadata": {
        "id": "xmjE8ADC6Ikg"
      },
      "id": "xmjE8ADC6Ikg",
      "execution_count": 86,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 87,
      "id": "2605bf13-65a6-4afe-ba74-6cbff5433753",
      "metadata": {
        "id": "2605bf13-65a6-4afe-ba74-6cbff5433753"
      },
      "outputs": [],
      "source": [
        "# !pip install transformers datasets faiss-cpu psutil"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 88,
      "id": "564eb5d3-7d1f-4a4a-804f-481963598274",
      "metadata": {
        "id": "564eb5d3-7d1f-4a4a-804f-481963598274"
      },
      "outputs": [],
      "source": [
        "import torch\n",
        "from datasets import Features, Sequence, Value, load_dataset\n",
        "import os"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 89,
      "id": "d9052f82-efcd-41ad-8762-1b3efb012de1",
      "metadata": {
        "id": "d9052f82-efcd-41ad-8762-1b3efb012de1"
      },
      "outputs": [],
      "source": [
        "BATCH_SIZE = 1 #instead of 16"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 90,
      "id": "e1700ed1-3bcd-43a9-b12c-9f53fbe97dfb",
      "metadata": {
        "id": "e1700ed1-3bcd-43a9-b12c-9f53fbe97dfb"
      },
      "outputs": [],
      "source": [
        "!rm -rf $output_folder\n",
        "!mkdir $output_folder"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 91,
      "id": "d84de2ad-cfff-494e-957d-5afdc95d2371",
      "metadata": {
        "id": "d84de2ad-cfff-494e-957d-5afdc95d2371"
      },
      "outputs": [],
      "source": [
        "import logging\n",
        "import os\n",
        "from dataclasses import dataclass, field\n",
        "from functools import partial\n",
        "from pathlib import Path\n",
        "from tempfile import TemporaryDirectory\n",
        "from typing import List, Optional\n",
        "\n",
        "import torch\n",
        "from datasets import Features, Sequence, Value, load_dataset\n",
        "\n",
        "import faiss\n",
        "from transformers import (\n",
        "    DPRContextEncoder,\n",
        "    DPRContextEncoderTokenizerFast,\n",
        "    HfArgumentParser,\n",
        "    RagRetriever,\n",
        "    RagSequenceForGeneration,\n",
        "    RagTokenizer,\n",
        ")\n",
        "\n",
        "\n",
        "logger = logging.getLogger(__name__)\n",
        "torch.set_grad_enabled(False)\n",
        "device = \"cuda\" if torch.cuda.is_available() else \"cpu\"\n",
        "\n",
        "\n",
        "def split_text(text: str, n=100, character=\" \") -> List[str]:\n",
        "    \"\"\"Split the text every ``n``-th occurrence of ``character``\"\"\"\n",
        "    text = text.split(character)\n",
        "    return [character.join(text[i : i + n]).strip() for i in range(0, len(text), n)]\n",
        "\n",
        "\n",
        "def split_documents(documents: dict) -> dict:\n",
        "    \"\"\"Split documents into passages\"\"\"\n",
        "    titles, texts = [], []\n",
        "    for title, text in zip(documents[\"title\"], documents[\"text\"]):\n",
        "        if text is not None:\n",
        "            for passage in split_text(text):\n",
        "                titles.append(title if title is not None else \"\")\n",
        "                texts.append(passage)\n",
        "    return {\"title\": titles, \"text\": texts}\n",
        "\n",
        "\n",
        "# model(input_ids).pooler_output\n",
        "\n",
        "def embed(documents: dict, ctx_encoder: DPRContextEncoder, ctx_tokenizer: DPRContextEncoderTokenizerFast) -> dict:\n",
        "    \"\"\"Compute the DPR embeddings of document passages\"\"\"\n",
        "    print(\"documents is \",documents)\n",
        "    input_ids = ctx_tokenizer(\n",
        "        documents[\"title\"], documents[\"text\"], truncation=True, padding=\"longest\", return_tensors=\"pt\"\n",
        "    )[\"input_ids\"]\n",
        "    embeddings = ctx_encoder(input_ids.to(device=device), return_dict=True).pooler_output\n",
        "    return {\"embeddings\": embeddings.detach().cpu().numpy()}\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "@dataclass\n",
        "class RagExampleArguments:\n",
        "    csv_path: str = field(\n",
        "        default=str(\"\"),\n",
        "        metadata={\"help\": \"Path to a tab-separated csv file with columns 'title' and 'text'\"},\n",
        "    )\n",
        "    question: Optional[str] = field(\n",
        "        default=None,\n",
        "        metadata={\"help\": \"Question that is passed as input to RAG. Default is 'What does Moses' rod turn into ?'.\"},\n",
        "    )\n",
        "    rag_model_name: str = field(\n",
        "        default=\"facebook/rag-sequence-nq\",\n",
        "        metadata={\"help\": \"The RAG model to use. Either 'facebook/rag-sequence-nq' or 'facebook/rag-token-nq'\"},\n",
        "    )\n",
        "    dpr_ctx_encoder_model_name: str = field(\n",
        "        default= \"facebook/dpr-ctx_encoder-single-nq-base\", #\"facebook/dpr-ctx_encoder-multiset-base\",\n",
        "        metadata={\n",
        "            \"help\": \"The DPR context encoder model to use. Either 'facebook/dpr-ctx_encoder-single-nq-base' or 'facebook/dpr-ctx_encoder-multiset-base'\"\n",
        "        },\n",
        "    )\n",
        "    output_dir: Optional[str] = field(\n",
        "        default=None,\n",
        "        metadata={\"help\": \"Path to a directory where the dataset passages and the index will be saved\"},\n",
        "    )\n",
        "\n",
        "\n",
        "@dataclass\n",
        "class ProcessingArguments:\n",
        "    num_proc: Optional[int] = field(\n",
        "        default=None,\n",
        "        metadata={\n",
        "            \"help\": \"The number of processes to use to split the documents into passages. Default is single process.\"\n",
        "        },\n",
        "    )\n",
        "    batch_size: int = field(\n",
        "        default=BATCH_SIZE,\n",
        "        metadata={\n",
        "            \"help\": \"The batch size to use when computing the passages embeddings using the DPR context encoder.\"\n",
        "        },\n",
        "    )\n",
        "\n",
        "\n",
        "@dataclass\n",
        "class IndexHnswArguments:\n",
        "    d: int = field(\n",
        "        default=768,\n",
        "        metadata={\"help\": \"The dimension of the embeddings to pass to the HNSW Faiss index.\"},\n",
        "    )\n",
        "    m: int = field(\n",
        "        default=128,\n",
        "        metadata={\n",
        "            \"help\": \"The number of bi-directional links created for every new element during the HNSW index construction.\"\n",
        "        },\n",
        "    )\n",
        "\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 92,
      "id": "7e694f00-ebbc-45b9-a4e9-bc45f4ec0d47",
      "metadata": {
        "id": "7e694f00-ebbc-45b9-a4e9-bc45f4ec0d47"
      },
      "outputs": [],
      "source": [
        "# source_file = 'wikipedia_details.csv'\n",
        "\n",
        "# # Define the destination folder in Google Drive\n",
        "# destination_folder = '/content/drive/MyDrive/bio-llm/'"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 93,
      "id": "fa2a9196-3073-44fa-a686-50766101a3ea",
      "metadata": {
        "id": "fa2a9196-3073-44fa-a686-50766101a3ea"
      },
      "outputs": [],
      "source": [
        "#if __name__ == \"__main__\":\n",
        "\n",
        "# logging.basicConfig(level=logging.WARNING)\n",
        "# logger.setLevel(logging.INFO)\n",
        "\n",
        "# In place of parser, just create arguments objects.\n",
        "#parser = HfArgumentParser((RagExampleArguments, ProcessingArguments, IndexHnswArguments))\n",
        "#rag_args, processing_args, index_hnsw_args = parser.parse_args_into_dataclasses()\n",
        "\n",
        "rag_args = RagExampleArguments()\n",
        "processing_args = ProcessingArguments()\n",
        "index_hnsw_args = IndexHnswArguments()\n",
        "\n",
        "rag_args.csv_path = os.path.join(destination_folder,source_file)\n",
        "# \"./wikipedia_details.csv\"\n",
        "\n",
        "rag_args.output_dir = output_folder\n",
        "\n",
        "rag_args.question = \"what is BRCA1\"\n",
        "\n",
        "# Probably don't need this...\n",
        "#with TemporaryDirectory() as tmp_dir:\n",
        "#    rag_args.output_dir = rag_args.output_dir or tmp_dir\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "rag_args.csv_path"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "oiLu4HUH6cVs",
        "outputId": "37cd7b8b-6241-4807-f77a-97b6b8e8617c"
      },
      "id": "oiLu4HUH6cVs",
      "execution_count": 94,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'/content/drive/MyDrive/bio-llm/wikipedia_details.tsv'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 94
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 95,
      "id": "f383b87b-39ed-4516-895b-46b81f3e8fba",
      "metadata": {
        "id": "f383b87b-39ed-4516-895b-46b81f3e8fba"
      },
      "outputs": [],
      "source": [
        "# DPR, which stands for Dense Passage Retrieval, is a method for representing passages of text in a\n",
        "# dense vector space, such that similar passages are close to each other in this space.\n",
        "# DPR is commonly used in information retrieval and question-answering systems to efficiently\n",
        "# retrieve relevant passages given a query."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 96,
      "id": "7f82862b-0f19-49bf-8a7c-03411b3023a8",
      "metadata": {
        "id": "7f82862b-0f19-49bf-8a7c-03411b3023a8"
      },
      "outputs": [],
      "source": [
        "def print_dataset(dataset):\n",
        "    if len(dataset) > 0:\n",
        "        for i in range(min(5, len(dataset))):  # Print the first 5 rows or less if dataset is smaller\n",
        "            print(f\"Title: {dataset['title'][i]}\")\n",
        "            print(f\"Text: {dataset['text'][i]}\")\n",
        "            print()\n",
        "    else:\n",
        "        print(\"The dataset is empty.\")"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!ls drive/MyDrive"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "n92olBrO4R33",
        "outputId": "f33340fe-bb82-4bfb-c2ad-da30752e2674"
      },
      "id": "n92olBrO4R33",
      "execution_count": 97,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " 3129_vector_image_row_1023_col301.jpg\t'pza-ydds-vkk - Aug 24, 2023.gjam'\n",
            " bio-llm\t\t\t\t'scRNA-seq results kb count'\n",
            "'Colab Notebooks'\t\t\t Seminar\n",
            " ENCODE_annotation\t\t\t'Untitled document.gdoc'\n",
            " HW2.ipynb\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# from transformers import DPRContextEncoder, DPRContextEncoderTokenizer\n",
        "\n",
        "# tokenizer = DPRContextEncoderTokenizer.from_pretrained(\"facebook/dpr-ctx_encoder-multiset-base\")\n",
        "# model = DPRContextEncoder.from_pretrained(\"facebook/dpr-ctx_encoder-multiset-base\")\n",
        "# input_ids = tokenizer(\"Hello, is my dog cute ?\", return_tensors=\"pt\")[\"input_ids\"]\n",
        "# embeddings = model(input_ids).pooler_output\n",
        "# embeddings"
      ],
      "metadata": {
        "id": "WhMADKYn_4s6"
      },
      "id": "WhMADKYn_4s6",
      "execution_count": 98,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 99,
      "id": "5af9d929-fcf3-4b66-9969-6cc78b5c1461",
      "metadata": {
        "id": "5af9d929-fcf3-4b66-9969-6cc78b5c1461",
        "outputId": "e3760bbb-38d2-45c8-d370-32d86eabefdd",
        "colab": {
          "referenced_widgets": [
            "a9ef973b19b14ef9bcb1ba2625521986",
            "d88757a6201e49cb9c5d82d1c7f64efe",
            "f28ff87a34c44302b367a9315956ccbf",
            "0f1f370f83124da497ba999d02b360a4",
            "c9c605908284408990ef925af0ce5618",
            "eabea82257334e8aba1d8f78fd3f7fb7",
            "f4bb97a5117d4b5fa52e440adb0a5850",
            "dd54c9529745445e87257376b53ce28a",
            "844832f28c344024935db12c360faa2c",
            "f83d1793799d4515a581d2c33a883e38",
            "259a00a7d6f5446c8fb14270df8499d9",
            "e4b09e45b2b944f58c8c9cdf53959bc2",
            "916e059b806e4f589e5790111938444b",
            "e6a49d5c153e45dea4dbd86a47065555",
            "4d3d85dfb53b41e8b8076b7f367807ec",
            "dd2f9669a1a44ce483f7cfadcbd91ea2",
            "3c5b3026e46f4a96851df21e23403308",
            "709272c31bbe449582b7967374855ef6",
            "f3618e70d7104fb7a2a45e3d264859ce",
            "ac15b5d471e443b5a7212b193048de4d",
            "de040f2e881c4c92b81245fdebfb117f",
            "6234daf3ca07401ebcde190bf30c63a5",
            "1ff0ebcf1374432399baf9896d568854",
            "9bf2b258703e4e0cbe94d1cc5ccbf9aa",
            "33c3fe2bcd0a41a7a8ea7b76242a80a8",
            "17fed26d8e2e4411a7227d360bafe4f4",
            "07369acb7a6a49dea5e1b264e60044db",
            "b546febccf644a9d9bcba4e10a063f4e",
            "383d6f1ad3384f00b963474fd1869b41",
            "2f1e1d54ec9246de806b06ea965df07d",
            "6b57eaa5b5f641a287f9cfa718d18815",
            "f8e6d2bfa54b48cdad2a24aab7b6008e",
            "8ac15f98f3a0411aab0f014fb457a573",
            "d553c44ca4dc49669f86d7bca7eca5da",
            "eda69d38b4fa4829b8208428c1248e4f",
            "0fa67030428d4451a1940dbfe78a306a",
            "3d5c8589374848acb0334f9a714aa8b3",
            "f1a0538ce4944802b91df81adc08948c",
            "f23cff647572461b922747c852d94859",
            "8b97c6fe3f1c461185ab5d847e9a5cc0",
            "ccfb45edecd44efdac42748efd96196e",
            "43fb15847ae845aeadce0d22ce5ee28c",
            "095f596857874d06a4249be6240cfaa6",
            "644b898858824b88bfae10753486fcac",
            "450652541b5f4097a637562fecd20bcf",
            "5b65666c89354117922abccb13b3e8a2",
            "74538a43a24743e5b65f5518dbfe9687",
            "2adf5ea0150b4987a14a7c7b4bffc076",
            "637c6f020ee84650a07dcfeb878e0fc7",
            "d76c0a7a1a8e47edb570ea0275c35d41",
            "d88a7b93ffbe4fbba06d619b5cc78992",
            "e3aa6b1a4a714a139270b5e351783ede",
            "6ca55c3528264adf91b548d23f4c651d",
            "286ef0b8466c41a696d959212006ab8c",
            "e95d14fbf2fe4fc5b57f858abae8e7cf",
            "8efb25ea71a64177a3251845e7f61875",
            "ac00903f4c0c4fd1883295a2494df9e7",
            "5dd6390508894c368749fa0709ea3d24",
            "b8ac99e3f8b44079b313b1f748e9b21d",
            "eefc76cbb10445cdb970dc0615b7a0a8",
            "40ff7806ec454193aa5b2b28a2990115",
            "b345565cc109428cbb15dd7e1f2ef97d",
            "7d83d91a1728481bb2d1469407848374",
            "2be99a51abd8474d870647100000f960",
            "61bc1df5c13a4f02b2147f40ec89ce4a",
            "9c06004501de43f78c119aabe46325f0"
          ],
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Downloading data files:   0%|          | 0/1 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "a9ef973b19b14ef9bcb1ba2625521986"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Extracting data files:   0%|          | 0/1 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e4b09e45b2b944f58c8c9cdf53959bc2"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Generating train split: 0 examples [00:00, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "1ff0ebcf1374432399baf9896d568854"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Map:   0%|          | 0/15 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "d553c44ca4dc49669f86d7bca7eca5da"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Some weights of the model checkpoint at facebook/dpr-ctx_encoder-single-nq-base were not used when initializing DPRContextEncoder: ['ctx_encoder.bert_model.pooler.dense.weight', 'ctx_encoder.bert_model.pooler.dense.bias']\n",
            "- This IS expected if you are initializing DPRContextEncoder from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
            "- This IS NOT expected if you are initializing DPRContextEncoder from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
            "The tokenizer class you load from this checkpoint is not the same type as the class this function is called from. It may result in unexpected tokenization. \n",
            "The tokenizer class you load from this checkpoint is 'DPRQuestionEncoderTokenizer'. \n",
            "The class this function is called from is 'DPRContextEncoderTokenizerFast'.\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Map:   0%|          | 0/294 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "450652541b5f4097a637562fecd20bcf"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "documents is  {'title': ['title'], 'text': ['text']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome in affected persons. Only 5–10% of breast cancer cases in women are attributed to BRCA1 and BRCA2 mutations (with BRCA1 mutations being slightly more common than BRCA2 mutations), but the impact on women with the gene mutation is more profound.[2] Women with']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal.[3] The risk of breast and ovarian cancer is higher for women with a high-risk BRCA1 mutation than with a BRCA2 mutation. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.High-risk mutations, which disable an important error-free DNA repair process (homology']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"directed repair), significantly increase the person's risk of developing breast cancer, ovarian cancer and certain other cancers. Why BRCA1 and BRCA2 mutations lead preferentially to cancers of the breast and ovary is not known, but lack of BRCA1 function seems to lead to non-functional X-chromosome inactivation. Not all mutations are high-risk; some appear to be harmless variations.  The cancer risk associated with any given mutation varies significantly and depends on the exact type and location of the mutation and possibly other individual factors.Mutations can be inherited from either parent and may be passed on to both sons and daughters.\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['Each child of a genetic carrier, regardless of sex, has a 50% chance of inheriting the mutated gene from the parent who carries the mutation. As a result, half of the people with BRCA gene mutations are male, who would then pass the mutation on to 50% of their offspring, male or female.  The risk of BRCA-related breast cancers for men with the mutation is higher than for other men, but still low.[4] However, BRCA mutations can increase the risk of other cancers, such as colon cancer, pancreatic cancer, and prostate cancer.Methods to diagnose the likelihood of a']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics.[5][6] Myriad's business model of exclusively offering the diagnostic test led to Myriad growing from being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012;[7] it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.[8]Biallelic and homozygous inheritance of a BRCA gene leads to a severe\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['form of Fanconi anemia, and is embryonically lethal in the majority of the cases.Women with deleterious mutations in either the BRCA1 or BRCA2 genes have a high risk of developing breast and/or ovarian cancer.  Because different studies look at different populations, and because different types of mutations have somewhat different risks, the risk is best expressed as a range, rather than a single number.[9]:\\u200a89–111\\u200aApproximately 50% to 65% of women born with a deleterious mutation in BRCA1 will develop breast cancer by age 70, and 35% to 46% will develop ovarian cancer by age 70.  Approximately 40% to 57%']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"of women with a deleterious mutation in BRCA2 will develop breast cancer by age 70, and 13% to 23% will develop ovarian cancer by age 70.[9]:\\u200a89–111\\u200a[10]Women with a breast cancer associated with a BRCA mutation have up to a 40% probability of developing a new primary breast cancer within 10 years following initial diagnosis if they did not receive tamoxifen treatment or have an oophorectomy.[4] The woman's ten-year risk for ovarian cancer is also increased by 6-12% under these conditions.[4]Statistics for BRCA-related ovarian cancer typically encompass not only cancer of the ovaries themselves, but also peritoneal cancer and the very\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['rare, but somewhat easier to detect, cancer of the Fallopian tubes.  Women with a BRCA mutation have more than 100 times the normal rate of Fallopian tube cancer.[9]:\\u200a275–302\\u200a  These three types of these cancers can be difficult to distinguish in their advanced stages.BRCA-related breast cancer appears at an earlier age than sporadic breast cancer.[9]:\\u200a89–111\\u200a  It has been asserted that BRCA-related breast cancer is more aggressive than normal breast cancer, however most studies in specific populations suggest little or no difference in survival rates despite seemingly worse prognostic factors.[11][12][13]BRCA-related ovarian and Fallopian tube cancer is more treatable than']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['average because it is unusually susceptible to platinum-based chemotherapy like cisplatin.[9]:\\u200a275–302\\u200a BRCA1-related ovarian cancer appears at younger ages, but the risk for women with BRCA2 climbs markedly at or shortly after menopause.[9]:\\u200a275–302\\u200aA 25-year-old woman with no mutation in her BRCA genes has an 84% probability to reach at least the age of 70.[14] Of those not surviving, 11% die from either breast or ovarian cancer, and 89% from other causes.Compared to that, a woman with a high-risk BRCA1 mutation, if she had breast cancer screening but no prophylactic medical or surgical intervention, would have only 59% chance to reach age']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['70, twenty-five percentage points lower than normal. Of those women not surviving, 26% would die of breast cancer, 46% ovarian cancer, and 28% other causes.[14]Women with high-risk BRCA2 mutations, with screening but with no prophylactic medical or surgical intervention, would have only 71% chance to reach age 70, thirteen percentage points lower than normal. Of those not surviving, 21% would die of breast cancer, 25% ovarian cancer and 54% other causes.[14]The likelihood of surviving to at least age 70 can be improved by several medical interventions, notably prophylactic mastectomy and oophorectomy.[14]Men with a BRCA mutation have a dramatically elevated relative']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['risk of developing breast cancer, but because the overall incidence of breast cancer in men is so low, the absolute risk is equal to or lower than the risk for women without a BRCA mutation.[9]:\\u200aCh8\\u200a  Approximately 1% to 2% of men with a BRCA1 mutation will develop breast cancer by age 70.  Approximately 6% of men with a BRCA2 mutation will develop breast cancer by age 70, which is approximately equal to the risk for women without a BRCA mutation.  Very few men, with or without a predisposing mutation, develop breast cancer before age 50.[9]:\\u200aCh8\\u200aApproximately half of']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['men who develop breast cancer have a mutation in a BRCA gene or in one of the other genes associated with hereditary breast–ovarian cancer syndromes.Breast cancer in men can be treated as successfully as breast cancer in women, but men often ignore the signs and symptoms of cancer, such as a painful area or an unusual swelling, which may be no bigger than a grain of rice, until it has reached a late stage.[9]:\\u200aCh8\\u200aUnlike other men, men with a BRCA mutation, especially a BRCA2 mutation, may benefit from professional and self breast exams.  Medical imaging is not usually recommended,']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['but because male BRCA2 carriers have a risk of breast cancer that is very similar to the general female population, the standard annual mammogram program can be adapted to these high-risk men.[9]:\\u200aCh8\\u200aMutations have been associated with increased risk of developing any kind of invasive cancer, including stomach cancer, pancreatic cancer, prostate cancer, and colon cancer.[15] Carriers have the normal risks of developing cancer (and other diseases) associated with increased age, smoking, alcohol consumption, poor diet, lack of exercise, and other known risk factors, plus the additional risk from the genetic mutations and an increased susceptibility to damage from ionizing radiation,']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['including natural background radiation.[9]:\\u200a39–50\\u200aMen with BRCA mutations cannot get ovarian cancer, but they may be twice as likely as non-carriers to develop prostate cancer at a younger age.[9]:\\u200aCh8\\u200a   The risk is smaller and disputed for BRCA1 carriers; up to one-third of BRCA2 mutation carriers are expected to develop prostate cancer before age 65.  Prostate cancer in BRCA mutation carriers tends to appear a decade earlier than normal, and it tends to be more aggressive than normal.  As a result, annual prostate screening, including a digital rectal examination, is appropriate at age 40 among known carriers, rather']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['than age 50.[9]:\\u200aCh8\\u200aCancer of the pancreas tends to run in families, even among BRCA families.[9]:\\u200aCh8\\u200a   A BRCA1 mutation approximately doubles or triples the lifetime risk of developing pancreatic cancer; a BRCA2 mutation triples to quintuples it.  Between 4% and 7% of people with pancreatic cancer have a BRCA mutation.[15] However, since pancreatic cancer is relatively rare, people with a BRCA2 mutation probably face an absolute risk of about 5%.  Like ovarian cancer, it tends not to produce symptoms in the early, treatable stages.  Like prostate cancer, pancreatic cancer associated with a BRCA mutation tends to']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['appear about a decade earlier than non-hereditary cases.[15] Asymptomatic screening is invasive and may be recommended only to BRCA2 carriers who also have a family history of pancreatic cancer.[9]:\\u200aCh8\\u200aMelanoma is the most deadly skin cancer, although it is easily cured in the early stages.  The normal likelihood of developing melanoma depends on race, the number of moles the person has, family history, age, sex, and how much the person has been exposed to UV radiation. BRCA2 mutation carriers have approximately double or triple the risk that they would normally have, including a higher than average risk of melanoma of']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['the eye.[9]:\\u200aCh8\\u200a[15]Cancer of the colon is approximately as common in both men and women in the developed world as breast cancer is among average-risk women, with about 6% of people being diagnosed with it, usually over the age of 50.[9]:\\u200aCh8\\u200a   Like sporadic prostate cancer, it is a multifactorial disease, and is affected by age, diet, and similar factors.  BRCA mutation carriers have a higher than average risk of this common cancer, but the risk is not as high as in some other hereditary cancers.  The risk might be as high as four times normal in some']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['BRCA1 families, and double the normal risk among BRCA2 carriers.  Like pancreatic cancer, it may be that only some BRCA mutations or some BRCA families have the extra risk; unlike other BRCA-caused cancers, it does not appear at an earlier age than usual.[9]:\\u200aCh8\\u200a   Normal colon cancer screening is usually recommended to BRCA mutation carriers.Mutations in BRCA1 and BRCA2 are strongly implicated in some hematological malignancies.  BRCA1 mutations are associated acute myelogenous leukemia and chronic myelogenous leukemia.[16] Mutations of BRCA2 are also found in many T-cell lymphomas and chronic lymphocytic leukemias.[16]The dilemma of whether or not to']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['have children may be a source of stress for women who learn of their BRCA mutations during their childbearing years.[17]There is likely little or no effect of a BRCA gene mutation on overall fertility,[18] although women with a BRCA mutation may be more likely to have primary ovarian insufficiency.[19][20] BRCA mutation carriers may be more likely to give birth to girls than boys,[21] however this observation has been attributed to ascertainment bias.[22][23]If both parents are carriers of a BRCA mutation, then pre-implantation genetic diagnosis is sometimes used to prevent the birth of a child with BRCA mutations.[9]:\\u200a82–85\\u200a  Inheriting two']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"BRCA1 mutations (one from each parent) has never been reported and is believed to be a lethal birth defect.  Inheriting one BRCA1 mutation and one BRCA2 mutation has been reported occasionally; the child's risk for any given type of cancer is the higher risk of the two genes (e.g., the ovarian cancer risk from BRCA1 and the pancreatic cancer risk from BRCA2).  Inheriting two BRCA2 mutations produces Fanconi anemia.[9]:\\u200a82–85\\u200aEach pregnancy in genetically typical women is associated with a significant reduction in the mother's risk of developing breast cancer after age 40.[17] The younger the woman is at the\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['time of her first birth, the more protection against breast cancer she receives.[9]:\\u200a113–142\\u200a  Breastfeeding for more than one year protects against breast cancer.[9]:\\u200a113–142\\u200a  Pregnancy also protects against ovarian cancer in genetically typical women.[17]Although some studies have produced different results, women with BRCA mutations are generally not expected to receive these significant protective benefits.[9]:\\u200a113–142\\u200a[17] Current research is too limited and imprecise to permit calculation of specific risks.[17] However, the following general trends have been identified:Reports of patients biallelic or homozygous for a deleterious BRCA allele conferring a greatly increased risk of breast cancer are rare. This is because deleterious']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['BRCA alleles are lethal alleles; this condition is embryonically lethal in the majority of the cases. [25] For live cases, inheriting both mutations lead to a grave prognosis, characterized by Wilms tumors, leukemias, and early-onset brain malignancies.[26]Both BRCA genes are tumor suppressor genes that produce proteins that are used by the cell in an enzymatic pathway that makes very precise, perfectly matched repairs to DNA molecules that have double-stranded breaks.[9]:\\u200a39–50\\u200a[27] The pathway requires proteins produced by several other genes, including CHK2, FANCD2 and ATM.[15] Harmful mutations in any of these genes disable the gene or the protein that it produces.The']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"cancer risk caused by BRCA1 and BRCA2 mutations are inherited in a dominant fashion even though usually only one mutated allele is directly inherited.[28] This is because people with the mutation are likely to acquire a second mutation, leading to dominant expression of the cancer. A mutated BRCA gene can be inherited from either parent.  Because they are inherited from the parents, they are classified as  hereditary or germline mutations rather than acquired or somatic mutations.  Cancer caused by a mutated gene inherited from an individual's parents is a hereditary cancer rather than a sporadic cancer.Because humans\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['have a diploid genome, each cell has two copies of the gene (one from each biological parent).  Typically only one copy contains a disabling, inherited mutation, so the affected person is heterozygous for the mutation.  If the functional copy is harmed, however, then the cell is forced to use alternate DNA repair mechanisms, which are more error-prone.  The loss of the functional copy is called loss of heterozygosity (LOH).[29] Any resulting errors in DNA repair may result in cell death or a cancerous transformation of the cell.[9]:\\u200a39–50\\u200aThere are many variations in BRCA genes, and not all changes']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['confer the same risks.[9]:\\u200a39–50\\u200aSome variants are harmless; others are known to be very harmful.  Some single nucleotide polymorphisms may confer only a small risk, or may only confer risk in the presence of other mutations or under certain circumstances.  In other cases, whether the variant is harmful is unknown.  Variants are classified as follows:[9]:\\u200a39–50\\u200a:\\u200a109\\u200aDeleterious mutations have high, but not complete, genetic penetrance, which means that people with the mutation have a high risk of developing disease as a result, but that some people will not develop cancer despite carrying a harmful mutation.Genetic counseling is recommended in women']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['whose personal or family health history suggests a greater than average likelihood of a mutation.[30] The purpose of genetic counseling is to educate the person about the likelihood of a positive result, the risks and benefits of being tested, the limitations of the tests, the practical meaning of the results, and the risk-reducing actions that could be taken if the results are positive.  They are also trained to support people through any emotional reactions and to be a neutral person who helps the client make his or her own decision in an informed consent model, without pushing the client']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"to do what the counselor might do.  Because the knowledge of a mutation can produce substantial anxiety, some people choose not to be tested or to postpone testing until a later date.[9]:\\u200a51–74\\u200aRelative indications for testing for a mutation in BRCA1 or BRCA2 for newly diagnosed or family members include a family history among 1st (FDR), 2nd (SDR), or 3rd(TDR) degree relatives usually on the same side of the family but not limited:[31]Testing young children is considered medically unethical because the test results would not change the way the child's health is cared for.[9]:\\u200a82–85\\u200aTwo types of tests are available.[9]:\\u200a51–74\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['Both commonly use a blood sample, although testing can be done on saliva. The quickest, simplest, and lowest cost test uses positive test results from a blood relative and checks only for the single mutation that is known to be present in the family.  If no relative has previously disclosed positive test results, then a full test that checks the entire sequence of both BRCA1 and BRCA2 can be performed.  In some cases, because of the founder effect, Jewish ethnicity can be used to narrow the testing to quickly check for the three most common mutations seen among']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['Ashkenazi Jews.[9]:\\u200a51–74\\u200aTesting is commonly covered by health insurance and public healthcare programs for people at high risk for having a mutation, and not covered for people at low risk.[9]:\\u200a51–74\\u200a The purpose of limiting the testing to high-risk people is to increase the likelihood that the person will receive a meaningful, actionable result from the test, rather than identifying a variant of unknown significance (VUS). In Canada, people who demonstrate their high-risk status by meeting specified guidelines are referred initially to a specialized program for hereditary cancers, and, if they choose to be tested, the cost of the test is fully']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['covered.  In the US in 2010, single-site testing had a retail cost of US$400 to $500, and full-length analysis cost about $3,000 per gene, and the costs were commonly covered by private health insurance for people deemed to be at high risk.The test is ordered by a physician, usually an oncologist, and the results are always returned to the physician, rather than directly to the patient.  How quickly results are returned depends on the test—single-site analysis requires less lab time—and on the infrastructure in place.  In the US, test results are commonly returned within one to several']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['weeks; in Canada, patients commonly wait for eight to ten months for test results.[9]:\\u200a51–74\\u200aA positive test result for a known deleterious mutation is proof of a predisposition, although it does not guarantee that the person will develop any type of cancer.  A negative test result, if a specific mutation is known to be present in the family, shows that the person does not have a BRCA-related predisposition for cancer, although it does not guarantee that the person will not develop a non-hereditary case of cancer.  By itself, a negative test result does not mean that the patient has']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['no hereditary predisposition for breast or ovarian cancer.  The family may have some other genetic predisposition for cancer, involving some other gene.[9]:\\u200a89–111\\u200aA variety of screening options and interventions are available to manage BRCA-related cancer risks.  Screenings are adjusted to individual and familial risk factors.[citation needed]As these screening methods do not prevent cancer, but merely attempt to catch it early, numerous methods of prevention are sometimes practiced, with varying results.[9]:\\u200a175–207\\u200aAn intensive cancer screening regimen is usually advised for women with deleterious or suspected deleterious BRCA mutations in order to detect new cancers as early as possible.  A typical']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['recommendation includes frequent breast cancer screening as well as tests to detect ovarian cancer.[9]:\\u200a175–207\\u200aBreast imaging studies usually include a breast MRI (magnetic resonance imaging) once a year, beginning between ages 20 and 30, depending on the age at which any relatives were diagnosed with breast cancer. Mammograms are typically used only at advanced age as there is reason to believe that BRCA carriers are more susceptible to breast cancer induction by X-ray damage than general population.[34]Alternatives include breast ultrasonography, CT scans, PET scans, scintimammography, elastography, thermography, ductal lavage, and experimental screening protocols, some of which hope to identify biomarkers for']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['breast cancer (molecules that appear in the blood when breast cancer begins).[9]:\\u200a175–207\\u200aOvarian cancer screening usually involves ultrasonography of the pelvic region, typically twice a year.[9]:\\u200a175–207\\u200a  Women may also use a blood test for CA-125 and clinical pelvic exams.  The blood test has relatively poor sensitivity and specificity for ovarian cancer.[9]:\\u200a175–207\\u200a[35]In both breast and ovarian screening, areas of tissue that look suspicious are investigated with either more imaging, possibly using a different type of imaging or after a delay, or with biopsies of the suspicious areas.Birth control pills are associated with substantially lower risk of ovarian cancer in women']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['with BRCA mutations.[36][37] A 2013 meta-analysis found that oral contraceptive use was associated with a 42% reduction of the relative risk of ovarian cancer, the association was similar for BRCA1 and BRCA2 mutations. Use of oral contraceptives was not significantly associated with breast cancer risk although a small increase of risk that did not reach statistical significance was observed.[36][37] A 2011 meta-analysis found that OC use was associated with a 43% relative reduction in risk of ovarian cancer in women with BRCA mutations, while data on the risk of breast cancer in BRCA mutation carriers with oral contraceptive use were']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['heterogeneous and results were inconsistent.[38]Selective estrogen receptor modulators, specifically tamoxifen, have been found to reduce breast cancer risk in women with BRCA mutations who do not have their breast removed.[9]:\\u200a113–142\\u200a   It is effective as for primary prevention (preventing the first case of breast cancer) in women with BRCA2 mutations, but not BRCA1 mutations, and for secondary prevention (preventing a second, independent breast cancer) in both groups of women.  Taking tamoxifen for five years has been found to halve the breast cancer risk in women who have a high risk of breast cancer for any reason, but potentially']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['serious adverse effects like cataracts, blood clots, and endometrial cancer, along with quality of life issues like hot flashes, result in some women discontinuing its use and some physicians limiting its use to women with atypical growths in the breasts.  Tamoxifen is contraindicated for women who are most likely to be harmed by the common complications.  Raloxifene (Evista), which has a reduced risk of side effects, is used as an alternative, but it has not been studied in BRCA mutation carriers specifically.  Tamoxifen use can be combined with oophorectomy for even greater reduction of breast cancer risk,']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['particularly in women with BRCA2 mutations.[9]:\\u200a113–142\\u200aAromatase inhibitors are medications that prevent estrogen production in the adrenal glands and adipose tissue.  They have fewer side effects than selective estrogen receptor modulators like tamoxifen, but do not work in premenopausal women, because they do not prevent the ovaries from producing estrogen.[9]:\\u200a113–142\\u200aSeveral type of preventive surgeries are known to substantially reduce cancer risk for women with high-risk BRCA mutations.[39] The surgeries may be used alone, in combination with each other, or in combination with non-surgical interventions to reduce the risk of breast and ovarian cancer. Surgeries such as mastectomy and oophorectomy do']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['not eliminate the chance of breast cancer; cases have reportedly emerged despite these procedures.[40]Whether and when to perform which preventive surgeries is a complex personal decision. Current medical knowledge offers some guidance about the risks and benefits. Even carriers of the same mutation or from the same family may have substantially different risks for the kind and severity of cancer they are likely to get, as well as the age at which they may get them. Different people also have different values. They may choose to focus on total cancer prevention, psychological benefits, current quality of life, or overall survival.']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['The possible impact of future medical developments in treatment or prognosis may also be of some importance for very young women and family planning.  The decision is individualized and is usually based on many factors, such as earliest occurrence of BRCA-related cancer in close relatives. An increasing number women who test positive for faulty BRCA1 or BRCA2 genes choose to have risk-reducing surgery. At the same time the average waiting time for undergoing the procedure is two-years which is much longer than recommended.[42][43]The protective effect of prophylactic surgery is greater when done at young age; however, oophorectomy also has']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['adverse effects that are greatest when done long before natural menopause.  For this reason, oophorectomy is mostly recommended after age 35 or 40, assuming childbearing is complete.  The risk of ovarian cancer is low before this age, and the negative effects of oophorectomy are less serious as the woman nears natural menopause.[14][44]For comparison, women in the general population have an 84% chance of living to age 70.Research has looked into the effects of risk-reducing surgery on the psychological and social wellbeing of women with a BRCA mutation.[45] Due to limited evidence, a 2019 meta analysis was unable to']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"draw conclusions on whether interventions can help with the psychological effects of surgery in female BRCA carriers. More research is needed to conclude how best to support women who choose surgery.[45]In a woman who has not developed breast cancer, removing the breasts may reduce her risk of ever being diagnosed with breast cancer by 90%, to a level that is approximately half the average woman's risk.[9]:\\u200a209–244\\u200aBilateral mastectomy is the removal of both breasts by a breast surgeon.[9]:\\u200a209–244\\u200a The modified radical mastectomy is only used in women diagnosed with invasive breast cancer.  Techniques for prophylactic mastectomies include:[9]:\\u200a209–244\\u200aWhich technique is used\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': [\"is determined by the existence of any cancer and overall health, as well as by the woman's desire, if any, for breast reconstruction surgery for aesthetic purposes.[9]:\\u200a209–244\\u200a  Women who choose a flat-chested appearance or use external breast prostheses typically choose simple mastectomy, with its greater risk reduction.[9]:\\u200a209–244\\u200aBreast reconstruction is usually done by a plastic surgeon, and may be started as part of the same multi-hour surgery that removes the breasts.  Multiple techniques for reconstruction have been used, with different locations and amounts of scarring.  Some techniques use tissue from another part of the body, such as fat\"]}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['tissue from the lower abdomen or occasionally muscles from other parts of the torso.  Others use breast implants, possibly preceded by tissue expanders, to provide volume.  Some reconstruction techniques require multiple surgeries.  Afterwards, some women have tattoos added to simulate breast areolas or have the skin reshaped to form a nipple.[9]:\\u200a209–244\\u200aOophorectomy (surgical removal of the ovaries) and salpingectomy (surgical removal of the Fallopian tubes) are strongly recommended to women with BRCA mutations.[9]:\\u200a275–302\\u200a Salpingo-oophorectomy is the single most effective method of preventing ovarian and Fallopian tube cancer in women with a BRCA mutation.  However, a small risk']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['of primary peritoneal cancer remains, at least among women with BRCA1 mutations, since the peritoneal lining is the same type of cells as parts of the ovary.  This risk is estimated to produce about five cases of peritoneal cancer per 100 women with harmful BRCA1 mutations in the 20 years after the surgery.[9]:\\u200a275–302\\u200aBRCA2 related ovarian cancer tends to present in perimenopausal or menopausal women, so salpingo-oophorectomy is recommended between ages 45 and 50.[9]:\\u200a275–302\\u200aThe surgery is often done in conjunction with a hysterectomy (surgical removal of the uterus) and sometimes a cervicectomy (surgical removal of the cervix), especially in women']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['who want to take tamoxifen, which is known to cause uterine cancer, or who have uterine fibroids.[9]:\\u200a275–302\\u200a  Multiple styles of surgery are available, including laparoscopic (keyhole) surgery.  Because about 5% of women with a BRCA mutation have undetected ovarian cancer at the time of their planned surgery, the surgery should be treated as if it were a removal of a known cancer.[9]:\\u200a275–302\\u200aSalpingo-oophorectomy makes the woman sterile (unable to bear children).  Infertility services can be used to preserve her eggs, if wanted.  However, as the benefits to the surgery are greatest close to menopause, most women simply']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['postpone the surgery until they have already borne as many children as they choose to.[9]:\\u200a275–302\\u200aThe surgery also artificially induces menopause, which causes hot flashes, sleep disturbances, mood swings, vaginal dryness, sexual difficulties, difficulty with word recall, and other medical signs and symptoms. The side effects range from mild to severe; most can be treated at least partially.  Many women with a BRCA take hormone replacement therapy to reduce these effects:  estrogen-progesterone combinations for women who have a uterus, and unopposed estrogen for women whose uterus was removed.  Estrogen can cause breast cancer, but as the amount of']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['estrogen taken is less than the amount produced by the now-removed ovaries, the net risk is usually judged to be acceptable.[9]:\\u200a303–317\\u200aSome sources assume that oophorectomy before age 50 doubles the risk of cardiovascular disease and increases risk of hip fractures caused by osteoporosis in the relevant population.[14]Given the high risks and the low benefit of lifestyle choices in BRCA mutation carriers, no lifestyle choices provide sufficient protection.[9]:\\u200a113–142\\u200aHaving her first child at a younger age, having more children than average, and breastfeeding for more than one year decreases the risk of breast cancer for an average-risk woman.[9]:\\u200a113–142\\u200a  Studies about this']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['effect among BRCA mutation carriers have produced conflicting results, but generally speaking, having children is believed to provide little or no protection against breast cancer for women with BRCA1 mutations, and to paradoxically increase the risk of breast cancer for women with BRCA2 mutations.[9]:\\u200a113–142\\u200a[17]Being physically active and maintaining a healthy body weight prevents breast and other cancers in the general population, as well as preventing heart disease and other medical conditions.  Among women with a BRCA mutation, being physically active and having had a healthy body weight as an adolescent has no effect on ovarian cancer and delays, but']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['does not entirely prevent, breast cancer after menopause.[9]:\\u200a113–142\\u200a[46] In some studies, only significant, strenuous exercise produced any benefit.[9]:\\u200a113–142\\u200a Obesity and weight gain as an adult are associated with breast cancer diagnoses.[9]:\\u200a113–142\\u200aStudies on specific foods, diets, or dietary supplements have generally produced conflicting information or, in the case of dietary fat, soy consumption, and drinking green tea, have only been conducted in average-risk women.[9]:\\u200a113–142\\u200a  The only dietary intervention that is generally accepted as preventing breast cancer in BRCA mutation carriers is minimizing consumption of alcoholic beverages.  Consuming more than one alcoholic drink per day is strongly associated with a']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['higher risk of developing breast cancer, and carriers are usually encouraged to consume no more than one alcoholic drink per day, and no more than four total in a week.[9]:\\u200a113–142\\u200aIn a study conducted with Ashkenazi Jewish women, it was observed that mutation carriers born before 1940 have a much lower risk of being diagnosed with breast cancer by age 50 than those born after 1940; this was also observed in the non-carrier population.[46] The reasons for the difference is unknown.  Unlike the general population, age at menarche and age at menopause has no effect on breast cancer risk for']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['BRCA mutation carriers.[9]:\\u200a113–142\\u200aSeveral hypotheses propose that BRCA mutations might have evolutionary advantages, such as higher intelligence. The Ashkenazi intelligence hypothesis was proposed by Gregory Cochran and asserts that a defect in the BRCA1 gene might unleash neural growth.[47]Studies have shown that BRCA1 mutations are not random, but under adaptive selection, indicating that although BRCA1 mutations are linked to breast cancer, the mutations likely have a beneficial effect as well.[48]A patent application for the isolated BRCA1 gene and cancer-cancer promoting mutations discussed above, as well as methods to diagnose the likelihood of getting breast cancer, was filed by the University of']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics in 1994;[5] over the next year, Myriad, in collaboration with investigators from Endo Recherche, Inc., HSC Research & Development Limited Partnership, and University of Pennsylvania, isolated and sequenced the BRCA2 gene and identified key mutations, and the first BRCA2 patent was filed in the US by Myriad and other institutions in 1995.[6] Myriad is the exclusive licensee of these patents and has enforced them in the US against clinical diagnostic labs.[8] This business model led to Myriad growing being a startup in 1994 to being a publicly traded company']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['with 1200 employees and about $500M in annual revenue in 2012;[7] it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.[8][49] The patents began to expire in 2014.According to an article published in the journal, Genetic Medicine, in 2010, \"The patent story outside the United States is more complicated.... For example, patents have been obtained but the patents are being ignored by provincial health systems in Canada. In Australia and the UK, Myriad\\'s licensee permitted use']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['by health systems, but announced a change of plans in August 2008. ... Only a single mutation has been patented in Myriad\\'s lone European-wide patent, although some patents remain under review of an opposition proceeding. In effect, the United States is the only jurisdiction where Myriad\\'s strong patent position has conferred sole-provider status.\"[50][51] Peter Meldrum, CEO of Myriad Genetics, has acknowledged that Myriad has \"other competitive advantages that may make such [patent] enforcement unnecessary\" in Europe.[52]Legal decisions surrounding the BRCA1 and BRCA2 patents will affect the field of genetic testing in general.[53] In June 2013, in  Association for Molecular']}\n",
            "documents is  {'title': ['BRCA_mutation'], 'text': ['Pathology v. Myriad Genetics (No. 12-398), the US Supreme Court unanimously ruled that, \"A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,\" invalidating Myriad\\'s patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature could still be eligible for patent protection.[54]']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['1JM7, 1JNX, 1N5O, 1OQA, 1T15, 1T29, 1T2U, 1T2V, 1Y98, 2ING, 3COJ, 3K0H, 3K0K, 3K15, 3PXA, 3PXB, 3PXC, 3PXD, 3PXE, 4IFI, 4IGK, 4JLU, 4OFB, 4U4A, 4Y18, 4Y2G67212189ENSG00000012048ENSMUSG00000017146P38398P48754NM_007299NM_007300NM_007301NM_007302NM_007303NM_007305NM_007306NM_009764NP_009225NP_009228NP_009229NP_009230NP_009231NP_033894Breast cancer type 1 susceptibility protein is a protein that in humans is encoded by the BRCA1  (/ˌbrækəˈwʌn/) gene.[5] Orthologs are common in other vertebrate species, whereas invertebrate genomes may encode a more distantly related gene.[6] BRCA1 is a human tumor suppressor gene[7][8] (also known as a caretaker gene) and is responsible for repairing DNA.[9]BRCA1 and BRCA2 are unrelated proteins,[10] but both are normally expressed in the cells of breast and other tissue, where']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['they help repair damaged DNA, or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double-strand breaks.[11][12] If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer.[13][14] BRCA1 and BRCA2 have been described as \"breast cancer susceptibility genes\" and \"breast cancer susceptibility proteins\".  The predominant allele has a normal, tumor suppressive function whereas high penetrance mutations in these genes cause a loss of tumor suppressive function which']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['correlates with an increased risk of breast cancer.[15]BRCA1 combines with other tumor suppressors, DNA damage sensors and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC).[16] The BRCA1 protein associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. Thus, this protein plays a role in transcription, and DNA repair of double-strand DNA breaks[14] ubiquitination, transcriptional regulation as well as other functions.[17]Methods to test for the likelihood of a patient with mutations in BRCA1 and BRCA2 developing cancer were covered by patents owned or controlled by']}\n",
            "documents is  {'title': ['BRCA1'], 'text': [\"Myriad Genetics.[18][19]  Myriad's business model of offering the diagnostic test exclusively led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012;[20] it also led to controversy over high prices and the inability to obtain second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.[21]The first evidence for the existence of a gene encoding a DNA repair enzyme involved in breast cancer susceptibility was provided by Mary-Claire King's laboratory at UC Berkeley in 1990.[22]\"]}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['Four years later, after an international race to find it,[23] the gene was cloned in 1994 by scientists at University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics.[18][24]The human BRCA1 gene is located on the long (q) arm of chromosome 17 at region 2 band 1, from base pair 41,196,312 to base pair 41,277,500 (Build GRCh37/hg19) (map).[25] BRCA1 orthologs have been identified in most vertebrates for which complete genome data are available.[6]The BRCA1 protein contains the following domains:[26]This protein also contains nuclear localization signals and nuclear export signal motifs.[27]The human BRCA1 protein consists of four']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['major protein domains; the Znf C3HC4- RING domain, the BRCA1 serine domain and two BRCT domains. These domains encode approximately 27% of BRCA1 protein. There are six known isoforms of BRCA1,[28] with isoforms 1 and 2 comprising 1863 amino acids each.[citation needed]BRCA1 is unrelated to BRCA2, i.e. they are not homologs or paralogs.[10]The RING motif, a Zn finger found in eukaryotic peptides, is 40–60 amino acids long and consists of eight conserved metal-binding residues, two quartets of cysteine or histidine residues that coordinate two zinc atoms.[30]  This motif contains a short anti-parallel beta-sheet, two zinc-binding loops and a central']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['alpha helix in a small domain.  This RING domain interacts with associated proteins, including BARD1, which also contains a RING motif, to form a heterodimer. The BRCA1 RING motif is flanked by alpha helices formed by residues 8–22 and 81–96 of the BRCA1 protein. It interacts with a homologous region in BARD1 also consisting of a RING finger flanked by two alpha-helices formed from residues 36–48 and 101–116. These four helices combine to form a heterodimerization interface and stabilize the BRCA1-BARD1 heterodimer complex. Additional stabilization is achieved by interactions between adjacent residues in the flanking region and hydrophobic interactions.']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression.[30]The ring domain is an important element of ubiquitin E3 ligases, which catalyze protein ubiquitination. Ubiquitin is a small regulatory protein found in all tissues that direct proteins to compartments within the cell. BRCA1 polypeptides, in particular, Lys-48-linked polyubiquitin chains are dispersed throughout the resting cell nucleus, but at the start of DNA replication, they gather in restrained groups that also contain BRCA2 and BARD1. BARD1 is thought to']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['be involved in the recognition and binding of protein targets for ubiquitination.[31] It attaches to proteins and labels them for destruction. Ubiquitination occurs via the BRCA1 fusion protein and is abolished by zinc chelation.[30] The enzyme activity of the fusion protein is dependent on the proper folding of the ring domain.[citation needed]BRCA1 serine cluster domain (SCD) spans amino acids 1280–1524. A portion of the domain is located in exons 11–13. High rates of mutation occur in exons 11–13. Reported phosphorylation sites of BRCA1 are concentrated in the SCD, where they are phosphorylated by ATM/ATR kinases both in vitro and in']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['vivo. ATM/ATR are kinases activated by DNA damage. Mutation of serine residues may affect localization of BRCA1 to sites of DNA damage and DNA damage response function.[29]The dual repeat BRCT domain of the BRCA1 protein is an elongated structure approximately 70 Å long and 30–35 Å wide.[32] The 85–95 amino acid domains in BRCT can be found as single modules or as multiple tandem repeats containing two domains.[33] Both of these possibilities can occur in a single protein in a variety of different conformations.[32] The C-terminal BRCT region of the BRCA1 protein is essential for repair of DNA, transcription regulation']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['and tumor suppressor function.[34] In BRCA1 the dual tandem repeat BRCT domains are arranged in a head-to-tail-fashion in the three-dimensional structure, burying 1600 Å of hydrophobic, solvent-accessible surface area in the interface. These all contribute to the tightly packed knob-in-hole structure that comprises the interface. These homologous domains interact to control cellular responses to DNA damage. A missense mutation at the interface of these two proteins can perturb the cell cycle, resulting a greater risk of developing cancer.[citation needed]BRCA1 is part of a complex that repairs double-strand breaks in DNA. The strands of the DNA double helix are continuously breaking']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['as they become damaged. Sometimes only one strand is broken, sometimes both strands are broken simultaneously. DNA cross-linking agents are an important source of chromosome/DNA damage. Double-strand breaks occur as intermediates after the crosslinks are removed, and indeed, biallelic mutations in BRCA1 have been identified to be responsible for Fanconi Anemia, Complementation Group S (FA-S),[35] a genetic disease associated with hypersensitivity to DNA crosslinking agents. BRCA1 is part of a protein complex that repairs DNA when both strands are broken. When this happens, it is difficult for the repair mechanism to \"know\" how to replace the correct DNA sequence, and']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['there are multiple ways to attempt the repair. The double-strand repair mechanism in which BRCA1 participates is homology-directed repair, where the repair proteins copy the identical sequence from the intact sister chromatid.[36] FA-S is almost always a lethal condition in utero; only a handful cases of biallelic BRCA1 mutations have been reported in literature despite the high carrier frequencies in the Ashkenazim, and none since 2013.[37]In the nucleus of many types of normal cells, the BRCA1 protein interacts with RAD51 during repair of DNA double-strand breaks.[38] These breaks can be caused by natural radiation or other exposures, but also occur']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['when chromosomes exchange genetic material (homologous recombination, e.g., \"crossing over\" during meiosis). The BRCA2 protein, which has a function similar to that of BRCA1, also interacts with the RAD51 protein. By influencing DNA damage repair, these three proteins play a role in maintaining the stability of the human genome.[citation needed]BRCA1 is also involved in another type of DNA repair, termed mismatch repair.  BRCA1 interacts with the DNA mismatch repair protein MSH2.[39]  MSH2, MSH6, PARP and some other proteins involved in single-strand repair are reported to be elevated in BRCA1-deficient mammary tumors.[40]A protein called valosin-containing protein (VCP, also known']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['as p97) plays a role to recruit BRCA1 to the damaged DNA sites.  After ionizing radiation, VCP is recruited to DNA lesions and cooperates with the ubiquitin ligase RNF8 to orchestrate assembly of signaling complexes for efficient DSB repair.[41]  BRCA1 interacts with VCP.[42] BRCA1 also interacts with c-Myc, and other proteins that are critical to maintain genome stability.[43]BRCA1 directly binds to DNA, with higher affinity for branched DNA structures. This ability to bind to DNA contributes to its ability to inhibit the nuclease activity of the MRN complex as well as the nuclease activity of Mre11 alone.[44] This']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['may explain a role for BRCA1 to promote lower fidelity DNA repair by non-homologous end joining (NHEJ).[45] BRCA1 also colocalizes with γ-H2AX (histone H2AX phosphorylated on serine-139) in DNA double-strand break repair foci, indicating it may play a role in recruiting repair factors.[17][46]Formaldehyde and acetaldehyde are common environmental sources of DNA cross links that often require repairs mediated by BRCA1 containing pathways.[47]This DNA repair function is essential; mice with loss-of-function mutations in both BRCA1 alleles are not viable, and as of 2015 only two adults were known to have loss-of-function mutations in both alleles (leading to FA-S); both had congenital']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['or developmental issues, and both had cancer. One was presumed to have survived to adulthood because one of the BRCA1 mutations was hypomorphic.[48]BRCA1 was shown to co-purify with the human RNA Polymerase II holoenzyme in HeLa extracts, implying it is a component of the holoenzyme.[49] Later research, however, contradicted this assumption, instead showing that the predominant complex including BRCA1 in HeLa cells is a 2 megadalton complex containing SWI/SNF.[50] SWI/SNF is a chromatin remodeling complex. Artificial tethering of BRCA1 to chromatin was shown to decondense heterochromatin, though the SWI/SNF interacting domain was not necessary for this role.[46] BRCA1 interacts with']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['the NELF-B (COBRA1) subunit of the NELF complex.[46]Certain variations of the BRCA1 gene lead to an increased risk for breast cancer as part of a hereditary breast–ovarian cancer syndrome. Researchers have identified hundreds of mutations in the BRCA1 gene, many of which are associated with an increased risk of cancer. Females with an abnormal BRCA1 or BRCA2 gene have up to an 80% risk of developing breast cancer by age 90; increased risk of developing ovarian cancer is about 55% for females with BRCA1 mutations and about 25% for females with BRCA2 mutations.[52]These mutations can be changes in one or']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['a small number of DNA base pairs (the building-blocks of DNA), and can be identified with PCR and DNA sequencing.[53]In some cases, large segments of DNA are rearranged. Those large segments, also called large rearrangements, can be a deletion or a duplication of one or several exons in the gene. Classical methods for mutation detection (sequencing) are unable to reveal these types of mutation.[54] Other methods have been proposed: traditional quantitative PCR,[55] multiplex ligation-dependent probe amplification (MLPA),[56] and Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF).[57] Newer methods have also been recently proposed: heteroduplex analysis (HDA) by multi-capillary electrophoresis or']}\n",
            "documents is  {'title': ['BRCA1'], 'text': [\"also dedicated oligonucleotides array based on comparative genomic hybridization (array-CGH).[58]Some results suggest that hypermethylation of the BRCA1 promoter, which has been reported in some cancers, could be considered as an inactivating mechanism for BRCA1 expression.[59]A mutated BRCA1 gene usually makes a protein that does not function properly. Researchers believe that the defective BRCA1 protein is unable to help fix DNA damage leading to mutations in other genes. These mutations can accumulate and may allow cells to grow and divide uncontrollably to form a tumor. Thus, BRCA1 inactivating mutations lead to a predisposition for cancer.[citation needed]BRCA1 mRNA 3' UTR can be\"]}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['bound by an miRNA, Mir-17 microRNA. It has been suggested that variations in this miRNA along with Mir-30 microRNA could confer susceptibility to breast cancer.[60]In addition to breast cancer, mutations in the BRCA1 gene also increase the risk of ovarian and prostate cancers. Moreover, precancerous lesions (dysplasia) within the Fallopian tube have been linked to BRCA1 gene mutations. Pathogenic mutations anywhere in a model pathway containing BRCA1 and BRCA2 greatly increase risks for a subset of leukemias and lymphomas.[14]Women who have inherited a defective BRCA1 or BRCA2 gene are at a greatly elevated risk to develop breast and ovarian cancer.']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['Their risk of developing breast and/or ovarian cancer is so high, and so specific to those cancers, that many mutation carriers choose to have prophylactic surgery. There has been much conjecture to explain such apparently striking tissue specificity. Major determinants of where BRCA1/2 hereditary cancers occur are related to tissue specificity of the cancer pathogen, the agent that causes chronic inflammation or the carcinogen. The target tissue may have receptors for the pathogen, may become selectively exposed to an inflammatory process or to a carcinogen. An innate genomic deficit in a tumor suppressor gene impairs normal responses and exacerbates the']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['susceptibility to disease in organ targets. This theory also fits data for several tumor suppressors beyond BRCA1 or BRCA2. A major advantage of this model is that it suggests there may be some options in addition to prophylactic surgery.[61]As aforementioned, biallelic and homozygous inheritance of the BRCA1 gene leads to FA-S, which is almost always an embryonically lethal condition.BRCA1 expression is reduced or undetectable in the majority of high grade, ductal breast cancers.[62]  It has long been noted that loss of BRCA1 activity, either by germ-line mutations or by down-regulation of gene expression, leads to tumor formation in specific']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['target tissues.  In particular, decreased BRCA1 expression contributes to both sporadic and inherited breast tumor progression.[63]  Reduced expression of BRCA1 is tumorigenic because it plays an important role in the repair of DNA damages, especially double-strand breaks, by the potentially error-free pathway of homologous recombination.[64]  Since cells that lack the BRCA1 protein tend to repair DNA damages by alternative more error-prone mechanisms, the reduction or silencing of this protein generates mutations and gross chromosomal rearrangements that can lead to progression to breast cancer.[64]Similarly, BRCA1 expression is low in the majority (55%) of sporadic epithelial ovarian cancers (EOCs)']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['where EOCs are the most common type of ovarian cancer, representing approximately 90% of ovarian cancers.[65]  In serous ovarian carcinomas, a sub-category constituting about 2/3 of EOCs, low BRCA1 expression occurs in more than 50% of cases.[66]  Bowtell[67] reviewed the literature indicating that deficient homologous recombination repair caused by BRCA1 deficiency is tumorigenic.  In particular this deficiency initiates a cascade of molecular events that sculpt the evolution of high-grade serous ovarian cancer and dictate its response to therapy.  Especially noted was that BRCA1 deficiency could be the cause of tumorigenesis whether due to BRCA1 mutation or']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['any other event that causes a deficiency of BRCA1 expression.Only about 3%–8% of all women with breast cancer carry a mutation in BRCA1 or BRCA2.[68]  Similarly, BRCA1 mutations are only seen in about 18% of ovarian cancers (13% germline mutations and 5% somatic mutations).[69]Thus, while BRCA1 expression is low in the majority of these cancers, BRCA1 mutation is not a major cause of reduced expression. Certain latent viruses, which are frequently detected in breast cancer tumors, can decrease the expression of the BRCA1 gene and cause the development of breast tumors.[70]BRCA1 promoter hypermethylation was present in only 13% of']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['unselected primary breast carcinomas.[71]  Similarly, BRCA1 promoter hypermethylation was present in only 5% to 15% of EOC cases.[65]Thus, while BRCA1 expression is low in these cancers, BRCA1 promoter methylation is only a minor cause of reduced expression.There are a number of specific microRNAs, when overexpressed, that directly reduce expression of specific DNA repair proteins (see MicroRNA section DNA repair and cancer)  In the case of breast cancer, microRNA-182 (miR-182) specifically targets BRCA1.[72]  Breast cancers can be classified based on receptor status or histology, with triple-negative breast cancer (15%–25% of breast cancers), HER2+ (15%–30% of breast cancers), ER+/PR+']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['(about 70% of breast cancers), and Invasive lobular carcinoma (about 5%–10% of invasive breast cancer).  All four types of breast cancer were found to have an average of about 100-fold increase in miR-182, compared to normal breast tissue.[73]  In breast cancer cell lines, there is an inverse correlation of BRCA1 protein levels with miR-182 expression.[72] Thus it appears that much of the reduction or absence of BRCA1 in high grade ductal breast cancers may be due to over-expressed miR-182.In addition to miR-182, a pair of almost identical microRNAs, miR-146a and miR-146b-5p, also repress BRCA1 expression.  These two']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['microRNAs are over-expressed in triple-negative tumors and their over-expression results in BRCA1 inactivation.[74]  Thus, miR-146a and/or miR-146b-5p may also contribute to reduced expression of BRCA1 in these triple-negative breast cancers.In both serous tubal intraepithelial carcinoma (the precursor lesion to high grade serous ovarian carcinoma (HG-SOC)), and in HG-SOC itself, miR-182 is overexpressed in about 70% of cases.[75]  In cells with over-expressed miR-182, BRCA1 remained low, even after exposure to ionizing radiation (which normally raises BRCA1 expression).[75]  Thus much of the reduced or absent BRCA1 in HG-SOC may be due to over-expressed miR-182.Another microRNA known to reduce expression']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['of BRCA1 in ovarian cancer cells is miR-9.[65]  Among 58 tumors from patients with stage IIIC or stage IV serous ovarian cancers (HG-SOG), an inverse correlation was found between expressions of miR-9 and BRCA1,[65] so that increased miR-9 may also contribute to reduced expression of BRCA1 in these ovarian cancers.DNA damage appears to be the primary underlying cause of cancer,[76] and deficiencies in DNA repair appears to underlie many forms of cancer.[77]  If DNA repair is deficient, DNA damage tends to accumulate. Such excess DNA damage may increase mutational errors during DNA replication due to error-prone translesion synthesis.']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['Excess DNA damage may also increase epigenetic alterations due to errors during DNA repair.[78][79] Such mutations and epigenetic alterations may give rise to cancer.  The frequent microRNA-induced deficiency of BRCA1 in breast and ovarian cancers likely contribute to the progression of those cancers.All germ-line BRCA1 mutations identified to date have been inherited, suggesting the possibility of a large \"founder\" effect in which a certain mutation is common to a well-defined population group and can, in theory, be traced back to a common ancestor. Given the complexity of mutation screening for BRCA1, these common mutations may simplify the methods required']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['for mutation screening in certain populations. Analysis of mutations that occur with high frequency also permits the study of their clinical expression.[80] Examples of manifestations of a founder effect are seen among Ashkenazi Jews. Three mutations in BRCA1 have been reported to account for the majority of Ashkenazi Jewish patients with inherited BRCA1-related breast and/or ovarian cancer: 185delAG, 188del11 and 5382insC in the BRCA1 gene.[81][82] In fact, it has been shown that if a Jewish woman does not carry a BRCA1 185delAG, BRCA1 5382insC founder mutation, it is highly unlikely that a different BRCA1 mutation will be found.[83] Additional examples']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['of founder mutations in BRCA1 are given in Table 1 (mainly derived from[80]).As women age, reproductive performance declines, leading to menopause. This decline is tied to a reduction in the number of ovarian follicles. Although about 1 million oocytes are present at birth in the human ovary, only about 500 (about 0.05%) of these ovulate. The decline in ovarian reserve appears to occur at a constantly increasing rate with age,[115] and leads to nearly complete exhaustion of the reserve by about age 52. As ovarian reserve and fertility decline with age, there is also a parallel increase in pregnancy failure']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['and meiotic errors, resulting in chromosomally abnormal conceptions.[116]Women with a germ-line BRCA1 mutation appear to have a diminished oocyte reserve and decreased fertility compared to normally aging women.[117] Furthermore, women with an inherited BRCA1 mutation undergo menopause prematurely.[118]  Since BRCA1 is a key DNA repair protein, these findings suggest that naturally occurring DNA damages in oocytes are repaired less efficiently in women with a BRCA1 defect, and that this repair inefficiency leads to early reproductive failure.[117]As noted above, the BRCA1 protein plays a key role in homologous recombinational repair.  This is the only known cellular process that can']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['accurately repair DNA double-strand breaks. DNA double-strand breaks accumulate with age in humans and mice in primordial follicles.[119]  Primordial follicles contain oocytes that are at an intermediate (prophase I) stage of meiosis.  Meiosis is the general process in eukaryotic organisms by which germ cells are formed, and it is likely an adaptation for removing DNA damages, especially double-strand breaks, from germ line DNA.[120] (Also see article Meiosis).  Homologous recombinational repair employing BRCA1 is especially promoted during meiosis.  It was found that expression of four key genes necessary for homologous recombinational repair of DNA double-strand breaks (BRCA1,']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['MRE11, RAD51 and ATM) decline with age in the oocytes of humans and mice,[119] leading to the hypothesis that DNA double-strand break repair is necessary for the maintenance of oocyte reserve and that a decline in efficiency of repair with age plays a role in ovarian aging.Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide.  At diagnosis, almost 70% of persons with NSCLC have locally advanced or metastatic disease.  Persons with NSCLC are often treated with therapeutic platinum compounds (e.g. cisplatin, carboplatin or oxaliplatin) that cause inter-strand cross-links in DNA.  Among individuals with']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['NSCLC, low expression of BRCA1 in the primary tumor correlated with improved survival after platinum-containing chemotherapy.[121][122]  This correlation implies that low BRCA1 in cancer, and the consequent low level of DNA repair, causes vulnerability of cancer to treatment by the DNA cross-linking agents.  High BRCA1 may protect cancer cells by acting in a pathway that removes the damages in DNA introduced by the platinum drugs.  Thus the level of BRCA1 expression is a potentially important tool for tailoring chemotherapy in lung cancer management.[121][122]Level of BRCA1 expression is also relevant to ovarian cancer treatment.  Patients having sporadic']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['ovarian cancer who were treated with platinum drugs had longer median survival times if their BRCA1 expression was low compared to patients with higher BRCA1 expression (46 compared to 33 months).[123]A patent application for the isolated BRCA1 gene and cancer promoting mutations discussed above, as well as methods to diagnose the likelihood of getting breast cancer, was filed by the University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics in 1994;[18] over the next year, Myriad, (in collaboration with investigators at Endo Recherche, Inc., HSC Research & Development Limited Partnership, and University of Pennsylvania), isolated and']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['sequenced the BRCA2 gene and identified key mutations, and the first BRCA2 patent was filed in the U.S. by Myriad and other institutions in 1995.[19]  Myriad is the exclusive licensee of these patents and has enforced them in the US against clinical diagnostic labs.[21]  This business model led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012;[20] it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['Association for Molecular Pathology v. Myriad Genetics lawsuit.[21][124]  The patents began to expire in 2014.According to an article published in the journal, Genetic Medicine, in 2010, \"The patent story outside the United States is more complicated.... For example, patents have been obtained but the patents are being ignored by provincial health systems in Canada. In Australia and the UK, Myriad\\'s licensee permitted use by health systems but announced a change of plans in August 2008. Only a single mutation has been patented in Myriad\\'s lone European-wide patent, although some patents remain under review of an opposition proceeding. In effect,']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['the United States is the only jurisdiction where Myriad\\'s strong patent position has conferred sole-provider status.\"[125][126]  Peter Meldrum, CEO of Myriad Genetics, has acknowledged that Myriad has \"other competitive advantages that may make such [patent] enforcement unnecessary\" in Europe.[127]As with any gene, finding variation in BRCA1 is not hard. The real value comes from understanding what the clinical consequences of any particular variant are. Myriad has a large, proprietary database of such genotype-phenotype correlations. In response, parallel open-source databases are being developed.Legal decisions surrounding the BRCA1 and BRCA2 patents will affect the field of genetic testing in general.[128]']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['A June 2013 article, in  Association for Molecular Pathology v. Myriad Genetics (No. 12-398), quoted the US Supreme Court\\'s unanimous ruling that, \"A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,\" invalidating Myriad\\'s patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature could still be eligible for patent protection.[129]  The Federal Court of Australia came to the opposite conclusion, upholding the validity of an Australian Myriad Genetics patent over the BRCA1 gene']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['in February 2013.[130]  The Federal Court also rejected an appeal in September 2014.[131] Yvonne D\\'Arcy won her case against US-based biotech company Myriad Genetics in the High Court of Australia. In their unanimous decision on October 7, 2015, the \"high court found that an isolated nucleic acid, coding for a BRCA1 protein, with specific variations from the norm that are indicative of susceptibility to breast cancer and ovarian cancer was not a \\'patentable invention.\\'\"[132]BRCA1 has been shown to interact with the following proteins:1jm7: Solution structure of the BRCA1/BARD1 RING-domain heterodimer1jnx: Crystal structure of the BRCT repeat region from the']}\n",
            "documents is  {'title': ['BRCA1'], 'text': ['breast cancer associated protein, BRCA11n5o: Structural consequences of a cancer-causing BRCA1-BRCT missense mutation1oqa: Solution structure of the BRCT-c domain from human BRCA11t15: Crystal Structure of the Brca1 BRCT Domains in Complex with the Phosphorylated Interacting Region from Bach1 Helicase1t29: Crystal structure of the BRCA1 BRCT repeats bound to a phosphorylated BACH1 peptide1t2u: Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1: structure of BRCA1 missense variant V1809F1t2v: Structural basis of phospho-peptide recognition by the BRCT domain of BRCA1, structure with phosphopeptide1y98: Structure of the BRCT repeats of BRCA1 bound to a CtIP phosphopeptide.']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['1N0W, 3EU767512190ENSG00000139618ENSMUSG00000041147P51587P97929NM_000059NM_001081001NM_009765NP_000050NP_001074470NP_033895BRCA2 and BRCA2 (/ˌbrækəˈtuː/[5]) are a human gene and its protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (originally breast cancer 2; currently BRCA2, DNA repair associated) are maintained by the HUGO Gene Nomenclature Committee. One alternative symbol, FANCD1, recognizes its association with the FANC protein complex. Orthologs, styled Brca2 and Brca2, are common in other vertebrate species.[6][7] BRCA2 is a human tumor suppressor gene[8][9] (specifically, a caretaker gene), found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['for repairing DNA.[10]BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks.[11][12] If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer.[13][14] BRCA1 and BRCA2 have been described as \"breast cancer susceptibility genes\" and \"breast cancer susceptibility proteins\".  The predominant allele has a normal']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['tumor suppressive function whereas high penetrance mutations in these genes cause a loss of tumor suppressive function, which correlates with an increased risk of breast cancer.[15]The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3).[16] The human reference BRCA2 gene contains 27 exons, and the cDNA has  10,254 base pairs[17] coding for a protein of 3418 amino acids.[18][19]Although the structures of the BRCA1 and BRCA2 genes are very different, at least some functions are interrelated. The proteins made by both genes are essential for repairing damaged DNA (see Figure of recombinational repair']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['steps). BRCA2 binds the single strand DNA and directly interacts with the recombinase RAD51 to stimulate[27] and maintain [28] strand invasion, a vital step of homologous recombination. The localization of RAD51 to the DNA double-strand break requires the formation of the BRCA1-PALB2-BRCA2 complex. PALB2 (Partner and localizer of BRCA2)[29] can function synergistically with a BRCA2 chimera (termed piccolo, or piBRCA2) to further promote strand invasion.[30] These breaks can be caused by natural and medical radiation or other environmental exposures, but also occur when chromosomes exchange genetic material during a special type of cell division that creates sperm and eggs (meiosis).']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['Double strand breaks are also generated during repair of DNA cross links. By repairing DNA, these proteins play a role in maintaining the stability of the human genome and prevent dangerous gene rearrangements that can lead to hematologic and other cancers.BRCA2 has been shown to possess a crucial role in protection from the MRE11-dependent nucleolytic degradation of the reversed forks that are forming during DNA replication fork stalling (caused by obstacles such as mutations, intercalating agents etc.).[31]Like BRCA1, BRCA2 probably regulates the activity of other genes and plays a critical role in embryo development.Certain variations of the BRCA2 gene increase']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['risks for breast cancer as part of a hereditary breast–ovarian cancer syndrome. Researchers have identified hundreds of mutations in the BRCA2 gene, many of which cause an increased risk of cancer. BRCA2 mutations are usually insertions or deletions of a small number of DNA base pairs in the gene. As a result of these mutations, the protein product of the BRCA2 gene is abnormal, and does not function properly. Researchers believe that the defective BRCA2 protein is unable to fix DNA damage that occurs throughout the genome.  As a result, there is an increase in mutations due to error-prone']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['translesion synthesis past un-repaired DNA damage, and some of these mutations can cause cells to divide in an uncontrolled way and form a tumor.People who have two mutated copies of the BRCA2 gene have one type of Fanconi anemia. This condition is caused by extremely reduced levels of the BRCA2 protein in cells, which allows the accumulation of damaged DNA. Patients with Fanconi anemia are prone to several types of leukemia (a type of blood cell cancer); solid tumors, particularly of the head, neck, skin, and reproductive organs; and bone marrow suppression (reduced blood cell production that leads to anemia).']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['Women having inherited a defective BRCA1 or BRCA2 gene have risks for breast and ovarian cancer that are so high and seem so selective that many mutation carriers choose to have prophylactic surgery. There has been much conjecture to explain such apparently striking tissue specificity. Major determinants of where BRCA1- and BRCA2-associated hereditary cancers occur are related to tissue specificity of the cancer pathogen, the agent that causes chronic inflammation, or the carcinogen. The target tissue may have receptors for the pathogen, become selectively exposed to carcinogens and an infectious process. An innate genomic deficit impairs normal responses and']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['exacerbates the susceptibility to disease in organ targets. This theory also fits data for several tumor suppressors beyond BRCA1 or BRCA2. A major advantage of this model is that it suggests there are some options in addition to prophylactic surgery.[33]In addition to breast cancer in men and women, mutations in BRCA2 also lead to an increased risk of ovarian, uterine tube, prostate and pancreatic cancer. In some studies, mutations in the central part of the gene have been associated with a higher risk of ovarian cancer and a lower risk of prostate cancer than mutations in other parts of the']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['gene. Several other types of cancer have also been seen in certain families with BRCA2 mutations.In general, strongly inherited gene mutations (including mutations in BRCA2) account for only 5-10% of breast cancer cases; the specific risk of getting breast or other cancer for anyone carrying a BRCA2 mutation depends on many factors.[34]The gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the University of Pennsylvania.[41]Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics.[42][43]']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['Myriad\\'s business model of exclusively offering the diagnostic test led from Myriad\\'s beginnings as a startup in 1994 to its being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012;[44] it also led to controversy over high test prices and the unavailability of second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.[45]All germline BRCA2 mutations identified to date have been inherited, suggesting the possibility of a large \"founder\" effect in which a certain mutation is common to a well-defined population group and']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['can theoretically be traced back to a common ancestor. Given the complexity of mutation screening for BRCA2, these common mutations may simplify the methods required for mutation screening in certain populations. Analysis of mutations that occur with high frequency also permits the study of their clinical expression.[46] A striking example of a founder mutation is found in Iceland, where a single BRCA2 (999del5) mutation accounts for virtually all breast/ovarian cancer families.[47][48] This frame-shift mutation leads to a highly truncated protein product. In a large study examining hundreds of cancer and control individuals, this 999del5 mutation was found in 0.6% of']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['the general population. Of note, while 72% of patients who were found to be carriers had a moderate or strong family history of breast cancer, 28% had little or no family history of the disease. This strongly suggests the presence of modifying genes that affect the phenotypic expression of this mutation, or possibly the interaction of the BRCA2 mutation with environmental factors. Additional examples of founder mutations in BRCA2 are given in the table below.In the plant Arabidopsis thaliana, loss of the BRCA2 homolog AtBRCA2 causes severe defects in both male meiosis and in the development of the female gametocyte.[64]']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['AtBRCA2 protein is required for proper localization of the synaptonemal complex protein AtZYP1 and the recombinases AtRAD51 and AtDMC1.  Furthermore, AtBRCA2 is required for proper meiotic synapsis.  Thus AtBRCA2 is likely important for meiotic recombination.  It appears that AtBRCA2 acts during meiosis to control the single-strand invasion steps mediated by AtRAD51 and AtDMC1 occurring during meiotic homologous recombinational repair of DNA damages.[64]Homologs of BRCA2 are also essential for meiosis in the fungus Ustilago maydis,[65] the worm Caenorhabditis elegans,[66][67] and the fruitfly Drosophila melanogaster.[68]Mice that produce truncated versions of BRCA2 are viable but sterile.[69]  BRCA2 mutant']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['rats have a phenotype of growth inhibition and sterility in both sexes.[70]  Aspermatogenesis in these mutant rats is due to a failure of homologous chromosome synapsis during meiosis.DMC1 (DNA meiotic recombinase 1) is a meiosis specific homolog of RAD51 that mediates strand exchange during homologous recombinational repair.  DMC1 promotes the formation of DNA strand invasion products (joint molecules) between homologous DNA molecules.  Human DMC1 interacts directly with each of a series of repeat sequences in the BRCA2 protein (called BRC repeats) that stimulate joint molecule formation by DMC1.[71]  BRC repeats conform to a motif consisting of']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['a sequence of about 35 highly conserved amino acids that are present at least once in all BRCA2-like proteins.  The BRCA2 BRC repeats stimulate joint molecule formation by promoting the interaction of single-stranded DNA (ssDNA) with DMC1.[71]  The ssDNA complexed with DMC1 can pair with homologous ssDNA from another chromosome during the synopsis stage of meiosis to form a joint molecule, a central step in homologous recombination. Thus the BRC repeat sequences of BRCA2 appear to play a key role in recombinational repair of DNA damages during meiotic recombination.Overall, it appears that homologous recombination during meiosis functions to']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['repair DNA damages,[citation needed] and that BRCA2 plays a key role in performing this function.BRCA2 is required in the mouse for neurogenesis and suppression of medulloblastoma.[72]  ‘’BRCA2’’ loss profoundly affects neurogenesis, particularly during embryonic and postnatal neural development.  These neurological defects arise from DNA damage.[72]Epigenetic alterations in expression of BRCA2 (causing over-expression or under-expression) are very frequent in sporadic cancers (see Table below) while mutations in BRCA2 are rarely found.[73][74][75]In non-small cell lung cancer, BRCA2 is epigenetically repressed by hypermethylation of the promoter.[76]  In this case, promoter hypermethylation is significantly associated with low mRNA expression and low']}\n",
            "documents is  {'title': ['BRCA2'], 'text': [\"protein expression but not with loss of heterozygosity of the gene.In sporadic ovarian cancer, an opposite effect is found.  BRCA2 promoter and 5'-UTR regions have relatively few or no methylated CpG dinucleotides in the tumor DNA compared with that of non-tumor DNA, and a significant correlation is found between hypomethylation and a >3-fold over-expression of BRCA2.[77]  This indicates that hypomethylation of the BRCA2 promoter and 5'-UTR regions leads to over-expression of BRCA2 mRNA.One report indicated some epigenetic control of BRCA2 expression by the microRNAs miR-146a and miR-148a.[78]In eukaryotes, BRCA2 protein has an important role in homologous recombinational repair.\"]}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['In mice and humans, BRCA2 primarily mediates orderly assembly of RAD51 on single-stranded (ss) DNA, the form that is active for homologous pairing and strand invasion.[79] BRCA2 also redirects RAD51 from double-stranded DNA and prevents dissociation from ssDNA.[79]  In addition, the four paralogs of RAD51, consisting of RAD51B (RAD51L1), RAD51C (RAD51L2), RAD51D (RAD51L3), XRCC2 form a complex called the BCDX2 complex (see Figure: Recombinational repair of DNA). This complex participates in RAD51 recruitment or stabilization at damage sites.[26]  The BCDX2 complex appears to act by facilitating the assembly or stability of the RAD51 nucleoprotein filament.  RAD51 catalyses']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['strand transfer between a broken sequence and its undamaged homologue to allow re-synthesis of the damaged region (see homologous recombination models).Some studies of cancers report over-expressed BRCA2 whereas other studies report under-expression of BRCA2.  At least two reports found over-expression in some sporadic breast tumors and under-expression in other sporadic breast tumors.[80][81] (see Table).Many cancers have epigenetic deficiencies in various DNA repair genes (see Frequencies of epimutations in DNA repair genes in cancers).  These repair deficiencies likely cause increased unrepaired DNA damages. The over-expression of BRCA2 seen in many cancers may reflect compensatory BRCA2 over-expression and increased homologous']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['recombinational repair to at least partially deal with such excess DNA damages.  Egawa et al.[82] suggest that increased expression of BRCA2 can be explained by the genomic instability frequently seen in cancers, which induces BRCA2 mRNA expression due to an increased need for BRCA2 for DNA repair.Under-expression of BRCA2 would itself lead to increased unrepaired DNA damages.  Replication errors past these damages (see translesion synthesis) would lead to increased mutations and cancer.BRCA2 has been shown to interact withBRCA2 contains a number of 39 amino acid repeats that are critical for binding to RAD51 (a key protein in DNA']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['recombinational repair) and resistance to methyl methanesulphonate treatment.[101][108][109][117]The BRCA2 helical domain adopts a helical structure, consisting of a four-helix cluster core (alpha 1, alpha 8, alpha 9, alpha 10) and two successive beta-hairpins (beta 1 to beta 4). An approximately 50-amino acid segment that contains four short helices (alpha 2 to alpha 4), meanders around the surface of the core structure. In BRCA2, the alpha 9 and alpha 10 helices pack with the BRCA2 OB1 domain through van der Waals contacts involving hydrophobic and aromatic residues, and also through side-chain and backbone hydrogen bonds. This domain binds the 70-amino acid']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['DSS1 (deleted in split-hand/split foot syndrome) protein, which was originally identified as one of three genes that map to a 1.5-Mb locus deleted in an inherited developmental malformation syndrome.[115]The BRCA OB1 domain assumes an OB fold, which consists of a highly curved five-stranded beta-sheet that closes on itself to form a beta-barrel. OB1 has a shallow groove formed by one face of the curved sheet and is demarcated by two loops, one between beta 1 and beta 2 and another between beta 4 and beta 5, which allows for weak single strand DNA binding. The domain also binds the 70-amino']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['acid DSS1 (deleted in split-hand/split foot syndrome) protein.[115]The BRCA OB3 domain assumes an OB fold, which consists of a highly curved five-stranded beta-sheet that closes on itself to form a beta-barrel. OB3 has a pronounced groove formed by one face of the curved sheet and is demarcated by two loops, one between beta 1 and beta 2 and another between beta 4 and beta 5, which allows for strong ssDNA binding.[115]The Tower domain adopts a secondary structure consisting of a pair of long, antiparallel alpha-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['helix-turn-helix motif and is similar to the DNA binding domains of the bacterial site-specific recombinases, and of eukaryotic Myb and homeodomain transcription factors. The Tower domain has an important role in the tumour suppressor function of BRCA2, and is essential for appropriate binding of BRCA2 to DNA.[115] Studies shown that conformation of this tower domain is allosterically controlled by a small protein \"DSS1\", which interacts with helical, OB1 and OB2 domains of BRCA2.[118]A patent application for the isolated BRCA1 gene and cancer-cancer promoting mutations, as well as methods to diagnose the likelihood of getting breast cancer, was filed by the']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics in 1994;[42]  over the next year, Myriad, in collaboration with other investigators, isolated and sequenced the BRCA2 gene and identified relevant mutations, and the first BRCA2 patent was filed in the U.S. by Myriad and the other institutions in 1995.[41]  Myriad is the exclusive licensee of these patents and has enforced them in the US against clinical diagnostic labs.[45]  This business model led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['revenue in 2012;[44] it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.[45][119]  The patents begin to expire in 2014.Peter Meldrum, CEO of Myriad Genetics, has acknowledged that Myriad has \"other competitive advantages that may make such [patent] enforcement unnecessary\" in Europe.[120]Legal decisions surrounding the BRCA1 and BRCA2 patents will affect the field of genetic testing in general.[121]  In June 2013, in  Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the US']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['Supreme Court unanimously ruled that, \"A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,\" invalidating Myriad\\'s patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature could still be eligible for patent protection.[122]  The Federal Court of Australia came to the opposite conclusion, upholding the validity of an Australian Myriad Genetics patent over the BRCA1 gene in February 2013,[123] but this decision is being appealed and the appeal will include consideration of the US']}\n",
            "documents is  {'title': ['BRCA2'], 'text': ['Supreme Court ruling.[124]1n0w: Crystal structure of a RAD51-BRCA2 BRC repeat complex']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['A tumor suppressor gene (TSG), or anti-oncogene, is a gene that regulates a cell during cell division and replication.[1] If the cell grows uncontrollably, it will result in cancer. When a tumor suppressor gene is mutated, it results in a loss or reduction in its function. In combination with other genetic mutations, this could allow the cell to grow abnormally. The loss of function for these genes may be even more significant in the development of human cancers, compared to the activation of oncogenes.[2]TSGs can be grouped into the following categories: caretaker genes, gatekeeper genes, and more recently landscaper genes.']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['Caretaker genes ensure stability of the genome via DNA repair and subsequently when mutated allow mutations to accumulate.[3] Meanwhile, gatekeeper genes directly regulate cell growth by either inhibiting cell cycle progression or inducing apoptosis.[3] Lastly landscaper genes regulate growth by contributing to the surrounding environment, when mutated can cause an environment that promotes unregulated proliferation.[4] The classification schemes are evolving as medical advances are being made from fields including molecular biology, genetics, and epigenetics.The discovery of oncogenes and their ability to deregulate cellular processes related to cell proliferation and development appeared first in the literature as opposed to the idea']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': [\"of tumor suppressor genes.[5] However, the idea of genetic mutation leading to increased tumor growth gave way to another possible genetic idea of genes playing a role in decreasing cellular growth and development of cells. This idea was not solidified until experiments by Henry Harris were conducted with somatic cell hybridization in 1969.[6]Within Harris's experiments, tumor cells were fused with normal somatic cells to make hybrid cells. Each cell had chromosomes from both parents and upon growth, a majority of these hybrid cells did not have the capability of developing tumors within animals.[6] The suppression of tumorigenicity in these hybrid\"]}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['cells prompted researchers to hypothesize that genes within the normal somatic cell had inhibitory actions to stop tumor growth.[6] This initial hypothesis eventually lead to the discovery of the first classic tumor suppressor gene by Alfred Knudson, known as the Rb gene, which codes for the retinoblastoma tumor suppressor protein.[5]Alfred Knudson, a pediatrician and cancer geneticist, proposed that in order to develop retinoblastoma, two allelic mutations are required to lose functional copies of both the Rb genes to lead to tumorigenicity.[6] Knudson observed that retinoblastoma often developed early in life for younger patients in both eyes, while in some rarer']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['cases retinoblastoma would develop later in life and only be unilateral.[5] This unique development pattern allowed Knudson and several other scientific groups in 1971 to correctly hypothesize that the early development of retinoblastoma was caused by inheritance of one loss of function mutation to an RB germ-line gene followed by a later de novo mutation on its functional Rb gene allele. The more sporadic occurrence of unilateral development of retinoblastoma was hypothesized to develop much later in life due to two de novo mutations that were needed to fully lose tumor suppressor properties.[5] This finding formed the basis of the']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['two-hit hypothesis. In order to verify that the loss of function of tumor suppressor genes causes increased tumorigenicity, interstitial deletion experiments on  chromosome 13q14 were conducted to observe the effect of deleting the loci for the Rb gene. This deletion caused increased tumor growth in retinoblastoma, suggesting that loss or inactivation of a tumor suppressor gene can increase tumorigenicity.[6]Unlike oncogenes, tumor suppressor genes generally follow the two-hit hypothesis, which states both alleles that code for a particular protein must be affected before an effect is manifested.[7] If only one allele for the gene is damaged, the other can still']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['produce enough of the correct protein to retain the appropriate function. In other words, mutant tumor suppressor alleles are usually recessive, whereas mutant oncogene alleles are typically dominant.Proposed by A.G. Knudson for cases of retinoblastoma.[7] He observed that 40% of U.S cases were caused by a mutation in the germ-line. However, affected parents could have children without the disease, but the unaffected children became parents of children with retinoblastoma.[8] This indicates that one could inherit a mutated germ-line but not display the disease. Knudson observed that the age of onset of retinoblastoma followed 2nd order kinetics, implying that two independent']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['genetic events were necessary. He recognized that this was consistent with a recessive mutation involving a single gene, but requiring bi-allelic mutation. Hereditary cases involve an inherited mutation and a single mutation in the normal allele.[8] Non-hereditary retinoblastoma involves two mutations, one on each allele.[8] Knudson also noted that hereditary cases often developed bilateral tumors and would develop them earlier in life, compared to non-hereditary cases where individuals were only affected by a single tumor.[8]There are exceptions to the two-hit rule for tumor suppressors, such as certain mutations in the p53 gene product.  p53 mutations can function as a']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['dominant negative, meaning that a mutated p53 protein can prevent the function of the natural protein produced from the non-mutated allele.[9] Other tumor-suppressor genes that do not follow the two-hit rule are those that exhibit haploinsufficiency, including PTCH in medulloblastoma and NF1 in neurofibroma.  Another example is p27, a cell-cycle inhibitor, that when one allele is mutated causes increased carcinogen susceptibility.[10]The proteins encoded by most tumor suppressor genes inhibit cell proliferation or survival. Inactivation of tumor suppressor genes therefore leads to tumor development by eliminating negative regulatory proteins. In most cases, tumor suppressor proteins inhibit the same cell regulatory']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['pathways that are stimulated by the products of oncogenes.[11] While tumor suppressor genes have the same main function, they have various mechanisms of action, that their transcribed products perform, which include the following:[12]Expression of genes, including tumor suppressors, can be altered through biochemical alterations known as DNA methylation.[22] Methylation is an example of epigenetic modifications, which commonly regulate expression in mammalian genes. The addition of a methyl group to either histone tails or directly on DNA causes the nucleosome to pack tightly together restricting the transcription of any genes in this region. This process not only has the capabilities to']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['inhibit gene expression, it can also increase the chance of mutations. Stephen Baylin observed that if promoter regions experience a phenomenon known as hypermethylation, it could result in later transcriptional errors, tumor suppressor gene silencing,  protein misfolding, and eventually cancer growth. Baylin et al. found methylation inhibitors known as azacitidine and decitabine. These compounds can actually help prevent cancer growth by inducing re-expression of previously silenced genes, arresting the cell cycle of the tumor cell and forcing it into apoptosis.[23]There are further clinical trials under current investigation regarding treatments for hypermethylation as well as alternate tumor suppression therapies that']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['include prevention of tissue hyperplasia, tumor development, or metastatic spread of tumors.[24] The team working with Wajed have investigated neoplastic tissue methylation in order to one day identify early treatment options for gene modification that can silence the tumor suppressor gene.[25]   In addition to DNA methylation, other epigenetic modifications like histone deacetylation or chromatin-binding proteins can prevent DNA polymerase from effectively transcribing desired sequences, such as ones containing tumor suppressor genes.Gene therapy is used to reinstate the function of a mutated or deleted gene type. When tumor suppressor genes are altered in a way that results in less']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['or no expression, several severe problems can arise for the host. This is why tumor suppressor genes have commonly been studied and used for gene therapy. The two main approaches used currently to introduce genetic material into cells are viral and non-viral delivery methods.[25]The viral method of transferring genetic material harnesses the power of viruses.[25]  By using viruses that are durable to genetic material alterations, viral methods of gene therapy for tumor suppressor genes have shown to be successful.[26] In this method, vectors from viruses are used. The two most commonly used vectors are adenoviral vectors and adeno-associated vectors.']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['In vitro genetic manipulation of these types of vectors is easy and in vivo application is relatively safe compared to other vectors.[25][27] Before the vectors are inserted into the tumors of the host, they are prepared by having the parts of their genome that control replication either mutated or deleted. This makes them safer for insertion. Then, the desired genetic material is inserted and ligated to the vector.[26] In the case with tumor suppressor genes, genetic material which encodes p53 has been used successfully, which after application, has shown reduction in tumor growth or proliferation.[27][28]The non-viral method of transferring genetic']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['material is used less often than the viral method.[25][27] However, the non-viral method is a more cost-effective, safer, available method of gene delivery not to mention that non-viral methods have shown to induce fewer host immune responses and possess no restrictions on size or length of the transferable genetic material.[25]  Non-viral gene therapy uses either chemical or physical methods to introduce genetic material to the desired cells.[25][27] The chemical methods are used primarily for tumor suppressor gene introduction and are divided into two categories which are naked plasmid or liposome-coated plasmids.[27] The naked plasmid strategy has garnered interest because']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['of its easy to use methods.[25]  Direct injection into the muscles allows for the plasmid to be taken up into the cell of possible tumors where the genetic material of the plasmid can be incorporated into the genetic material of the tumor cells and revert any previous damage done to tumor suppressor genes.[25][27] The liposome-coated plasmid method has recently also been of interest since they produce relatively low host immune response and are efficient with cellular targeting.[27] The positively charged capsule in which the genetic material is packaged helps with electrostatic attraction to the negatively charged membranes of the']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['cells as well as the negatively charged DNA of the tumor cells.[25][27] In this way, non-viral methods of gene therapy are highly effective in restoring tumor suppressor gene function to tumor cells that have either partially or entirely lost this function.The viral and non-viral gene therapies mentioned above are commonly used but each has some limitations which must be considered. The most important limitation these methods have is the efficacy at which the adenoviral and adeno-associated vectors, naked plasmids, or liposome-coated plasmids are taken in by the host’s tumor cells. If proper uptake by the host’s tumor cells is not']}\n",
            "documents is  {'title': ['Tumor_suppressor_genes'], 'text': ['achieved, re-insertion introduces problems such as the host’s immune system recognizing these vectors or plasmids and destroying them which impairs the overall effectiveness of the gene therapy treatment further.[28][25]As the cost of DNA sequencing continues to diminish, more cancers can be sequenced. This allows for the discovery of novel tumor suppressors and can give insight on how to treat and cure different cancers in the future. Other examples of tumor suppressors include pVHL, APC, CD95, ST5, YPEL3, ST7, and ST14, p16, BRCA2.[34]']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['1DEB, 1EMU, 1JPP, 1M5I, 1T08, 1TH1, 1V18, 2RQU, 3AU3, 3NMW, 3NMX, 3NMZ, 3QHE, 3RL7, 3RL8, 3T7U, 4G69, 4YJL, 4YK6, 4YJE32411789ENSG00000134982ENSMUSG00000005871P25054Q61315NM_001127511NM_000038NM_001127510NM_007462NM_001360979NM_001360980NP_001341826NP_001341827NP_001341828NP_001341829NP_001341830NP_001341831NP_001341832NP_001341833NP_001341834NP_001341835n/aAdenomatous polyposis coli (APC) also known as deleted in polyposis 2.5 (DP2.5) is a protein that in humans is encoded by the APC gene.[4] The APC protein is a negative regulator  that controls beta-catenin concentrations and interacts with E-cadherin, which are involved in cell adhesion. Mutations in the APC gene may result in colorectal cancer and desmoid tumors.[5][6]APC is classified as a tumor suppressor gene. Tumor suppressor genes prevent the uncontrolled growth of cells that may result in cancerous tumors.']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['The protein made by the APC gene plays a critical role in several cellular processes that determine whether a cell may develop into a tumor. The APC protein helps control how often a cell divides, how it attaches to other cells within a tissue, how the cell polarizes and the morphogenesis of the 3D structures,[7] or whether a cell moves within or away from tissue. This protein also helps ensure that the chromosome number in cells produced through cell division is correct. The APC protein accomplishes these tasks mainly through association with other proteins, especially those that are involved in']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['cell attachment and signaling. The activity of one protein in particular, beta-catenin, is controlled by the APC protein (see: Wnt signaling pathway). Regulation of beta-catenin prevents genes that stimulate cell division from being turned on too often and prevents cell overgrowth.The human APC gene is located on the long (q) arm of chromosome 5 in band q22.2 (5q22.2). The APC gene has been shown to contain an internal ribosome entry site. APC orthologs[8] have also been identified in all mammals for which complete genome data are available.The full-length human protein comprises 2,843 amino acids with a (predicted) molecular mass of']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['311646 Da. Several N-terminal domains have been structurally elucidated in unique atomistic high-resolution complex structures. Most of the protein is predicted to be intrinsically disordered. It is not known if this large predicted unstructured region from amino acid 800 to 2843 persists in vivo or would form stabilised complexes – possibly with yet unidentified interacting proteins.[9] Recently, it has been experimentally confirmed that the mutation cluster region around the center of APC is intrinsically disordered in vitro.[10]The most common mutation in colon cancer is inactivation of APC. In absence of APC inactivating mutations, colon cancers commonly carry activating mutations in']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['beta catenin or inactivating mutations in RNF43.[11] Mutations in APC can be inherited, or arise sporadically in the somatic cells, often as the result of mutations in other genes that result in the inability to repair mutations in the DNA. In order for cancer to develop, both alleles (copies of the APC gene) must be mutated.  Mutations in APC or β-catenin must be followed by other mutations to become cancerous; however, in carriers of an APC-inactivating mutation, the risk of colorectal cancer by age 40 is almost 100%.[5]Familial adenomatous polyposis (FAP) is caused by an inherited, inactivating mutation in']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['the APC gene.[12] More than 800 mutations[citation needed] in the APC gene have been identified in families with classic and attenuated types of familial adenomatous polyposis. Most of these mutations cause the production of an APC protein that is abnormally short and presumably nonfunctional. This short protein cannot suppress the cellular overgrowth that leads to the formation of polyps, which can become cancerous. The most common mutation in familial adenomatous polyposis is a deletion of five bases in the APC gene. This mutation changes the sequence of amino acids in the resulting APC protein beginning at position 1309. Mutations in']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['the APC gene have also been found to lead to the development of desmoid tumors in FAP patients.[6]Another mutation is carried by approximately 6 percent[citation needed] of people of Ashkenazi (eastern and central European) Jewish heritage. This mutation results in the substitution of the amino acid lysine for isoleucine at position 1307 in the APC protein (also written as I1307K or Ile1307Lys). This change has been shown to be associated with an increased risk of colon cancer,[13] with moderate effect size.[14]  APC I1307K has also been implicated as a risk factor for certain other cancers.[14]The (Adenomatous Polyposis Coli) APC']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['protein normally builds a \"destruction complex\" with glycogen synthase kinase 3-alpha and or beta (GSK-3α/β) and Axin via interactions with the 20 AA and SAMP repeats.[15][16][17] This complex is then able to bind β-catenins in the cytoplasm, that have dissociated from adherens contacts between cells. With the help of casein kinase 1 (CK1), which carries out an initial phosphorylation of β-catenin, GSK-3β is able to phosphorylate β-catenin a second time. This targets β-catenin for ubiquitination and degradation by cellular proteasomes. This prevents it from translocating into the nucleus, where it acts as a transcription factor for proliferation genes.[18] APC is']}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': [\"also thought to be targeted to microtubules via the PDZ binding domain, stabilizing them.[19] The deactivation of the APC protein can take place after certain chain reactions in the cytoplasm are started, e.g. through the Wnt signals that destroy the conformation of the complex.[citation needed] In the nucleus it complexes with legless/BCL9, TCF, and Pygo.[citation needed]The ability of APC to bind β-catenin has been classically considered to be an integral part of the protein's mechanistic function in the destruction complex, along with binding to Axin through the SAMP repeats.[20]  These models have been substantiated by observations that common APC\"]}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': [\"loss of function mutations in the mutation cluster region often remove several β-catenin binding sites and SAMP repeats.  However, recent evidence from Yamulla and colleagues have directly tested those models and imply that APC's core mechanistic functions may not require direct binding to β-catenin, but necessitate interactions with Axin.[21]   The researchers hypothesized that APC's many β-catenin binding sites increase the protein's efficiency at destroying β-catenin, yet are not absolutely necessary for the protein's mechanistic function.  Further research is clearly necessary to elucidate the precise mechanistic function of APC in the destruction complex.Mutations in APC often occur\"]}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': [\"early on in cancers such as colon cancer.[9] Patients with familial adenomatous polyposis (FAP) have germline mutations, with 95% being nonsense/frameshift mutations leading to premature stop codons. 33% of mutations occur between amino acids 1061–1309. In somatic mutations, over 60% occur within a mutation cluster region (1286–1513), causing loss of axin-binding sites in all but one of the 20AA repeats. Mutations in APC lead to loss of β-catenin regulation, altered cell migration and chromosome instability.[11]Rosenberg et al. found that APC directs cholinergic synapse assembly between neurons, a finding with implications for autonomic neuropathies, for Alzheimer's disease, for age-related hearing loss,\"]}\n",
            "documents is  {'title': ['Adenomatous_polyposis_coli'], 'text': ['and for some forms of epilepsy and schizophrenia.[22] (29)APC (gene) has been shown to interact with:1deb: CRYSTAL STRUCTURE OF THE N-TERMINAL COILED COIL DOMAIN FROM APC1m5i: Crystal Structure of the coiled coil region 129-250 of the tumor suppressor gene product APC1th1: Beta-catenin in complex with a phosphorylated APC 20aa repeat fragment1v18: THE CRYSTAL STRUCTURE OF BETA-CATENIN ARMADILLO REPEAT COMPLEXED WITH A PHOSPHORYLATED APC 20MER REPEAT.']}\n",
            "documents is  {'title': ['ATOH1'], 'text': ['47411921ENSG00000172238ENSMUSG00000073043Q92858P48985NM_005172NM_007500NP_005163NP_031526Protein atonal homolog 1 is a protein that in humans is encoded by the ATOH1 gene.[5][6]This protein belongs to the basic helix-loop-helix (BHLH) family of transcription factors. It activates E-box dependent transcription along with TCF3 (E47).[6] ATOH1 is required for the formation of both neural and non-neural cell types. Using genetic deletion in mice, Atoh1 has been shown to be essential for formation of cerebellar granule neurons, inner ear hair cells, spinal cord interneurons, Merkel cells of the skin, and intestinal secretory cells (goblet, enteroendocrine, and Paneth cells). ATOH1 is a mammalian homolog of the Drosophila melanogaster gene atonal.']}\n",
            "documents is  {'title': ['ATOH1'], 'text': ['ATOH1 is considered part of the Notch signaling pathway.In 2009, ATOH1 was identified as a tumor suppressor gene. [7][8]This article incorporates text from the United States National Library of Medicine, which is in the public domain.This article on a gene on human chromosome 4 is a stub. You can help Wikipedia by expanding it.']}\n",
            "documents is  {'title': ['BCL10'], 'text': ['2MB9891512042ENSG00000142867ENSMUSG00000028191O95999Q9Z0H7NM_003921NM_001320715NM_009740NP_001307644NP_003912NP_001307644.1NP_033870B-cell lymphoma/leukemia 10 is a protein that in humans is encoded by the BCL10 gene.[5][6] Like BCL2, BCL3, BCL5, BCL6, BCL7A, and BCL9, it has clinical significance in lymphoma.Bcl10 was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to activate NF-κB. This protein is reported to interact with other CARD and coiled coil domain containing proteins including CARD9, -10, -11 and -14, which are thought to function as upstream regulators in NF-κB signaling. This protein is found to form']}\n",
            "documents is  {'title': ['BCL10'], 'text': ['a complex with the paracaspase MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and Bcl10 thought to synergize in the activation of NF-κB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.[6] Bcl10 is evolutionary conserved since cnidaria and has been shown to be functionally conserved all the way back to zebrafish.[7][8] Notably, just like the upstream CARD-CC family, Bcl10 is absent in insects and nematodes, and the correlated phylogenetic distribution of Bcl10 and CARD-CC proteins indicate a conserved complex.BCL10 has been shown']}\n",
            "documents is  {'title': ['BCL10'], 'text': ['to interact with:']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['1O6S, 2O72, 2OMT, 2OMU, 2OMV, 2OMX, 2OMY, 2OMZ, 3FF7, 3FF8, 3L6X, 3L6Y, 4ZT1, 4ZTE99912550ENSG00000039068ENSMUSG00000000303P12830P09803NM_004360NM_001317184NM_001317185NM_001317186NM_009864NP_001304113NP_001304114NP_001304115NP_004351NP_033994Cadherin-1 or Epithelial cadherin (E-cadherin), (not to be confused with the APC/C activator protein CDH1) is a protein that in humans is encoded by the CDH1 gene.[5] Mutations are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. CDH1 has also been designated as CD324 (cluster of differentiation 324). It is a tumor suppressor gene.[6][7]The discovery of cadherin cell-cell adhesion proteins is attributed to Masatoshi Takeichi, whose experience with adhering epithelial cells began in 1966.[8] His work originally began by studying lens differentiation in chicken embryos at']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['Nagoya University, where he explored how retinal cells regulate lens fiber differentiation. To do this, Takeichi initially collected media that had previously cultured neural retina cells (CM) and suspended lens epithelial cells in it. He observed that cells suspended in the CM media had delayed attachment compared to cells in his regular medium. His interest in cell adherence was sparked, and he moved on to examine attachment in other conditions such as in the presence of protein, magnesium, and calcium. At this point in 1970s, little was understood about the specific roles these ions played.[9] Therefore, Takeichi’s work in discovering']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['calcium’s role in cell-cell adhesion was highly transformative.[10][11]Takeichi went on to discover the existence of multiple cadherins, beginning with E-cadherin. Using rats immunized with F9 cells, he worked with an undergraduate student in the Okada laboratory, Noboru Suzuki, to generate mouse antibodies called ECCD1. This antibody blocked cell-adhesion ability and showed a calcium-dependent interaction with its antigen, E-cadherin.[12] They went on to find that ECCD1 reacted to a variety of epithelial cells when comparing antibody distributions.[13] The delay Takeichi experienced in specifically discovering Ecadherin was most likely due to the model he used to initially investigate cell adherence. The chinese']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['hamster V79 cells apparently did not express E-cadherin, but instead 20 other subtypes that have since been discovered.[14]Cadherin-1 is a classical member of the cadherin superfamily. The encoded protein is a calcium-dependent cell–cell adhesion glycoprotein composed of five extracellular cadherin repeats, a transmembrane region, and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells, and the cytoplasmic domain is required for internalization.']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['Identified transcript variants arise from mutation at consensus splice sites.[15]E-cadherin (epithelial) is the most well-studied member of the cadherin family and is an essential transmembrane protein within adherens junctions. In addition to E-cadherin, adherens junctions are composed of the intracellular components, p120-catenin, beta-catenin, and alpha-catenin.[16] Together, these proteins stabilize epithelial tissues and regulate intercellular exchange. The structure of E-cadherin consists of 5 cadherin repeats (EC1 ~ EC5) in the extracellular domain, one transmembrane domain, and a highly-phosphorylated intracellular domain. This region is vital to beta-catenin binding and, therefore, to E-cadherin function.[17] Beta-catenin can also bind to alpha-catenin. Alpha-catenin participates in']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['regulation of actin-containing cytoskeletal filaments. In epithelial cells, E-cadherin-containing cell-to-cell junctions are often adjacent to actin-containing filaments of the cytoskeleton.E-cadherin is first expressed in the 2-cell stage of mammalian development, and becomes phosphorylated by the 8-cell stage, where it causes compaction.[18] In adult tissues, E-cadherin is expressed in epithelial tissues, where it is constantly regenerated with a 5-hour half-life on the cell surface.[citation needed]  Cell–cell interactions mediated by E-cadherin are crucial to blastula formation in many animals.[19]E-cadherin has been known to mediate adhesion-dependent proliferation inhibition by triggering cell cycle exit via contact inhibition of proliferation (CIP) and recruitment of']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['the Hippo pathway.[20] E-cadherin adhesions inhibit growth signals, which initiates a kinase cascade that excludes the transcription factor YAP from the nucleus. Conversely, decreasing cell density (decreasing cell-cell adhesion) or applying mechanical stretch to place E-cadherins under increased tension promotes cell cycle entry and YAP nuclear localization.[21]E-cadherin has been found to have a role in epithelial morphogenesis and branching, such as during the formation of epithelial buds. Physiologically, branching is an important feature that allows tissues, such as salivary glands and pancreatic buds, to maximize functional surface areas.[22] It has been discovered that the application of appropriate growth factors and']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['extracellular matrix can induce branching in tissue, but the mechanisms of branching appear to differ between single-layered and stratified epithelium.[23][24]Single-layered branching occurs as nearby mechanical influences, such as airway smooth muscle cells, cause epithelial sheets buckle.[25] Stratified epithelial cannot respond to stimulus in the same way due to the absence of internal space (i.e. lumen) that allows tissue sheet flexibility.[26] Instead, it appears stratified epithelial buds are generated by the clefting of one original epithelial cell cluster. Investigations in salivary glands revealed that buds expand as new cells are uniformly distributed across the peripheral surface. Surface-derived cells continue to replicate']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['and produce daughter cells, which then move from the interior back to the surface. This movement is maintained by an E-cadherin gradient, in which surface cells have low levels of E-cadherin and interior cells have high levels of E-cadherin. Such a system allows for increased interactions between interior cells, limiting mobility and ensuring they remain more static, while likewise ensuring the surface cells are comparatively less hindered. This gives a fluidity to their movement within the stratified epithelia, until they begin to accumulate at the edges of the forming bud.[27]While this gradient is important for cell sorting within the tissue']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['layers, additional experiments show that the physical generation of buds is dependent on cell-matrix interactions[13]. As low-E-cadherin cells accumulate at the surface, they tightly adhere to the basement membrane, allowing the epithelia to cleft and bud as the surface area expands and folds. If the structure of the basement membrane is disrupted, such as by collagenase, the low-E-cadherin cells no longer have a barrier to interact with. Surface-derived daughter cells fail to remain at the periphery to initiate budding under these conditions, yet budding can be reestablished with basement membrane restoration.The adhesive qualities of E-cadherin indicate it could be a']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['relevant player within germ-layer organization during gastrulation. Gastrulation is a fundamental phase of vertebrate development in which three primary germ layers are defined, ectoderm, mesoderm, and endoderm.[28] Cell adhesion has been linked to progenitor sorting, where ectoderm was found to be the least cohesive and mesoderm was comparable to endoderm cohesion.[29] Initial work depleting calcium from media and, more strikingly, the impairment of E-cadherin both greatly impaired primary germ layer cohesion. As cohesive properties of progenitors were further examined, higher concentrations of CDH-1 were found on mesoderm or endoderm than on ectoderm. While adhesion is a factor in gastrulation, the']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['driving factor in cell sorting was instead found to be in cell-cortex tension[15]. Disrupting the actomyosin-dependent cell cortex with actin depolymerizers and myosin-II inhibitors interrupted impeded tension balances and was sufficient to inhibit cell sorting. This is likely because cell sorting is driven by energy minimization. WIthin tissue energetics, tension plays an important role in ensuring: (1) lower surface tension surrounds the higher surface tension germ layers; (2) aggregate surface tension is appropriately increased; and (3) tension is higher at the cell-to-medium interface than cell-to-cell interface[8]. Cellular adhesion must still be considered for a complete understanding of progenitor sorting, as']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['it directly\\xa0 diminishes the energetic effects of tension. Combined, tension and adhesion increase aggregate surface tension, which allows for unique interactions between differing germ layers and appropriate cell sorting.[30]Cell migration is vital for constructing and maintaining multicellular organization. Morphogenesis involves numerous events of cell migration, such as the migration of epithelial sheets in gastrulation, the neural crest cell migration, or posterior lateral line primordium migration.[31] It is known that cells that begin to internalize at the dorsal surface of the embryo mobilize to extend the axis and direct posterior prechordal plate and notochord precursors. How cells are able to orient']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['themselves during this process is dependent on the protrusions of “follower cells” to guide the leading cells in the appropriate direction.[32]E-cadherin has an active role in collective cell dynamics, such as by directing the migration of mesendoderm towards the animal pole.[33] It has been demonstrated that the genetic knockdown of E-cadherin results in random orientations of the cellular protrusions, resulting in cellular migration that is random and no longer unified.[34] Knockdowns in leading and following cell groups both resulted in a loss of orientation, which could be rescued by re-expressing E-cadherin. The information E-cadherin transmitted from cell to cell was']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['directional information inherent to cytoskeletal tension. Restoring only the external adhesion capability of E-cadherin was not enough to rescue protrusion orientation during knockdown experiments. The intracellular domain of E-cadherin is essential due to its mechanotransduction characteristics; it interacts with alpha-catenin and vinculin and altogether allows for the mechanosensation of tension.[35][36][37] The exact mechanism on how mechanosensation directs actin-rich protrusions is yet to be elucidated, however initial investigations suggest regulation of PI3K activity is involved.[38]Adherens junctions (AJs) form homotypic dimers between neighboring cells, where the intracellular protein complex interacts with the actomyosin cytoskeleton. p120-catenin controls E-cadherin membrane localization, while β-catenin and']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['α-catenin provide the link that connect AJs to the cytoskeleton. If AJs experience tensile force when β-catenin is bound, the interaction, known as a catch bond interaction, between α-catenin and F-actin is reinforced. This exposes the a previously inaccessible actin binding site within α-catenin.[39] The binding of vinculin to α-catenin offers the protein complex another linkage with actin in addition to recruiting proteins such as Mena/VASP.[40]Coordination of the actomyosin network between neighboring cells permits collective cellular activity, such as contractility during morphogenesis. This network is better equipped to maintain tissue integrity if under intercellular stress, but should not be considered']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['a static system. E-cadherin is involved in cellular responses and transcriptional activators that impact migration, growth, and reorganization.[41][42]E-cadherin interacts with its environment through numerous pathways. One mechanism that it is involved in is the migration of tissue sheets via cryptic lamellipodia. Rac1 and its effectors act at the front edge of this structure to initiate actin polymerization, allowing the cell to generate force at the cellular margin and forward movement.[43] As leader cells extend their lamellipodia, followers also extend protrusions to collect information on where the tissue sheet it moving. Cell migration is dependent on the generation of a polarized']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['state, with Rac1 at the front and Rho-mediated adhesion at the rear. The release of Merlin from cell contacts partially mediates concomitant migration by acting as a mechanochemical transducer.[44] This tumour suppressor protein relocalizes from cortical cell-cell junctions to the cytoplasm during migration to coordinate Rac1 activation. Other pathways can then modulate Merlin activity, such as circumferential actin belts, which suppresses the nuclear export of Merlin and its interaction with E-cadherin.[45]CDH1 (gene) has been shown to interact with Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis.[63][64]  E-cadherin downregulation decreases the strength of cellular']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.[64] E-cadherin is also used by pathologists to diagnose different kinds of breast cancer. When compared with invasive ductal carcinoma, E-cadherin expression is markedly reduced or absent in the great majority of invasive lobular carcinomas when studied by immunohistochemistry.[65] E-cadherin and N-cadherin temporal-spatial expression are tightly regulated during cranial suture fusion in craniofacial development.[66]Transitions between epithelial and mesenchymal states play important roles in embryonic development and cancer metastasis. E-cadherin level changes in EMT (epithelial-mesenchymal']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['transition) and MET (mesenchymal-epithelial transition). E-cadherin acts as an invasion suppressor and a classical tumor suppressor gene in pre-invasive lobular breast carcinoma.[67]E-cadherin is a crucial type of cell–cell adhesion to hold the epithelial cells tight together. E-cadherin can sequester β-catenin on the cell membrane by the cytoplasmic tail of E-cadherin. Loss of E-cadherin expression results in releasing β-catenin into the cytoplasm. Liberated β-catenin molecules may migrate into the nucleus and trigger the expression of EMT-inducing transcription factors. Together with other mechanisms, such as constitutive RTK activation, E-cadherin loss can lead cancer cells to the mesenchymal state and undergo metastasis. E-cadherin']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['is an important switch in EMT.[67]The mesenchymal state cancer cells migrate to new sites and may undergo METs in certain favorable microenvironment. For example, the cancer cells can recognize differentiated epithelial cell features in the new sites and upregulate E-cadherin expression. Those cancer cells can form cell–cell adhesions again and return to an epithelial state.[67]Several proteins such as SNAI1,[73][74] ZEB2,[75] SNAI2,[76][77] TWIST1[78] and ZEB1[79] have been found to downregulate E-cadherin expression. When expression of those transcription factors is altered, transcriptional repressors of E-cadherin were overexpressed in tumor cells. Another group of genes, such as AML1, p300 and HNF3,[80] can upregulate']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['the expression of E-cadherin.[81]In order to study the epigenetic regulation of E-cadherin, M Lombaerts et al. performed a genome wide expression study on 27 human mammary cell lines. Their results revealed two main clusters that have the fibroblastic or epithelial phenotype, respectively. In close examination, the clusters showing fibroblast phenotypes only have either partial or complete CDH1 promoter methylation, while the clusters with epithelial phenotypes have both wild-type cell lines and cell lines with mutant CDH1 status. The authors also found that EMT can happen in breast cancer cell lines with hypermethylation of CDH1 promoter, but in breast cancer cell']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['lines with a CDH1 mutational inactivation EMT cannot happen. It contradicts the hypothesis that E-cadherin loss is the initial or primary cause for EMT. In conclusion, the results suggest that “E-cadherin transcriptional inactivation is an epi-phenomenon and part of an entire program, with much more severe effects than loss of E-cadherin expression alone”.[81]Other studies also show that epigenetic regulation of E-cadherin expression occurs during metastasis. The methylation patterns of the E-cadherin 5’ CpG island are not stable. During metastatic progression of many cases of epithelial tumors, a transient loss of E-cadherin is seen and the heterogeneous loss of E-cadherin expression']}\n",
            "documents is  {'title': ['Cadherin-1'], 'text': ['results from a heterogeneous pattern of promoter region methylation of E-cadherin.[82]This article incorporates text from the United States National Library of Medicine, which is in the public domain.1i7w: BETA-CATENIN/PHOSPHORYLATED E-CADHERIN COMPLEX1i7x: BETA-CATENIN/E-CADHERIN COMPLEX1o6s: INTERNALIN (LISTERIA MONOCYTOGENES) / E-CADHERIN (HUMAN) RECOGNITION COMPLEX2omv: Crystal structure of InlA S192N Y369S/hEC1 complex2omy: Crystal structure of InlA S192N/hEC1 complex']}\n",
            "documents is  {'title': ['Capicua_(protein)'], 'text': ['2M41, 4J2J, 4J2L2315271722ENSG00000079432ENSMUSG00000005442Q96RK0Q924A2NM_001379485NM_001386298NM_001110131NM_001110132NM_027882NM_001302811NP_001366414NP_001289740NP_082158Capicua transcriptional repressor is a protein that in humans is encoded by the CIC gene.[5][6][7] Capicua functions as a transcriptional repressor in a way that ensures its impact on the progression of cancer, and plays a significant role in the operation of the central nervous system through its interaction with ataxin 1. The name of the protein derives from the Catalan expression cap-i-cua which literally translates to \"head-and-tail\".[8]Capicua is a highly conserved protein, with a lot of similarity between human and Drosophila melanogaster.[9] In the human body, capicua exists in two isoforms, the short (CIC-S) and the long']}\n",
            "documents is  {'title': ['Capicua_(protein)'], 'text': ['(CIC-L) one, which differ in their N-terminal section. The two evolutionarily conserved domains of the protein are HMG-box (high-mobility group box) and the C1 domain: they work together to recognize specific octameric DNA sequences.[9] Capicua also contains a nuclear localisation sequence that allows it to enter the nucleus of the cell. A new disorder called autosomal dominant intellectual developmental disorder 45 caused by mutations of the CIC gene was first described in 2017.[10]Capicua forms a complex with ataxin 1 (CIC-ATXN1 complex) and owing to this interaction it plays a crucial role in the development of spinocerebellar ataxia type 1. While']}\n",
            "documents is  {'title': ['Capicua_(protein)'], 'text': ['in a healthy organism this complex serves to ensure correct cellular function, in patients with ATXN1 mutations a modified complex has a toxic effect on cerebellar cells, resulting in the motor symptoms typical for this disorder.[9] Blocking the formation of the complex in a murine model of ataxia reduces the symptoms.CIC has been shown to act as a tumor suppressor in numerous types of cancer,[9] and, vice versa, mutations of CIC have been found in some types of tumors. According to a review published in 2020, CIC mutations were most often discovered in oligodendroglioma.[9] A genomic translocation resulting in the']}\n",
            "documents is  {'title': ['Capicua_(protein)'], 'text': ['formation of a hybrid CIC-DUX4 gene may cause an aggressive Ewing-like sarcoma.[11] Instead of acting as a suppressor, a hybrid protein produced by fusion of CIC and DUX4 has been shown to act as an activator of genes.[12]According to a review published in 2017, the CIC gene is deleted in 46-53% of analyzed oligodendroglioma tumors as part of the 1p/19q codeletion, a mutation that may also affect the FUBP1 gene.[13]According to a study published in 2021, CIC mutations may be among the causes of cerebral folate deficiency.[15]The CIC gene was first identified in Drosophila in 2000.[9] It was shown to']}\n",
            "documents is  {'title': ['Capicua_(protein)'], 'text': ['encode a transcriptional repressor participating in the regulation of embryogenesis. In a mutated fly which at the embryonic stage had only the first and the last segments present, with the intermediate segments missing, scientists discovered a mutation of the CIC gene, and this prompted them to call the protein capicua (\"head-and-tail\" in Catalan). This article on a gene on human chromosome 19 is a stub. You can help Wikipedia by expanding it.']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['2AST, 1H27, 1JSU102712576ENSG00000111276ENSMUSG00000003031P46527P46414NM_004064NM_009875NP_004055NP_034005Cyclin-dependent kinase inhibitor 1B (p27Kip1) is an enzyme inhibitor that in humans is encoded by the CDKN1B gene.[5] It encodes a protein which belongs to the Cip/Kip family of cyclin dependent kinase (Cdk) inhibitor proteins. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. It is often referred to as a cell cycle inhibitor protein because its major function is to stop or slow down the cell division cycle.The p27Kip1 gene has a DNA sequence similar to other members of the \"Cip/Kip\"']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['family which include the p21Cip1/Waf1 and p57Kip2 genes.  In addition to this structural similarity the \"Cip/Kip\" proteins share the functional characteristic of being able to bind several different classes of Cyclin and Cdk molecules.  For example, p27Kip1 binds to cyclin D either alone, or when complexed to its catalytic subunit CDK4.  In doing so p27Kip1 inhibits the catalytic activity of Cdk4, which means that it prevents Cdk4 from adding phosphate residues to its principal substrate, the retinoblastoma (pRb) protein.   Increased levels of the p27Kip1 protein typically cause cells to arrest in the G1 phase of']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['the cell cycle.  Likewise, p27Kip1 is able to bind other Cdk proteins when complexed to cyclin subunits such as Cyclin E/Cdk2 and Cyclin A/Cdk2.[6]In general, extracellular growth factors which promote cell division reduce transcription and translation of p27Kip1. Also, increased synthesis of CDk4,6/cyclin D causes binding of p27 to this complex, sequestering it from binding to the CDk2/cyclin E complex. Furthermore, an active CDK2/cyclin E complex will phosphorylate p27 and tag p27 for ubiquitination.[7]  A mutation of this gene may lead to loss of control over the cell cycle leading to uncontrolled cellular proliferation.[8][9][10] Loss of p27 expression']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': [\"has been observed in metastatic canine mammary carcinomas.[11][12][13] Decreased TGF-beta signalling has been suggested to cause loss of p27 expression in this tumor type.[14]A structured cis-regulatory element has been found in the 5' UTR of the P27 mRNA where it is thought to regulate translation relative to cell cycle progression.[15]P27 regulation is accomplished by two different mechanisms. In the first its concentration is changed by the individual rates of transcription, translation, and proteolysis. P27 can also be regulated by changing its subcellular location [16] Both mechanisms act to reduce levels of p27, allowing for the activation of Cdk1 and Cdk2,\"]}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['and for the cell to begin progressing through the cell cycle.Transcription of the CDKN1B gene is activated by Forkhead box class O family (FoxO) proteins which also acts downstream to promote p27 nuclear localization and decrease levels of COP9 subunit 5(COPS5) which helps in the degradation of p27.[17] Transcription for p27 is activated by FoxO in response to cytokines, promyelocytic leukaemia proteins, and nuclear Akt signaling.[17] P27 transcription has also been linked to another tumor suppressor gene, MEN1, in pancreatic islet cells where it promotes CDKN1B expression.[17]Translation of CDKN1B reaches its maximum during quiescence and early G1.[17] Translation is regulated']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['by polypyrimidine tract-binding protein(PTB), ELAVL1, ELAVL4, and microRNAs.[17] PTB acts by binding CDKN1b IRES to increase translation and when PTB levels decrease, G1 phase is shortened.[17] ELAVL1 and ELAVL4 also bind to CDKN1B IRES but they do so in order to decrease translation and so depletion of either results in G1 arrest.[17]Degradation of the p27 protein occurs as cells exit quiescence and enter G1.[17] Protein levels continue to fall rapidly as the cell continues through G1 and enters S phase. One of the most understood mechanisms for p27 proteolysis is the polyubiquitylation of p27 by the SCFSKP2  kinase associated']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['protein 1 (Skp1) and 2 (Skp2).[17] SKP1 and Skp2 degrades p27 after it has been phosphorylated at threonine 187 (Thr187) by either activating cyclin E- or cyclin A-CDK2.  Skp2 is mainly responsible for the degradation of p27 levels that continues through S phase.[18] However it is rarely expressed in early G1 where p27 levels first begin to decrease. During early G1 proteolysis of p27 is regulated by KIP1 Ubiquitylation Promoting Complex (KPC) which binds to its CDK inhibitory domain.[19] P27 also has three Cdk-inhibited tyrosines at residues 74, 88, and 89.[17] Of these, Tyr74 is of special interest because']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': [\"it is specific to p27-type inhibitors.[17]Alternatively to the transcription, translation, and proteolytic method of regulation, p27 levels can also be changed by exporting p27 to the cytoplasm. This occurs when p27 is phosphorylated on Ser(10) which allows for CRM1, a nuclear export carrier protein, to bind to and remove p27 from the nucleus.[20] Once p27 is excluded from the nucleus it cannot inhibit the cell's growth. In the cytoplasm it may be degraded entirely or retained.[16] This step occurs very early when the cell is exiting the quiescent phase and thus is independent of Skp2 degradation of p27.[20]Because p27 levels\"]}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['can be moderated at the translational level, it has been proposed that p27 may be regulated by miRNAs. Recent research has suggested that both miR-221 and miR-222 control p27 levels although the pathways are not well understood.[16]p27 is considered a tumor suppressor because of its function as a regulator of the cell cycle.[17] In cancers it is often inactivated via impaired synthesis, accelerated degradation, or mislocalization.[17] Inactivation of p27 is generally accomplished post-transcription by the oncogenic activation of various pathways including receptor tyrosine kinases (RTK), phosphatilidylinositol 3-kinase (PI3K), SRC, or Ras-mitogen activated protein kinase(MAPK).[17] These act to accelerate the proteolysis']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['of the p27 protein and allow the cancer cell to undergo rapid division and uncontrolled proliferation.[17] When p27 is phosphorylated by Src at tyrosine 74 or 88 it ceases to inhibit cyclinE-cdk2.[21] Src was also shown to reduce the half life of p27 meaning it is degraded faster.[21] Many epithelial cancers are known to overexpress EGFR which plays a role in the proteolysis of p27 and in Ras-driven proteolysis.[17] Non-epithelial cancers use different pathways to inactivate p27.[17] Many cancer cells also upregulate Skp2 which is known to play an active role in the proteolysis of p27[18] As a result, Skp2']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': [\"is inversely related to p27 levels and directly correlates with tumor grade in many malignancies.[18]In cancer cells, p27 can also be mislocalized to the cytoplasm in order to facilitate metastasis. The mechanisms by which it acts on motility differ between cancers. In hepatocellular carcinoma cells p27 co-localizes with actin fibers to act on GTPase Rac and induce cell migration.[22] In breast cancer cytoplasmic p27 reduced RHOA activity which increased a cell's propensity for motility.[23]This role for p27 may indicate why cancer cells rarely fully inactivate or delete p27. By retaining p27 in some capacity it can be exported to the\"]}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['cytoplasm during tumorigenesis and manipulated to aid in metastasis. 70% of metastatic melanomas were shown to exhibit cytoplasmic p27, while in benign melanomas p27 remained localized to the nucleus.[24] P27  is misplaced to the cytoplasm by the MAP2K, Ras, and Akt pathways although the mechanisms are not entirely understood.[25][26][27] Additionally, phosphorylation of p27 at T198 by RSK1 has been shown to mislocalize p27 to the cytoplasm as well as inhibit the RhoA pathway.[28] Because inhibition of RhoA results in a decrease in both stress fibers and focal adhesion, cell motility is increased.[29] P27 can also be exported to the']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['cytoplasm by oncogenic activation of the P13K pathway.[29]  Thus, mislocalization of p27 to the cytoplasm in cancer cells allows them to proliferate unchecked and provides for increased motility.In contrast to these results, p27 has also been shown to be an inhibitor of migration in sarcoma cells.[30] In these cells, p27 bound to stathmin which prevents stathmin from binding to tubulin and thus polymerization of microtubules increased and cell motility decreased.[30]Studies of various cell lines including glioblastoma cell lines, three prostate cancer cell lines, and a breast tumor cell line showed that suppressing miR-221 and miR-22 expression resulted in p27-dependent']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['G1 growth arrest[16] Then when p27 was knocked down, cell growth resumed indicating a strong role for miRNA regulated p27.[16] Studies in patients have demonstrated an inverse correlation between miR-221&22 and p27 protein levels. Additionally nearby healthy tissue showed high expression of the p27 protein while miR-221&22 concentrations were low.[16]In most cancers reduced levels of nuclear p27 are correlated with increased tumor size, increased tumor grade, and a higher propensity for metastasis. However the mechanisms by which levels of p27 are regulated vary between cancers.In breast cancer, Src activation has been shown to correlate with low levels of p27[21] Breast']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['cancers that were Estrogen receptor negative and progesterone receptor negative were more likely to display low levels of p27 and more likely to have a high tumor grade.[21] Similarly, breast cancer patients with BRCA1/2 mutations were more likely to have low levels of p27.[31]A mutation in the CDKN1B gene has been linked to an increased risk for hereditary prostate cancer in humans.[32]Mutations in the CDKN1B gene has been reported in families affected by the development of primary hyperparathyroidism and pituitary adenomas, and has been classified MEN4 (multiple endocrine neoplasia, type 4). Testing for CDKN1B mutations has been recommended in patients']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['with suspected MEN, in whom previous testing for, the more common MEN1/RET mutation, is negative.[33]Several studies have demonstrated that reduced p27 levels indicate a poorer patient prognosis.[17] However, because of the dual, contrasting roles p27 plays in cancer (as an inhibitor of growth and as a mechanism for metastasis) low levels of p27 may demonstrate that a cancer is not aggressive and will remain benign.[17]In ovarian cancer, p27 negative tumors progressed in 23 months compared to 85 months in p27 positive tumors and thus could be used as a prognostic marker.[34] Similar studies have correlated low levels of p27 with']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['a worse prognosis in breast cancer.[35] Colorectal carcinomas that lacked p27 were shown to have increased p27-specific proteolysis and a median survival of only 69 months compared to 151 months for patients with high or normal levels of p27.[36] The authors proposed clinicians could use patient specific levels of p27 to determine who would benefit from adjuvant therapy.[36] Similar correlations were observed in patients with non-small cell lung cancer,[37] those with colon,[37] and prostate cancer.[38]So far studies have only evaluated the prognostic value of p27 retrospectively and a standardized scoring system has not been established.[17] However it has been proposed']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': [\"that clinicians should evaluate a patient's p27 levels in order to determine if they will be responsive to certain chemotoxins which target fast growing tumors where p27 levels are low.[17] Or in contrast, if p27 levels are found to be high in a patient's cancer, their risk for metastasis is higher and the physician can make an informed decision about their treatment plan.[17] Because p27 levels are controlled post-transcriptionally, proteomic surveys can be used to establish and monitor a patient's individual levels which aids in the future of individualized medicine.The following cancers have been demonstrated to have an inverse correlation\"]}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['with p27 expression and prognosis: oro-pharyngo-laryngeal, oesophageal, gastric, colon, lung, melanoma, glioma, breast cancer, prostate, lymphoma, leukemia.[18]P27 may also allow clinicians to better select an appropriate treatment for a patient. For example, patients with non-small cell lung cancer who were treated with platinum based chemotherapy showed reduced survival if they had low levels of p27.[39]  Similarly low levels of p27 correlated with poor results from adjuvant chemotherapy in breast cancer patients.[40]P27 has been explored as a potential target for cancer therapy because its levels are highly correlated to patient prognosis.[41] This is true for a wide spectrum of cancers']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['including colon, breast, prostate, lung, liver, stomach, and bladder.[41]Because of the role miRNAs play in p27 regulation, research is underway to determine if antagomiRs that block the activity of the miR221&222 and allow for p27 cell grow inhibition to take place could act as therapeutic cancer drugs.[16]Knockdown of CDKN1B stimulates regeneration of cochlear hair cells in mice. Since CDKN1B prevents cells from entering the cell cycle, inhibition of the protein could cause re-entry and subsequent division. In mammals where regeneration of cochlear hair cells normally does not occur, this inhibition could help regrow damaged cells who are otherwise incapable of']}\n",
            "documents is  {'title': ['CDKN1B'], 'text': ['proliferation. In fact, when the CDKN1B gene is disrupted in adult mice, hair cells of the organ of Corti proliferate, while those in control mice do not. Lack of CDKN1B expression appears to release the hair cells from natural cell-cycle arrest.[42][43] Because hair cell death in the human cochlea is a major cause of hearing loss, the CDKN1B protein could be an important factor in the clinical treatment of deafness.CDKN1B has been shown to interact with:1jsu: P27(KIP1)/CYCLIN A/CDK2 COMPLEX']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['1GXC, 2CN5, 2CN8, 2W0J, 2W7X, 2WTC, 2WTD, 2XBJ, 2XM8, 2XM9, 2YCF, 2YCQ, 2YCR, 2YCS, 2YIQ, 2YIR, 2YIT, 3I6U, 3I6W, 4A9R, 4A9S, 4A9T, 4A9U, 4BDA, 4BDB, 4BDC, 4BDD, 4BDE, 4BDF, 4BDG, 4BDH, 4BDI, 4BDJ, 4BDK, 2WTI, 2WTJ, 2XK91120050883ENSG00000183765ENSMUSG00000029521O96017Q9Z265NM_001005735NM_001257387NM_007194NM_145862NM_001349956NM_016681NM_001363308NP_001005735NP_001244316NP_009125NP_665861NP_001336885NP_057890NP_001350237CHEK2 (Checkpoint kinase 2) is a tumor suppressor gene that encodes the protein CHK2, a serine-threonine kinase. CHK2 is involved in DNA repair, cell cycle arrest or apoptosis in response to DNA damage. Mutations to the CHEK2 gene have been linked to a wide range of cancers.[5]The CHEK2 gene is located on the long (q) arm of chromosome 22 at position 12.1. Its location']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['on chromosome 22 stretches from base pair 28,687,742 to base pair 28,741,904.[5]The CHEK2 protein encoded by the CHEK2 gene is a serine threonine kinase. The protein consists of 543 amino acids and the following domains:The SCD domain contains multiple SQ/TQ motifs that serve as sites for phosphorylation in response to DNA damage. The most notable and frequently phosphorylated site being Thr68.[6]CHK2 appears as a monomer in its inactive state. However, in the event of DNA damage SCD phosphorylation causes CHK2 dimerization. The phosphorylated Thr68 (located on the SCD) interacts with the FHA domain to form the dimer. After the protein']}\n",
            "documents is  {'title': ['CHEK2'], 'text': [\"dimerizes the KD is activated via autophosphorylation. Once the KD is activated the CHK2 dimer dissociates.[6]The CHEK2 gene encodes for checkpoint kinase 2 (CHK2), a protein that acts a tumor suppressor. CHK2 regulates cell division, and has the ability to prevent cells from dividing too rapidly or in an uncontrolled manner.[5]When DNA undergoes a double-strand break, CHK2 is activated. Specifically, DNA damage-activated phosphatidylinositol kinase family protein (PIKK) ATM phosphorylates site Thr68 and activates CHK2.[6] Once activated, CHK2 phosphorylates downstream targets including CDC25 phosphatases, responsible for dephosphorylating and activating the cyclin-dependent kinases (CDKs). Thus, CHK2's inhibition of the CDC25 phosphatases prevents\"]}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['entry of the cell into mitosis. Furthermore, the CHK2 protein interacts with several other proteins including p53 (p53). Stabilization of p53 by CHK2 leads to cell cycle arrest in phase G1. Furthermore, CHK2 is known to phosphorylate the cell-cycle transcription factor E2F1 and the promyelocytic leukemia protein (PML) involved in apoptosis (programmed cell death).[6]The CHK2 protein plays a critical role in the DNA damage checkpoint. Thus, mutations to the CHEK2 gene have been labeled as causes to a wide range of cancers.In 1999, genetic variations of CHEK2 were found to correspond to inherited cancer susceptibility.[7]Bell et al. (1999) discovered three']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['CHEK2 germline mutations among four Li–Fraumeni syndrome (LFS) and 18 Li–Fraumeni-like (LFL) families. Since the time of this discovery, two of the three variants (a deletion in the kinase domain in exon 10 and a missense mutation in the FHA domain in exon 3) have been linked to inherited susceptibility to breast as well as other cancers.[8]Beyond initial speculations, screening of LFS and LFL patients has revealed no or very rare individual missense variants in the CHEK2 gene. Additionally, the deletion in the kinase domain on exon 10 has been found rare among LFS/LFL patients. The evidence from these studies']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['has suggests that CHEK2 is not a predisposition gene to Li–Fraumeni syndrome.[8]Inherited mutations in the CHEK2 gene have been linked to certain cases of breast cancer. Most notably, the deletion of a single DNA nucleotide at position 1100 in exon 10 (1100delC) produces a nonfunctional version of the CHK2 protein, truncated at the kinase domain. The loss of normal CHK2 protein function leads to unregulated cell division, accumulated damage to DNA and in many cases, tumor development.[5] The CHEK2*1100del mutation is most commonly seen in individuals of Eastern and Northern European descent. Within these populations the CHEK2*1100delC mutation is seen']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['in 1 out of 100 to 1 out of 200 individuals. However, in North America the frequency drops to 1 out of 333 to 1 out of 500. The mutation is almost absent in Spain and India.[9] Studies show that a CHEK2 1100delC corresponds to a two-fold increased risk of breast cancer and a 10-fold increased risk of breast cancer in males.[10]A CHEK2 mutation known as the I157T variant to the FHA domain in exon 3 has also been linked to breast cancer but at a lower risk than the CHEK2*1100delC mutation. The estimated fraction of breast cancer attributed to']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['this variant is reported to be around 1.2% in the US.[8]Two more CHEK2 gene mutations, CHEK2*S428F, an amino-acid substitution to the kinase domain in exon 11 and CHEK2*P85L, an amino-acid substitution in the N-terminal region (exon 1) have been found in the Ashkenazi Jewish population.[9] Suggestion of a Hispanic founder mutation has also been described.[11]Mutations to CHEK2 have been found in hereditary and nonhereditary cases of cancer. Studies link the mutation to cases of prostate, lung, colon, kidney, and thyroid cancers. Links have also been drawn to certain brain tumors and osteosarcoma.[5]Unlike BRCA1 and BRCA2 mutations, CHEK2 mutations do not']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['appear to cause an elevated risk for ovarian cancer.[10] However, a large-effect genome-wide association for squamous lung cancer has been described for a rare variant in CHEK2 (p.Ile157Thr, rs17879961, OR = 0.38).[12]CHEK2 regulates cell cycle progression and spindle assembly during mouse oocyte maturation and early embryo development.[13][14] Although CHEK2 is a down stream effector of the ATM kinase that responds primarily to double-strand breaks it can also be activated by ATR (ataxia-telangiectasia and Rad3 related) kinase that responds primarily to single-strand breaks. In mice, CHEK2 is essential for DNA damage surveillance in female meiosis.  The response of oocytes to']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['DNA double-strand break damage involves a pathway hierarchy in which ATR kinase signals to CHEK2 which then activates p53 and p63 proteins.[15]In the fruit fly Drosophila, irradiation of germ line cells generates double-strand breaks that result in cell cycle arrest and apoptosis.  The Drosophila CHEK2 ortholog mnk and the p53 ortholog dp53 are required for much of the cell death observed in early oogenesis when oocyte selection and meiotic recombination occur.[16]CHEK2 has been shown to interact with:1gxc: FHA DOMAIN FROM HUMAN CHK2 KINASE IN COMPLEX WITH A SYNTHETIC PHOSPHOPEPTIDE2cn5: CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH ADP2cn8: CRYSTAL']}\n",
            "documents is  {'title': ['CHEK2'], 'text': ['STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH DEBROMOHYMENIALDISINEThis article incorporates text from the United States National Library of Medicine, which is in the public domain.']}\n",
            "documents is  {'title': ['Cyclin-dependent_kinase_inhibitor_1C'], 'text': ['1028n/aENSG00000273707ENSG00000129757n/aP49918n/aNM_000076NM_001122630NM_001122631NM_001362474NM_001362475n/aNP_000067NP_001116102NP_001116103NP_001349403NP_001349404n/aCyclin-dependent kinase inhibitor 1C (p57, Kip2), also known as CDKN1C, is a protein which in humans is encoded by the CDKN1C imprinted gene.[3]Cyclin-dependent kinase inhibitor 1C is a tight-binding inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation.  Mutations of CDKN1C are implicated in sporadic cancers and Beckwith-Wiedemann syndrome suggesting that it is a tumor suppressor candidate.[3]CDKN1C is a tumor suppressor human gene on chromosome 11 (11p15) and belongs to the cip/kip gene family. It encodes a cell cycle inhibitor that binds to G1 cyclin-CDK complexes.[4] Thus p57KIP2 causes arrest of the cell cycle in']}\n",
            "documents is  {'title': ['Cyclin-dependent_kinase_inhibitor_1C'], 'text': ['G1 phase.CDKN1C was found to lead to cancer cell dormancy; its gene expression is regulated through the activity of glucocorticoid receptors (GRs) through chromatin remodelling mediated by SWI/SNF.[5]Since it has been identified that mutation to this tumor suppressing gene can have dramatic effects in a newborn such as macroglossia there has been great research to determine the genetic significance. CDKN1C is prone to error during the process of gene imprinting. The process of gene imprinting is in concert with DNA methylation. This goes makes the gene become transcriptionally silent from the paternal side allowing the maternal gene to be active.[6]']}\n",
            "documents is  {'title': ['Cyclin-dependent_kinase_inhibitor_1C'], 'text': ['If this gene fails to be properly methylated, or obtains a mutation, there will be a lack of cell cycle suppression leading to the pediatric tumor growth.[7]Research methods for this gene have involved different sequencing methods such as Sanger Sequencing. This sequencing method is a three step process that involves PCR, Gel Electrophoresis, and computer analysis to determine DNA sequences.[8] Sequencing can be helpful in identifying base pair mutations. A study done to assess the phenotypic effects that mutations to this gene will have took genetic sequencing of a cohort of individuals known to be effected by a mutation on']}\n",
            "documents is  {'title': ['Cyclin-dependent_kinase_inhibitor_1C'], 'text': ['this gene. [9] In this study, they found 37 mutations associated with 38 different pedigrees. This went to prove that mutations to the CDKN1C on chromosome 11 would in fact have phenotypic effects on individuals. These effects are further discussed through the different clinical cases that can occur.A mutation of this gene may lead to loss of control over the cell cycle leading to uncontrolled cellular proliferation. p57KIP2 has been associated with Beckwith-Wiedemann syndrome (BWS) which is characterized by increased risk of tumor formation in childhood.[10] Loss-of-function mutations in this gene have also been shown associated to the IMAGe syndrome']}\n",
            "documents is  {'title': ['Cyclin-dependent_kinase_inhibitor_1C'], 'text': ['(Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia congenita, and Genital anomalies).[11]  Complete hydatidiform moles consist only of paternal DNA, and thus the cells lack p57 expression as the gene is paternally imprinted (silenced). Immuohistochemical stains for p57 can aid with the diagnosis of hydatidiform moles..[12]Cyclin-dependent kinase inhibitor 1C has been shown to interact with:']}\n",
            "documents is  {'title': ['DHX15'], 'text': ['166513204ENSG00000109606ENSMUSG00000029169O43143O35286NM_001358NM_001042620NM_007839NP_001349NP_001036085NP_031865Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 is an enzyme that in humans is encoded by the DHX15 gene.[5][6]The protein encoded by this gene is a putative ATP-dependent RNA helicase implicated in pre-mRNA splicing.[6] It may have tumor suppressor activity.[7]This article on a gene on human chromosome 4 is a stub. You can help Wikipedia by expanding it.']}\n",
            "documents is  {'title': ['Protein'], 'text': ['Proteins are large biomolecules and macromolecules that comprise one or more long chains of amino acid residues. Proteins perform a vast array of functions within organisms, including catalysing metabolic reactions, DNA replication, responding to stimuli, providing structure to cells and organisms, and transporting molecules from one location to another. Proteins differ from one another primarily in their sequence of amino acids, which is dictated by the nucleotide sequence of their genes, and which usually results in protein folding into a specific 3D structure that determines its activity.A linear chain of amino acid residues is called a polypeptide. A protein contains']}\n",
            "documents is  {'title': ['Protein'], 'text': ['at least one long polypeptide. Short polypeptides, containing less than 20–30 residues, are rarely considered to be proteins and are commonly called peptides. The individual amino acid residues are bonded together by peptide bonds and adjacent amino acid residues. The sequence of amino acid residues in a protein is defined by the sequence of a gene, which is encoded in the genetic code. In general, the genetic code specifies 20 standard amino acids; but in certain organisms the genetic code can include selenocysteine and—in certain archaea—pyrrolysine. Shortly after or even during synthesis, the residues in a protein are often chemically']}\n",
            "documents is  {'title': ['Protein'], 'text': [\"modified by post-translational modification, which alters the physical and chemical properties, folding, stability, activity, and ultimately, the function of the proteins. Some proteins have non-peptide groups attached, which can be called prosthetic groups or cofactors. Proteins can also work together to achieve a particular function, and they often associate to form stable protein complexes.Once formed, proteins only exist for a certain period and are then degraded and recycled by the cell's machinery through the process of protein turnover. A protein's lifespan is measured in terms of its half-life and covers a wide range. They can exist for minutes or years\"]}\n",
            "documents is  {'title': ['Protein'], 'text': ['with an average lifespan of 1–2 days in mammalian cells. Abnormal or misfolded proteins are degraded more rapidly either due to being targeted for destruction or due to being unstable.Like other biological macromolecules such as polysaccharides and nucleic acids, proteins are essential parts of organisms and participate in virtually every process within cells. Many proteins are enzymes that catalyse biochemical reactions and are vital to metabolism. Proteins also have structural or mechanical functions, such as actin and myosin in muscle and the proteins in the cytoskeleton, which form a system of scaffolding that maintains cell shape. Other proteins are important']}\n",
            "documents is  {'title': ['Protein'], 'text': ['in cell signaling, immune responses, cell adhesion, and the cell cycle. In animals, proteins are needed in the diet to provide the essential amino acids that cannot be synthesized. Digestion breaks the proteins down for metabolic use.Proteins may be purified from other cellular components using a variety of techniques such as ultracentrifugation, precipitation, electrophoresis, and chromatography; the advent of genetic engineering has made possible a number of methods to facilitate purification. Methods commonly used to study protein structure and function include immunohistochemistry, site-directed mutagenesis, X-ray crystallography, nuclear magnetic resonance and mass spectrometry.Proteins were recognized as a distinct class of biological']}\n",
            "documents is  {'title': ['Protein'], 'text': [\"molecules in the eighteenth century by Antoine Fourcroy and others, distinguished by the molecules' ability to coagulate or flocculate under treatments with heat or acid.[1] Noted examples at the time included albumin from egg whites, blood serum albumin, fibrin, and wheat gluten.Proteins were first described by the Dutch chemist Gerardus Johannes Mulder and named by the Swedish chemist Jöns Jacob Berzelius in 1838.[2][3] Mulder carried out elemental analysis of common proteins and found that nearly all proteins had the same empirical formula, C400H620N100O120P1S1.[4] He came to the erroneous conclusion that they might be composed of a single type of (very\"]}\n",
            "documents is  {'title': ['Protein'], 'text': ['large) molecule. The term \"protein\" to describe these molecules was proposed by Mulder\\'s associate Berzelius; protein is derived from the Greek word πρώτειος (proteios), meaning \"primary\",[5] \"in the lead\", or \"standing in front\",[6] + -in. Mulder went on to identify the products of protein degradation such as the amino acid leucine for which he found a (nearly correct) molecular weight of 131 Da.[4] Prior to \"protein\", other names were used, like \"albumins\" or \"albuminous materials\" (Eiweisskörper, in German).[7]Early nutritional scientists such as the German Carl von Voit believed that protein was the most important nutrient for maintaining the structure of']}\n",
            "documents is  {'title': ['Protein'], 'text': ['the body, because it was generally believed that \"flesh makes flesh.\"[8] Karl Heinrich Ritthausen extended known protein forms with the identification of glutamic acid. At the Connecticut Agricultural Experiment Station a detailed review of the vegetable proteins was compiled by Thomas Burr Osborne. Working with Lafayette Mendel and applying Liebig\\'s law of the minimum in feeding laboratory rats, the nutritionally essential amino acids were established. The work was continued and communicated by William Cumming Rose. The understanding of proteins as polypeptides came through the work of Franz Hofmeister and Hermann Emil Fischer in 1902.[9][10] The central role of proteins as']}\n",
            "documents is  {'title': ['Protein'], 'text': ['enzymes in living organisms was not fully appreciated until 1926, when James B. Sumner showed that the enzyme urease was in fact a protein.[11]The difficulty in purifying proteins in large quantities made them very difficult for early protein biochemists to study. Hence, early studies focused on proteins that could be purified in large quantities, e.g., those of blood, egg white, various toxins, and digestive/metabolic enzymes obtained from slaughterhouses. In the 1950s, the Armour Hot Dog Co. purified 1\\xa0kg of pure bovine pancreatic ribonuclease A and made it freely available to scientists; this gesture helped ribonuclease A become a major target']}\n",
            "documents is  {'title': ['Protein'], 'text': ['for biochemical study for the following decades.[4]Linus Pauling is credited with the successful prediction of regular protein secondary structures based on hydrogen bonding, an idea first put forth by William Astbury in 1933.[12] Later work by Walter Kauzmann on denaturation,[13][14] based partly on previous studies by Kaj Linderstrøm-Lang,[15] contributed an understanding of protein folding and structure mediated by hydrophobic interactions.The first protein to be sequenced was insulin, by Frederick Sanger, in 1949. Sanger correctly determined the amino acid sequence of insulin, thus conclusively demonstrating that proteins consisted of linear polymers of amino acids rather than branched chains, colloids, or cyclols.[16]']}\n",
            "documents is  {'title': ['Protein'], 'text': ['He won the Nobel Prize for this achievement in 1958.[17]With the development of X-ray crystallography, it became possible to sequence protein structures.[18] The first protein structures to be solved were hemoglobin by Max Perutz and myoglobin by John Kendrew, in 1958.[19][20] The use of computers and increasing computing power also supported the sequencing of complex proteins. In 1999, Roger Kornberg succeeded in sequencing the highly complex structure of RNA polymerase using high intensity X-rays from synchrotrons.[18]Since then, cryo-electron microscopy (cryo-EM) of large macromolecular assemblies[21] has been developed. Cryo-EM uses protein samples that are frozen rather than crystals, and beams of']}\n",
            "documents is  {'title': ['Protein'], 'text': ['electrons rather than x-rays. It causes less damage to the sample, allowing scientists to obtain more information and analyze larger structures.[18] Computational protein structure prediction of small protein domains[22] has also helped researchers to approach atomic-level resolution of protein structures.As of 2017[update], the Protein Data Bank has over 126,060 atomic-resolution structures of proteins.[23]The number of proteins encoded in a genome roughly corresponds to the number of genes (although there may be a significant number of genes that encode RNA of protein, e.g. ribosomal RNAs). Viruses typically encode a few to a few hundred proteins, archaea and bacteria a few hundred']}\n",
            "documents is  {'title': ['Protein'], 'text': ['to a few thousand, while eukaryotes typically encode a few thousand up to tens of thousands of proteins (see genome size for a list of examples).Most proteins consist of linear polymers built from series of up to 20 different L-α- amino acids. All proteinogenic amino acids possess common structural features, including an α-carbon to which an amino group, a carboxyl group, and a variable side chain are bonded. Only proline differs from this basic structure as it contains an unusual ring to the N-end amine group, which forces the CO–NH amide moiety into a fixed conformation.[24] The side chains of']}\n",
            "documents is  {'title': ['Protein'], 'text': ['the standard amino acids, detailed in the list of standard amino acids, have a great variety of chemical structures and properties; it is the combined effect of all of the amino acid side chains in a protein that ultimately determines its three-dimensional structure and its chemical reactivity.[25]The amino acids in a polypeptide chain are linked by peptide bonds. Once linked in the protein chain, an individual amino acid is called a residue, and the linked series of carbon, nitrogen, and oxygen atoms are known as the main chain or protein backbone.[26]:\\u200a19\\u200aThe peptide bond has two resonance forms that contribute some']}\n",
            "documents is  {'title': ['Protein'], 'text': ['double-bond character and inhibit rotation around its axis, so that the alpha carbons are roughly coplanar. The other two dihedral angles in the peptide bond determine the local shape assumed by the protein backbone.[26]:\\u200a31\\u200a The end with a free amino group is known as the N-terminus or amino terminus, whereas the end of the protein with a free carboxyl group is known as the C-terminus or carboxy terminus (the sequence of the protein is written from N-terminus to C-terminus, from left to right).The words protein, polypeptide, and peptide are a little ambiguous and can overlap in meaning. Protein is generally']}\n",
            "documents is  {'title': ['Protein'], 'text': ['used to refer to the complete biological molecule in a stable conformation, whereas peptide is generally reserved for a short amino acid oligomers often lacking a stable 3D structure. But the boundary between the two is not well defined and usually lies near 20–30 residues.[27] Polypeptide can refer to any single linear chain of amino acids, usually regardless of length, but often implies an absence of a defined conformation.Proteins can interact with many types of molecules, including with other proteins, with lipids, with carbohydrates, and with DNA.[28][29][26][30]It has been estimated that average-sized bacteria contain about 2 million proteins per cell']}\n",
            "documents is  {'title': ['Protein'], 'text': ['(e.g. E. coli and Staphylococcus aureus). Smaller bacteria, such as Mycoplasma or spirochetes contain fewer molecules, on the order of 50,000 to 1 million. By contrast, eukaryotic cells are larger and thus contain much more protein. For instance, yeast cells have been estimated to contain about 50 million proteins and human cells on the order of 1 to 3 billion.[31](see also: List of proteins in the human body) The concentration of individual protein copies ranges from a few molecules per cell up to 20 million.[32] Not all genes coding proteins are expressed in most cells and their number depends on,']}\n",
            "documents is  {'title': ['Protein'], 'text': ['for example, cell type and external stimuli. For instance, of the 20,000 or so proteins encoded by the human genome, only 6,000 are detected in lymphoblastoid cells.[33]Proteins are assembled from amino acids using information encoded in genes. Each protein has its own unique amino acid sequence that is specified by the nucleotide sequence of the gene encoding this protein. The genetic code is a set of three-nucleotide sets called codons and each three-nucleotide combination designates an amino acid, for example AUG (adenine–uracil–guanine) is the code for methionine. Because DNA contains four nucleotides, the total number of possible codons is 64;']}\n",
            "documents is  {'title': ['Protein'], 'text': ['hence, there is some redundancy in the genetic code, with some amino acids specified by more than one codon.[30]:\\u200a1002–42\\u200a Genes encoded in DNA are first transcribed into pre-messenger RNA (mRNA) by proteins such as RNA polymerase. Most organisms then process the pre-mRNA (also known as a primary transcript) using various forms of Post-transcriptional modification to form the mature mRNA, which is then used as a template for protein synthesis by the ribosome. In prokaryotes the mRNA may either be used as soon as it is produced, or be bound by a ribosome after having moved away from the nucleoid. In']}\n",
            "documents is  {'title': ['Protein'], 'text': ['contrast, eukaryotes make mRNA in the cell nucleus and then translocate it across the nuclear membrane into the cytoplasm, where protein synthesis then takes place. The rate of protein synthesis is higher in prokaryotes than eukaryotes and can reach up to 20 amino acids per second.[34]The process of synthesizing a protein from an mRNA template is known as translation. The mRNA is loaded onto the ribosome and is read three nucleotides at a time by matching each codon to its base pairing anticodon located on a transfer RNA molecule, which carries the amino acid corresponding to the codon it recognizes.']}\n",
            "documents is  {'title': ['Protein'], 'text': ['The enzyme aminoacyl tRNA synthetase \"charges\" the tRNA molecules with the correct amino acids. The growing polypeptide is often termed the nascent chain. Proteins are always biosynthesized from N-terminus to C-terminus.[30]:\\u200a1002–42\\u200aThe size of a synthesized protein can be measured by the number of amino acids it contains and by its total molecular mass, which is normally reported in units of daltons (synonymous with atomic mass units), or the derivative unit kilodalton (kDa). The average size of a protein increases from Archaea to Bacteria to Eukaryote (283, 311, 438 residues and 31, 34, 49 kDa respectively) due to a bigger number']}\n",
            "documents is  {'title': ['Protein'], 'text': ['of protein domains constituting proteins in higher organisms.[35] For instance, yeast proteins are on average 466 amino acids long and 53 kDa in mass.[27] The largest known proteins are the titins, a component of the muscle sarcomere, with a molecular mass of almost 3,000 kDa and a total length of almost 27,000 amino acids.[36]Short proteins can also be synthesized chemically by a family of methods known as peptide synthesis, which rely on organic synthesis techniques such as chemical ligation to produce peptides in high yield.[37] Chemical synthesis allows for the introduction of non-natural amino acids into polypeptide chains, such as']}\n",
            "documents is  {'title': ['Protein'], 'text': ['attachment of fluorescent probes to amino acid side chains.[38] These methods are useful in laboratory biochemistry and cell biology, though generally not for commercial applications. Chemical synthesis is inefficient for polypeptides longer than about 300 amino acids, and the synthesized proteins may not readily assume their native tertiary structure. Most chemical synthesis methods proceed from C-terminus to N-terminus, opposite the biological reaction.[39]Most\\xa0proteins fold into unique 3D structures. The shape into which a protein naturally folds is known as its native conformation.[26]:\\u200a36\\u200a Although many proteins can fold unassisted, simply through the chemical properties of their amino acids, others require the aid']}\n",
            "documents is  {'title': ['Protein'], 'text': ['of molecular chaperones to fold into their native states.[26]:\\u200a37\\u200a Biochemists often refer to four distinct aspects of a protein\\'s structure:[26]:\\u200a30–34\\u200aProteins are not entirely rigid molecules. In addition to these levels of structure, proteins may shift between several related structures while they perform their functions. In the context of these functional rearrangements, these tertiary or quaternary structures are usually referred to as \"conformations\", and transitions between them are called conformational changes. Such changes are often induced by the binding of a substrate molecule to an enzyme\\'s active site, or the physical region of the protein that participates in chemical catalysis. In']}\n",
            "documents is  {'title': ['Protein'], 'text': ['solution proteins also undergo variation in structure through thermal vibration and the collision with other molecules.[30]:\\u200a368–75\\u200aProteins can be informally divided into three main classes, which correlate with typical tertiary structures: globular proteins, fibrous proteins, and membrane proteins. Almost all globular proteins are soluble and many are enzymes. Fibrous proteins are often structural, such as collagen, the major component of connective tissue, or keratin, the protein component of hair and nails. Membrane proteins often serve as receptors or provide channels for polar or charged molecules to pass through the cell membrane.[30]:\\u200a165–85\\u200aA special case of intramolecular hydrogen bonds within proteins, poorly shielded']}\n",
            "documents is  {'title': ['Protein'], 'text': ['from water attack and hence promoting their own dehydration, are called dehydrons.[40]Many proteins are composed of several protein domains, i.e. segments of a protein that fold into distinct structural units. Domains usually also have specific functions, such as enzymatic activities (e.g. kinase) or they serve as binding modules (e.g. the SH3 domain binds to proline-rich sequences in other proteins).Short amino acid sequences within proteins often act as recognition sites for other proteins.[41] For instance, SH3 domains typically bind to short PxxP motifs (i.e. 2 prolines [P], separated by two unspecified amino acids [x], although the surrounding amino acids may determine']}\n",
            "documents is  {'title': ['Protein'], 'text': ['the exact binding specificity). Many such motifs has been collected in the Eukaryotic Linear Motif (ELM) database.Topology of a protein describes the entanglement of the backbone and the arrangement of contacts within the folded chain.[42] Two theoretical frameworks of knot theory and Circuit topology have been applied to characterise protein topology. Being able to describe protein topology opens up new pathways for protein engineering and pharmaceutical development, and adds to our understanding of protein misfolding diseases such as neuromuscular disorders and cancer.Proteins are the chief actors within the cell, said to be carrying out the duties specified by the information']}\n",
            "documents is  {'title': ['Protein'], 'text': ['encoded in genes.[27] With the exception of certain types of RNA, most other biological molecules are relatively inert elements upon which proteins act. Proteins make up half the dry weight of an Escherichia coli cell, whereas other macromolecules such as DNA and RNA make up only 3% and 20%, respectively.[43] The set of proteins expressed in a particular cell or cell type is known as its proteome.The chief characteristic of proteins that also allows their diverse set of functions is their ability to bind other molecules specifically and tightly. The region of the protein responsible for binding another molecule is']}\n",
            "documents is  {'title': ['Protein'], 'text': ['known as the binding site and is often a depression or \"pocket\" on the molecular surface. This binding ability is mediated by the tertiary structure of the protein, which defines the binding site pocket, and by the chemical properties of the surrounding amino acids\\' side chains. Protein binding can be extraordinarily tight and specific; for example, the ribonuclease inhibitor protein binds to human angiogenin with a sub-femtomolar dissociation constant (<10−15 M) but does not bind at all to its amphibian homolog onconase (>1 M). Extremely minor chemical changes such as the addition of a single methyl group to a binding']}\n",
            "documents is  {'title': ['Protein'], 'text': ['partner can sometimes suffice to nearly eliminate binding; for example, the aminoacyl tRNA synthetase specific to the amino acid valine discriminates against the very similar side chain of the amino acid isoleucine.[44]Proteins can bind to other proteins as well as to small-molecule substrates. When proteins bind specifically to other copies of the same molecule, they can oligomerize to form fibrils; this process occurs often in structural proteins that consist of globular monomers that self-associate to form rigid fibers. Protein–protein interactions also regulate enzymatic activity, control progression through the cell cycle, and allow the assembly of large protein complexes that carry']}\n",
            "documents is  {'title': ['Protein'], 'text': ['out many closely related reactions with a common biological function. Proteins can also bind to, or even be integrated into, cell membranes. The ability of binding partners to induce conformational changes in proteins allows the construction of enormously complex signaling networks.[30]:\\u200a830–49\\u200aAs interactions between proteins are reversible, and depend heavily on the availability of different groups of partner proteins to form aggregates that are capable to carry out discrete sets of function, study of the interactions between specific proteins is a key to understand important aspects of cellular function, and ultimately the properties that distinguish particular cell types.[45][46]The best-known role of']}\n",
            "documents is  {'title': ['Protein'], 'text': ['proteins in the cell is as enzymes, which catalyse chemical reactions. Enzymes are usually highly specific and accelerate only one or a few chemical reactions. Enzymes carry out most of the reactions involved in metabolism, as well as manipulating DNA in processes such as DNA replication, DNA repair, and transcription. Some enzymes act on other proteins to add or remove chemical groups in a process known as posttranslational modification. About 4,000 reactions are known to be catalysed by enzymes.[47] The rate acceleration conferred by enzymatic catalysis is often enormous—as much as 1017-fold increase in rate over the uncatalysed reaction in']}\n",
            "documents is  {'title': ['Protein'], 'text': ['the case of orotate decarboxylase (78 million years without the enzyme, 18 milliseconds with the enzyme).[48]The molecules bound and acted upon by enzymes are called substrates. Although enzymes can consist of hundreds of amino acids, it is usually only a small fraction of the residues that come in contact with the substrate, and an even smaller fraction—three to four residues on average—that are directly involved in catalysis.[49] The region of the enzyme that binds the substrate and contains the catalytic residues is known as the active site.Dirigent proteins are members of a class of proteins that dictate the stereochemistry of']}\n",
            "documents is  {'title': ['Protein'], 'text': ['a compound synthesized by other enzymes.[50]Many proteins are involved in the process of cell signaling and signal transduction. Some proteins, such as insulin, are extracellular proteins that transmit a signal from the cell in which they were synthesized to other cells in distant tissues. Others are membrane proteins that act as receptors whose main function is to bind a signaling molecule and induce a biochemical response in the cell. Many receptors have a binding site exposed on the cell surface and an effector domain within the cell, which may have enzymatic activity or may undergo a conformational change detected by']}\n",
            "documents is  {'title': ['Protein'], 'text': [\"other proteins within the cell.[29]:\\u200a251–81\\u200aAntibodies are protein components of an adaptive immune system whose main function is to bind antigens, or foreign substances in the body, and target them for destruction. Antibodies can be secreted into the extracellular environment or anchored in the membranes of specialized B cells known as plasma cells. Whereas enzymes are limited in their binding affinity for their substrates by the necessity of conducting their reaction, antibodies have no such constraints. An antibody's binding affinity to its target is extraordinarily high.[30]:\\u200a275–50\\u200aMany ligand transport proteins bind particular small biomolecules and transport them to other locations in the\"]}\n",
            "documents is  {'title': ['Protein'], 'text': ['body of a multicellular organism. These proteins must have a high binding affinity when their ligand is present in high concentrations, but must also release the ligand when it is present at low concentrations in the target tissues. The canonical example of a ligand-binding protein is haemoglobin, which transports oxygen from the lungs to other organs and tissues in all vertebrates and has close homologs in every biological kingdom.[30]:\\u200a222–29\\u200a Lectins are sugar-binding proteins which are highly specific for their sugar moieties. Lectins typically play a role in biological recognition phenomena involving cells and proteins.[51] Receptors and hormones are highly specific']}\n",
            "documents is  {'title': ['Protein'], 'text': ['binding proteins.Transmembrane proteins can also serve as ligand transport proteins that alter the permeability of the cell membrane to small molecules and ions. The membrane alone has a hydrophobic core through which polar or charged molecules cannot diffuse. Membrane proteins contain internal channels that allow such molecules to enter and exit the cell. Many ion channel proteins are specialized to select for only a particular ion; for example, potassium and sodium channels often discriminate for only one of the two ions.[29]:\\u200a232–34\\u200aStructural proteins confer stiffness and rigidity to otherwise-fluid biological components. Most structural proteins are fibrous proteins; for example, collagen and']}\n",
            "documents is  {'title': ['Protein'], 'text': ['elastin are critical components of connective tissue such as cartilage, and keratin is found in hard or filamentous structures such as hair, nails, feathers, hooves, and some animal shells.[30]:\\u200a178–81\\u200a Some globular proteins can also play structural functions, for example, actin and tubulin are globular and soluble as monomers, but polymerize to form long, stiff fibers that make up the cytoskeleton, which allows the cell to maintain its shape and size.Other proteins that serve structural functions are motor proteins such as myosin, kinesin, and dynein, which are capable of generating mechanical forces. These proteins are crucial for cellular motility of single']}\n",
            "documents is  {'title': ['Protein'], 'text': ['celled organisms and the sperm of many multicellular organisms which reproduce sexually. They also generate the forces exerted by contracting muscles[30]:\\u200a258–64,\\u200a272\\u200a and play essential roles in intracellular transport.A key question in molecular biology is how proteins evolve, i.e. how can mutations (or rather changes in amino acid sequence) lead to new structures and functions? Most amino acids in a protein can be changed without disrupting activity or function, as can be seen from numerous homologous proteins across species (as collected in specialized databases for protein families, e.g. PFAM).[52] In order to prevent dramatic consequences of mutations, a gene may be']}\n",
            "documents is  {'title': ['Protein'], 'text': ['duplicated before it can mutate freely. However, this can also lead to complete loss of gene function and thus pseudo-genes.[53] More commonly, single amino acid changes have limited consequences although some can change protein function substantially, especially in enzymes. For instance, many enzymes can change their substrate specificity by one or a few mutations.[54] Changes in substrate specificity are facilitated by substrate promiscuity, i.e. the ability of many enzymes to bind and process multiple substrates. When mutations occur, the specificity of an enzyme can increase (or decrease) and thus its enzymatic activity.[54] Thus, bacteria (or other organisms) can adapt to']}\n",
            "documents is  {'title': ['Protein'], 'text': [\"different food sources, including unnatural substrates such as plastic.[55]The activities and structures of proteins may be examined in vitro, in vivo, and in silico. In vitro studies of purified proteins in controlled environments are useful for learning how a protein carries out its function: for example, enzyme kinetics studies explore the chemical mechanism of an enzyme's catalytic activity and its relative affinity for various possible substrate molecules. By contrast, in vivo experiments can provide information about the physiological role of a protein in the context of a cell or even a whole organism. In silico studies use computational methods to\"]}\n",
            "documents is  {'title': ['Protein'], 'text': [\"study proteins.To perform in vitro analysis, a protein must be purified away from other cellular components. This process usually begins with cell lysis, in which a cell's membrane is disrupted and its internal contents released into a solution known as a crude lysate. The resulting mixture can be purified using ultracentrifugation, which fractionates the various cellular components into fractions containing soluble proteins; membrane lipids and proteins; cellular organelles, and nucleic acids. Precipitation by a method known as salting out can concentrate the proteins from this lysate. Various types of chromatography are then used to isolate the protein or proteins of\"]}\n",
            "documents is  {'title': ['Protein'], 'text': [\"interest based on properties such as molecular weight, net charge and binding affinity.[26]:\\u200a21–24\\u200a The level of purification can be monitored using various types of gel electrophoresis if the desired protein's molecular weight and isoelectric point are known, by spectroscopy if the protein has distinguishable spectroscopic features, or by enzyme assays if the protein has enzymatic activity. Additionally, proteins can be isolated according to their charge using electrofocusing.[56]For natural proteins, a series of purification steps may be necessary to obtain protein sufficiently pure for laboratory applications. To simplify this process, genetic engineering is often used to add chemical features to proteins\"]}\n",
            "documents is  {'title': ['Protein'], 'text': ['that make them easier to purify without affecting their structure or activity. Here, a \"tag\" consisting of a specific amino acid sequence, often a series of histidine residues (a \"His-tag\"), is attached to one terminus of the protein. As a result, when the lysate is passed over a chromatography column containing nickel, the histidine residues ligate the nickel and attach to the column while the untagged components of the lysate pass unimpeded. A number of different tags have been developed to help researchers purify specific proteins from complex mixtures.[57]The study of proteins in vivo is often concerned with the synthesis']}\n",
            "documents is  {'title': ['Protein'], 'text': ['and localization of the protein within the cell. Although many intracellular proteins are synthesized in the cytoplasm and membrane-bound or secreted proteins in the endoplasmic reticulum, the specifics of how proteins are targeted to specific organelles or cellular structures is often unclear. A useful technique for assessing cellular localization uses genetic engineering to express in a cell a fusion protein or chimera consisting of the natural protein of interest linked to a \"reporter\" such as green fluorescent protein (GFP).[58] The fused protein\\'s position within the cell can be cleanly and efficiently visualized using microscopy,[59] as shown in the figure opposite.Other']}\n",
            "documents is  {'title': ['Protein'], 'text': ['methods for elucidating the cellular location of proteins requires the use of known compartmental markers for regions such as the ER, the Golgi, lysosomes or vacuoles, mitochondria, chloroplasts, plasma membrane, etc. With the use of fluorescently tagged versions of these markers or of antibodies to known markers, it becomes much simpler to identify the localization of a protein of interest. For example, indirect immunofluorescence will allow for fluorescence colocalization and demonstration of location. Fluorescent dyes are used to label cellular compartments for a similar purpose.[60]Other possibilities exist, as well. For example, immunohistochemistry usually uses an antibody to one or more']}\n",
            "documents is  {'title': ['Protein'], 'text': ['proteins of interest that are conjugated to enzymes yielding either luminescent or chromogenic signals that can be compared between samples, allowing for localization information. Another applicable technique is cofractionation in sucrose (or other material) gradients using isopycnic centrifugation.[61] While this technique does not prove colocalization of a compartment of known density and the protein of interest, it does increase the likelihood, and is more amenable to large-scale studies.Finally, the gold-standard method of cellular localization is immunoelectron microscopy. This technique also uses an antibody to the protein of interest, along with classical electron microscopy techniques. The sample is prepared for normal']}\n",
            "documents is  {'title': ['Protein'], 'text': ['electron microscopic examination, and then treated with an antibody to the protein of interest that is conjugated to an extremely electro-dense material, usually gold. This allows for the localization of both ultrastructural details as well as the protein of interest.[62]Through another genetic engineering application known as site-directed mutagenesis, researchers can alter the protein sequence and hence its structure, cellular localization, and susceptibility to regulation. This technique even allows the incorporation of unnatural amino acids into proteins, using modified tRNAs,[63] and may allow the rational design of new proteins with novel properties.[64]The total complement of proteins present at a time in']}\n",
            "documents is  {'title': ['Protein'], 'text': ['a cell or cell type is known as its proteome, and the study of such large-scale data sets defines the field of proteomics, named by analogy to the related field of genomics. Key experimental techniques in proteomics include 2D electrophoresis,[65] which allows the separation of many proteins, mass spectrometry,[66] which allows rapid high-throughput identification of proteins and sequencing of peptides (most often after in-gel digestion), protein microarrays, which allow the detection of the relative levels of the various proteins present in a cell, and two-hybrid screening, which allows the systematic exploration of protein–protein interactions.[67] The total complement of biologically possible']}\n",
            "documents is  {'title': ['Protein'], 'text': ['such interactions is known as the interactome.[68] A systematic attempt to determine the structures of proteins representing every possible fold is known as structural genomics.[69]Discovering the tertiary structure of a protein, or the quaternary structure of its complexes, can provide important clues about how the protein performs its function and how it can be affected, i.e. in drug design. As proteins are too small to be seen under a light microscope, other methods have to be employed to determine their structure. Common experimental methods include X-ray crystallography and NMR spectroscopy, both of which can produce structural information at atomic resolution.']}\n",
            "documents is  {'title': ['Protein'], 'text': ['However, NMR experiments are able to provide information from which a subset of distances between pairs of atoms can be estimated, and the final possible conformations for a protein are determined by solving a distance geometry problem. Dual polarisation interferometry is a quantitative analytical method for measuring the overall protein conformation and conformational changes due to interactions or other stimulus. Circular dichroism is another laboratory technique for determining internal β-sheet / α-helical composition of proteins. Cryoelectron microscopy is used to produce lower-resolution structural information about very large protein complexes, including assembled viruses;[29]:\\u200a340–41\\u200a a variant known as electron crystallography can also']}\n",
            "documents is  {'title': ['Protein'], 'text': ['produce high-resolution information in some cases, especially for two-dimensional crystals of membrane proteins.[70] Solved structures are usually deposited in the Protein Data Bank (PDB), a freely available resource from which structural data about thousands of proteins can be obtained in the form of Cartesian coordinates for each atom in the protein.[71]Many more gene sequences are known than protein structures. Further, the set of solved structures is biased toward proteins that can be easily subjected to the conditions required in X-ray crystallography, one of the major structure determination methods. In particular, globular proteins are comparatively easy to crystallize in preparation for']}\n",
            "documents is  {'title': ['Protein'], 'text': ['X-ray crystallography. Membrane proteins and large protein complexes, by contrast, are difficult to crystallize and are underrepresented in the PDB.[72] Structural genomics initiatives have attempted to remedy these deficiencies by systematically solving representative structures of major fold classes. Protein structure prediction methods attempt to provide a means of generating a plausible structure for proteins whose structures have not been experimentally determined.[73]Complementary to the field of structural genomics, protein structure prediction develops efficient mathematical models of proteins to computationally predict the molecular formations in theory, instead of detecting structures with laboratory observation.[74] The most successful type of structure prediction, known as']}\n",
            "documents is  {'title': ['Protein'], 'text': ['homology modeling, relies on the existence of a \"template\" structure with sequence similarity to the protein being modeled; structural genomics\\' goal is to provide sufficient representation in solved structures to model most of those that remain.[75] Although producing accurate models remains a challenge when only distantly related template structures are available, it has been suggested that sequence alignment is the bottleneck in this process, as quite accurate models can be produced if a \"perfect\" sequence alignment is known.[76] Many structure prediction methods have served to inform the emerging field of protein engineering, in which novel protein folds have already been']}\n",
            "documents is  {'title': ['Protein'], 'text': ['designed.[77] Also proteins (in eukaryotes ~33%) contain large unstructured but biologically functional segments and can be classified as intrinsically disordered proteins.[78] Predicting and analysing protein disorder is, therefore, an important part of protein structure characterisation.[79]A vast array of computational methods have been developed to analyze the structure, function and evolution of proteins. The development of such tools has been driven by the large amount of genomic and proteomic data available for a variety of organisms, including the human genome. It is simply impossible to study all proteins experimentally, hence only a few are subjected to laboratory experiments while computational tools']}\n",
            "documents is  {'title': ['Protein'], 'text': ['are used to extrapolate to similar proteins. Such homologous proteins can be efficiently identified in distantly related organisms by sequence alignment. Genome and gene sequences can be searched by a variety of tools for certain properties. Sequence profiling tools can find restriction enzyme sites, open reading frames in nucleotide sequences, and predict secondary structures. Phylogenetic trees can be constructed and evolutionary hypotheses developed using special software like ClustalW regarding the ancestry of modern organisms and the genes they express. The field of bioinformatics is now indispensable for the analysis of genes and proteins.A more complex computational problem is the prediction']}\n",
            "documents is  {'title': ['Protein'], 'text': ['of intermolecular interactions, such as in molecular docking,[80] protein folding, protein–protein interaction and chemical reactivity. Mathematical models to simulate these dynamical processes involve molecular mechanics, in particular, molecular dynamics. In this regard, in silico simulations discovered the folding of small α-helical protein domains such as the villin headpiece,[81] the HIV accessory protein[82] and hybrid methods combining standard molecular dynamics with quantum mechanical mathematics have explored the electronic states of rhodopsins.[83]Beyond classical molecular dynamics, quantum dynamics methods allow the simulation of proteins in atomistic detail with an accurate description of quantum mechanical effects. Examples include the multi-layer multi-configuration time-dependent Hartree (MCTDH)']}\n",
            "documents is  {'title': ['Protein'], 'text': ['method and the hierarchical equations of motion (HEOM) approach, which have been applied to plant cryptochromes[84] and bacteria light-harvesting complexes,[85] respectively. Both quantum and classical mechanical simulations of biological-scale systems are extremely computationally demanding, so distributed computing initiatives (for example, the Folding@home project[86]) facilitate the molecular modeling by exploiting advances in GPU parallel processing and Monte Carlo techniques.The total nitrogen content of organic matter is mainly formed by the amino groups in proteins. The Total Kjeldahl Nitrogen (TKN) is a measure of nitrogen widely used in the analysis of (waste) water, soil, food, feed and organic matter in general. As']}\n",
            "documents is  {'title': ['Protein'], 'text': ['the name suggests, the Kjeldahl method is applied. More sensitive methods are available.[87][88]Most microorganisms and plants can biosynthesize all 20 standard amino acids, while animals (including humans) must obtain some of the amino acids from the diet.[43] The amino acids that an organism cannot synthesize on its own are referred to as essential amino acids. Key enzymes that synthesize certain amino acids are not present in animals—such as aspartokinase, which catalyses the first step in the synthesis of lysine, methionine, and threonine from aspartate. If amino acids are present in the environment, microorganisms can conserve energy by taking up the']}\n",
            "documents is  {'title': ['Protein'], 'text': [\"amino acids from their surroundings and downregulating their biosynthetic pathways.In animals, amino acids are obtained through the consumption of foods containing protein. Ingested proteins are then broken down into amino acids through digestion, which typically involves denaturation of the protein through exposure to acid and hydrolysis by enzymes called proteases. Some ingested amino acids are used for protein biosynthesis, while others are converted to glucose through gluconeogenesis, or fed into the citric acid cycle. This use of protein as a fuel is particularly important under starvation conditions as it allows the body's own proteins to be used to support life,\"]}\n",
            "documents is  {'title': ['Protein'], 'text': ['particularly those found in muscle.[89]In animals such as dogs and cats, protein maintains the health and quality of the skin by promoting hair follicle growth and keratinization, and thus reducing the likelihood of skin problems producing malodours.[90] Poor-quality proteins also have a role regarding gastrointestinal health, increasing the potential for flatulence and odorous compounds in dogs because when proteins reach the colon in an undigested state, they are fermented producing hydrogen sulfide gas, indole, and skatole.[91] Dogs and cats digest animal proteins better than those from plants, but products of low-quality animal origin are poorly digested, including skin, feathers, and']}\n",
            "documents is  {'title': ['Protein'], 'text': ['connective tissue.[91]']}\n",
            "after map\n",
            "Title: title\n",
            "Text: text\n",
            "\n",
            "Title: BRCA_mutation\n",
            "Text: A BRCA mutation is a mutation in either of the BRCA1 and BRCA2 genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, while others have no proven impact. Harmful mutations in these genes may produce a hereditary breast–ovarian cancer syndrome in affected persons. Only 5–10% of breast cancer cases in women are attributed to BRCA1 and BRCA2 mutations (with BRCA1 mutations being slightly more common than BRCA2 mutations), but the impact on women with the gene mutation is more profound.[2] Women with\n",
            "\n",
            "Title: BRCA_mutation\n",
            "Text: harmful mutations in either BRCA1 or BRCA2 have a risk of breast cancer that is about five times the normal risk, and a risk of ovarian cancer that is about ten to thirty times normal.[3] The risk of breast and ovarian cancer is higher for women with a high-risk BRCA1 mutation than with a BRCA2 mutation. Having a high-risk mutation does not guarantee that the woman will develop any type of cancer, or imply that any cancer that appears was actually caused by the mutation, rather than some other factor.High-risk mutations, which disable an important error-free DNA repair process (homology\n",
            "\n",
            "Title: BRCA_mutation\n",
            "Text: directed repair), significantly increase the person's risk of developing breast cancer, ovarian cancer and certain other cancers. Why BRCA1 and BRCA2 mutations lead preferentially to cancers of the breast and ovary is not known, but lack of BRCA1 function seems to lead to non-functional X-chromosome inactivation. Not all mutations are high-risk; some appear to be harmless variations.  The cancer risk associated with any given mutation varies significantly and depends on the exact type and location of the mutation and possibly other individual factors.Mutations can be inherited from either parent and may be passed on to both sons and daughters.\n",
            "\n",
            "Title: BRCA_mutation\n",
            "Text: Each child of a genetic carrier, regardless of sex, has a 50% chance of inheriting the mutated gene from the parent who carries the mutation. As a result, half of the people with BRCA gene mutations are male, who would then pass the mutation on to 50% of their offspring, male or female.  The risk of BRCA-related breast cancers for men with the mutation is higher than for other men, but still low.[4] However, BRCA mutations can increase the risk of other cancers, such as colon cancer, pancreatic cancer, and prostate cancer.Methods to diagnose the likelihood of a\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Saving the dataset (0/1 shards):   0%|          | 0/294 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8efb25ea71a64177a3251845e7f61875"
            }
          },
          "metadata": {}
        }
      ],
      "source": [
        "\n",
        "######################################\n",
        "logger.info(\"Step 1 - Create the dataset\")\n",
        "######################################\n",
        "\n",
        "# The dataset needed for RAG must have three columns:\n",
        "# - title (string): title of the document\n",
        "# - text (string): text of a passage of the document\n",
        "# - embeddings (array of dimension d): DPR representation of the passage\n",
        "\n",
        "# Let's say you have documents in tab-separated csv files with columns \"title\" and \"text\"\n",
        "assert os.path.isfile(rag_args.csv_path), \"Please provide a valid path to a csv file\"\n",
        "\n",
        "# You can load a Dataset object this way\n",
        "dataset = load_dataset(\n",
        "    \"csv\", data_files=[rag_args.csv_path], split=\"train\", delimiter=\"\\t\", column_names=[\"title\", \"text\"]\n",
        ")\n",
        "\n",
        "# print(\"csv dataset load\")\n",
        "# print_dataset(dataset)\n",
        "\n",
        "# More info about loading csv files in the documentation: https://huggingface.co/docs/datasets/loading_datasets.html?highlight=csv#csv-files\n",
        "\n",
        "# Then split the documents into passages of 100 words\n",
        "dataset = dataset.map(split_documents, batched=True, num_proc=processing_args.num_proc)\n",
        "\n",
        "# And compute the embeddings\n",
        "# tokenizer = DPRContextEncoderTokenizer.from_pretrained(\"facebook/dpr-ctx_encoder-multiset-base\") #ctx_tokenizer\n",
        "# model = DPRContextEncoder.from_pretrained(\"facebook/dpr-ctx_encoder-multiset-base\") #ctx_encoder\n",
        "# input_ids = tokenizer(\"Hello, is my dog cute ?\", return_tensors=\"pt\")[\"input_ids\"]\n",
        "# embeddings = model(input_ids).pooler_output\n",
        "# embeddings\n",
        "\n",
        "# And compute the embeddings\n",
        "ctx_encoder = DPRContextEncoder.from_pretrained(rag_args.dpr_ctx_encoder_model_name).to(device=device)\n",
        "ctx_tokenizer = DPRContextEncoderTokenizerFast.from_pretrained(rag_args.dpr_ctx_encoder_model_name)\n",
        "new_features = Features(\n",
        "    {\"text\": Value(\"string\"), \"title\": Value(\"string\"), \"embeddings\": Sequence(Value(\"float32\"))}\n",
        ")  # optional, save as float32 instead of float64 to save space\n",
        "dataset = dataset.map(\n",
        "    partial(embed, ctx_encoder=ctx_encoder, ctx_tokenizer=ctx_tokenizer),\n",
        "    batched=True,\n",
        "    batch_size=processing_args.batch_size,\n",
        "    features=new_features,\n",
        ")\n",
        "\n",
        "\n",
        "print(\"after map\")\n",
        "print_dataset(dataset)\n",
        "\n",
        "# And finally save your dataset\n",
        "passages_path = os.path.join(rag_args.output_dir, \"my_knowledge_dataset\")\n",
        "dataset.save_to_disk(passages_path)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 100,
      "id": "96051c6d-7141-476e-9115-d24abbceea86",
      "metadata": {
        "id": "96051c6d-7141-476e-9115-d24abbceea86"
      },
      "outputs": [],
      "source": [
        "# #debug\n",
        "# from datasets import load_from_disk\n",
        "# dataset = load_from_disk(passages_path)  # to reload the dataset\n",
        "# print_dataset(dataset)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 103,
      "id": "9c9f8d3d-6b58-4794-8162-2fdeb727232d",
      "metadata": {
        "id": "9c9f8d3d-6b58-4794-8162-2fdeb727232d",
        "outputId": "c9e45bc8-97a7-405c-ab6c-eb90e5963a98",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 49,
          "referenced_widgets": [
            "3783173ac48144ddbd14187af174dad5",
            "7a0aa9590f6d47109c5a125f13696c9e",
            "0f2cc680cc764d648a5ee25a06e94ee8",
            "a4e5413db12f4b31b373829680ee5072",
            "f8f3a7a9c236442c96a8d4f61efb4f9f",
            "0b4eafdcded44e579596e97b5c8569fd",
            "69e72020ba42419e878a2f6feb193a69",
            "71f32b135ac746779fdc512dcc9396d7",
            "90b1259a390d48dab3a4e6859bd31cf6",
            "5fa91cf42e684c21a77df765bb8be1bf",
            "754e18889f08400ea6c1bfcd7f8a9bd5"
          ]
        }
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "  0%|          | 0/1 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "3783173ac48144ddbd14187af174dad5"
            }
          },
          "metadata": {}
        }
      ],
      "source": [
        "######################################\n",
        "logger.info(\"Step 2 - Index the dataset\")\n",
        "######################################\n",
        "\n",
        "# Let's use the Faiss implementation of HNSW for fast approximate nearest neighbor search\n",
        "index = faiss.IndexHNSWFlat(index_hnsw_args.d, index_hnsw_args.m, faiss.METRIC_INNER_PRODUCT)\n",
        "dataset.add_faiss_index(\"embeddings\", custom_index=index)\n",
        "\n",
        "# And save the index\n",
        "faiss_index_name = \"wiki_index.faiss\"\n",
        "index_path = os.path.join(rag_args.output_dir, faiss_index_name)\n",
        "dataset.get_index(\"embeddings\").save(index_path)\n",
        "# dataset.load_faiss_index(\"embeddings\", index_path)  # to reload the index"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "a3e304fc-c311-4d28-b0da-a764f6bec26d",
      "metadata": {
        "id": "a3e304fc-c311-4d28-b0da-a764f6bec26d",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 253,
          "referenced_widgets": [
            "1fcc5253576d4a83aa64463f01304dde",
            "68ba3b6d444742cc899a5a2ff07aedd2",
            "2c595ac389e947a6a4f3754d5babfba2",
            "ecd8f06a4ed54c42afde7ed0d77da2fa",
            "243b258f0b0f41f7bce55530be576401",
            "1236e9fb43f8493b89b81cb89bb4bd11",
            "743be657b0684f7ca993133fc4cf200b",
            "607eea92e5284a9f96955a2a3063236d",
            "52a42ec0ab0145f0b584e25fd0ad84c4",
            "b063f920aef44bfe9faa1011a96bb7e1",
            "af1c65ded00248fc88325fe78aec5900"
          ]
        },
        "outputId": "b89082c1-b50f-4eb1-a613-b3e443979c6a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "The tokenizer class you load from this checkpoint is not the same type as the class this function is called from. It may result in unexpected tokenization. \n",
            "The tokenizer class you load from this checkpoint is 'RagTokenizer'. \n",
            "The class this function is called from is 'DPRQuestionEncoderTokenizer'.\n",
            "The tokenizer class you load from this checkpoint is not the same type as the class this function is called from. It may result in unexpected tokenization. \n",
            "The tokenizer class you load from this checkpoint is 'RagTokenizer'. \n",
            "The class this function is called from is 'DPRQuestionEncoderTokenizerFast'.\n",
            "The tokenizer class you load from this checkpoint is not the same type as the class this function is called from. It may result in unexpected tokenization. \n",
            "The tokenizer class you load from this checkpoint is 'RagTokenizer'. \n",
            "The class this function is called from is 'BartTokenizer'.\n",
            "The tokenizer class you load from this checkpoint is not the same type as the class this function is called from. It may result in unexpected tokenization. \n",
            "The tokenizer class you load from this checkpoint is 'RagTokenizer'. \n",
            "The class this function is called from is 'BartTokenizerFast'.\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Downloading pytorch_model.bin:   0%|          | 0.00/2.06G [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "1fcc5253576d4a83aa64463f01304dde"
            }
          },
          "metadata": {}
        }
      ],
      "source": [
        "######################################\n",
        "logger.info(\"Step 3 - Load RAG\")\n",
        "######################################\n",
        "\n",
        "# Easy way to load the model\n",
        "retriever = RagRetriever.from_pretrained(\n",
        "    rag_args.rag_model_name, index_name=\"custom\", indexed_dataset=dataset\n",
        ")\n",
        "model = RagSequenceForGeneration.from_pretrained(rag_args.rag_model_name, retriever=retriever)\n",
        "tokenizer = RagTokenizer.from_pretrained(rag_args.rag_model_name)\n",
        "\n",
        "# For distributed fine-tuning you'll need to provide the paths instead, as the dataset and the index are loaded separately.\n",
        "# retriever = RagRetriever.from_pretrained(rag_model_name, index_name=\"custom\", passages_path=passages_path, index_path=index_path)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "######################################\n",
        "logger.info(\"Step 4 - Have fun\")\n",
        "######################################\n",
        "\n",
        "question = rag_example_args.question or \"what is BRCA1 ?\"\n",
        "input_ids = tokenizer.question_encoder(question, return_tensors=\"pt\")[\"input_ids\"]\n",
        "generated = model.generate(input_ids)\n",
        "generated_string = tokenizer.batch_decode(generated, skip_special_tokens=True)[0]\n",
        "logger.info(\"Q: \" + question)\n",
        "logger.info(\"A: \" + generated_string)"
      ],
      "metadata": {
        "id": "6kIVz0GrNypa"
      },
      "id": "6kIVz0GrNypa",
      "execution_count": null,
      "outputs": []
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3 (ipykernel)",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.11.4"
    },
    "colab": {
      "provenance": [],
      "include_colab_link": true
    },
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "a9ef973b19b14ef9bcb1ba2625521986": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_d88757a6201e49cb9c5d82d1c7f64efe",
              "IPY_MODEL_f28ff87a34c44302b367a9315956ccbf",
              "IPY_MODEL_0f1f370f83124da497ba999d02b360a4"
            ],
            "layout": "IPY_MODEL_c9c605908284408990ef925af0ce5618"
          }
        },
        "d88757a6201e49cb9c5d82d1c7f64efe": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_eabea82257334e8aba1d8f78fd3f7fb7",
            "placeholder": "​",
            "style": "IPY_MODEL_f4bb97a5117d4b5fa52e440adb0a5850",
            "value": "Downloading data files: 100%"
          }
        },
        "f28ff87a34c44302b367a9315956ccbf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_dd54c9529745445e87257376b53ce28a",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_844832f28c344024935db12c360faa2c",
            "value": 1
          }
        },
        "0f1f370f83124da497ba999d02b360a4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f83d1793799d4515a581d2c33a883e38",
            "placeholder": "​",
            "style": "IPY_MODEL_259a00a7d6f5446c8fb14270df8499d9",
            "value": " 1/1 [00:00&lt;00:00, 40.28it/s]"
          }
        },
        "c9c605908284408990ef925af0ce5618": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "eabea82257334e8aba1d8f78fd3f7fb7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f4bb97a5117d4b5fa52e440adb0a5850": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "dd54c9529745445e87257376b53ce28a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "844832f28c344024935db12c360faa2c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "f83d1793799d4515a581d2c33a883e38": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "259a00a7d6f5446c8fb14270df8499d9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e4b09e45b2b944f58c8c9cdf53959bc2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_916e059b806e4f589e5790111938444b",
              "IPY_MODEL_e6a49d5c153e45dea4dbd86a47065555",
              "IPY_MODEL_4d3d85dfb53b41e8b8076b7f367807ec"
            ],
            "layout": "IPY_MODEL_dd2f9669a1a44ce483f7cfadcbd91ea2"
          }
        },
        "916e059b806e4f589e5790111938444b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3c5b3026e46f4a96851df21e23403308",
            "placeholder": "​",
            "style": "IPY_MODEL_709272c31bbe449582b7967374855ef6",
            "value": "Extracting data files: 100%"
          }
        },
        "e6a49d5c153e45dea4dbd86a47065555": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f3618e70d7104fb7a2a45e3d264859ce",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_ac15b5d471e443b5a7212b193048de4d",
            "value": 1
          }
        },
        "4d3d85dfb53b41e8b8076b7f367807ec": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_de040f2e881c4c92b81245fdebfb117f",
            "placeholder": "​",
            "style": "IPY_MODEL_6234daf3ca07401ebcde190bf30c63a5",
            "value": " 1/1 [00:00&lt;00:00,  3.10it/s]"
          }
        },
        "dd2f9669a1a44ce483f7cfadcbd91ea2": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3c5b3026e46f4a96851df21e23403308": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "709272c31bbe449582b7967374855ef6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f3618e70d7104fb7a2a45e3d264859ce": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "ac15b5d471e443b5a7212b193048de4d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "de040f2e881c4c92b81245fdebfb117f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6234daf3ca07401ebcde190bf30c63a5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "1ff0ebcf1374432399baf9896d568854": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_9bf2b258703e4e0cbe94d1cc5ccbf9aa",
              "IPY_MODEL_33c3fe2bcd0a41a7a8ea7b76242a80a8",
              "IPY_MODEL_17fed26d8e2e4411a7227d360bafe4f4"
            ],
            "layout": "IPY_MODEL_07369acb7a6a49dea5e1b264e60044db"
          }
        },
        "9bf2b258703e4e0cbe94d1cc5ccbf9aa": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b546febccf644a9d9bcba4e10a063f4e",
            "placeholder": "​",
            "style": "IPY_MODEL_383d6f1ad3384f00b963474fd1869b41",
            "value": "Generating train split: "
          }
        },
        "33c3fe2bcd0a41a7a8ea7b76242a80a8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_2f1e1d54ec9246de806b06ea965df07d",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_6b57eaa5b5f641a287f9cfa718d18815",
            "value": 1
          }
        },
        "17fed26d8e2e4411a7227d360bafe4f4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f8e6d2bfa54b48cdad2a24aab7b6008e",
            "placeholder": "​",
            "style": "IPY_MODEL_8ac15f98f3a0411aab0f014fb457a573",
            "value": " 15/0 [00:00&lt;00:00, 249.78 examples/s]"
          }
        },
        "07369acb7a6a49dea5e1b264e60044db": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b546febccf644a9d9bcba4e10a063f4e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "383d6f1ad3384f00b963474fd1869b41": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "2f1e1d54ec9246de806b06ea965df07d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "6b57eaa5b5f641a287f9cfa718d18815": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "f8e6d2bfa54b48cdad2a24aab7b6008e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8ac15f98f3a0411aab0f014fb457a573": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "d553c44ca4dc49669f86d7bca7eca5da": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_eda69d38b4fa4829b8208428c1248e4f",
              "IPY_MODEL_0fa67030428d4451a1940dbfe78a306a",
              "IPY_MODEL_3d5c8589374848acb0334f9a714aa8b3"
            ],
            "layout": "IPY_MODEL_f1a0538ce4944802b91df81adc08948c"
          }
        },
        "eda69d38b4fa4829b8208428c1248e4f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f23cff647572461b922747c852d94859",
            "placeholder": "​",
            "style": "IPY_MODEL_8b97c6fe3f1c461185ab5d847e9a5cc0",
            "value": "Map: 100%"
          }
        },
        "0fa67030428d4451a1940dbfe78a306a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_ccfb45edecd44efdac42748efd96196e",
            "max": 15,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_43fb15847ae845aeadce0d22ce5ee28c",
            "value": 15
          }
        },
        "3d5c8589374848acb0334f9a714aa8b3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_095f596857874d06a4249be6240cfaa6",
            "placeholder": "​",
            "style": "IPY_MODEL_644b898858824b88bfae10753486fcac",
            "value": " 15/15 [00:00&lt;00:00, 311.68 examples/s]"
          }
        },
        "f1a0538ce4944802b91df81adc08948c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f23cff647572461b922747c852d94859": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8b97c6fe3f1c461185ab5d847e9a5cc0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "ccfb45edecd44efdac42748efd96196e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "43fb15847ae845aeadce0d22ce5ee28c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "095f596857874d06a4249be6240cfaa6": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "644b898858824b88bfae10753486fcac": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "450652541b5f4097a637562fecd20bcf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_5b65666c89354117922abccb13b3e8a2",
              "IPY_MODEL_74538a43a24743e5b65f5518dbfe9687",
              "IPY_MODEL_2adf5ea0150b4987a14a7c7b4bffc076"
            ],
            "layout": "IPY_MODEL_637c6f020ee84650a07dcfeb878e0fc7"
          }
        },
        "5b65666c89354117922abccb13b3e8a2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d76c0a7a1a8e47edb570ea0275c35d41",
            "placeholder": "​",
            "style": "IPY_MODEL_d88a7b93ffbe4fbba06d619b5cc78992",
            "value": "Map: 100%"
          }
        },
        "74538a43a24743e5b65f5518dbfe9687": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_e3aa6b1a4a714a139270b5e351783ede",
            "max": 294,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_6ca55c3528264adf91b548d23f4c651d",
            "value": 294
          }
        },
        "2adf5ea0150b4987a14a7c7b4bffc076": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_286ef0b8466c41a696d959212006ab8c",
            "placeholder": "​",
            "style": "IPY_MODEL_e95d14fbf2fe4fc5b57f858abae8e7cf",
            "value": " 294/294 [03:29&lt;00:00,  2.42 examples/s]"
          }
        },
        "637c6f020ee84650a07dcfeb878e0fc7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d76c0a7a1a8e47edb570ea0275c35d41": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d88a7b93ffbe4fbba06d619b5cc78992": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e3aa6b1a4a714a139270b5e351783ede": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6ca55c3528264adf91b548d23f4c651d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "286ef0b8466c41a696d959212006ab8c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e95d14fbf2fe4fc5b57f858abae8e7cf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "8efb25ea71a64177a3251845e7f61875": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_ac00903f4c0c4fd1883295a2494df9e7",
              "IPY_MODEL_5dd6390508894c368749fa0709ea3d24",
              "IPY_MODEL_b8ac99e3f8b44079b313b1f748e9b21d"
            ],
            "layout": "IPY_MODEL_eefc76cbb10445cdb970dc0615b7a0a8"
          }
        },
        "ac00903f4c0c4fd1883295a2494df9e7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_40ff7806ec454193aa5b2b28a2990115",
            "placeholder": "​",
            "style": "IPY_MODEL_b345565cc109428cbb15dd7e1f2ef97d",
            "value": "Saving the dataset (1/1 shards): 100%"
          }
        },
        "5dd6390508894c368749fa0709ea3d24": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7d83d91a1728481bb2d1469407848374",
            "max": 294,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_2be99a51abd8474d870647100000f960",
            "value": 294
          }
        },
        "b8ac99e3f8b44079b313b1f748e9b21d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_61bc1df5c13a4f02b2147f40ec89ce4a",
            "placeholder": "​",
            "style": "IPY_MODEL_9c06004501de43f78c119aabe46325f0",
            "value": " 294/294 [00:00&lt;00:00, 5304.34 examples/s]"
          }
        },
        "eefc76cbb10445cdb970dc0615b7a0a8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "40ff7806ec454193aa5b2b28a2990115": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b345565cc109428cbb15dd7e1f2ef97d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "7d83d91a1728481bb2d1469407848374": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "2be99a51abd8474d870647100000f960": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "61bc1df5c13a4f02b2147f40ec89ce4a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9c06004501de43f78c119aabe46325f0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "3783173ac48144ddbd14187af174dad5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_7a0aa9590f6d47109c5a125f13696c9e",
              "IPY_MODEL_0f2cc680cc764d648a5ee25a06e94ee8",
              "IPY_MODEL_a4e5413db12f4b31b373829680ee5072"
            ],
            "layout": "IPY_MODEL_f8f3a7a9c236442c96a8d4f61efb4f9f"
          }
        },
        "7a0aa9590f6d47109c5a125f13696c9e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0b4eafdcded44e579596e97b5c8569fd",
            "placeholder": "​",
            "style": "IPY_MODEL_69e72020ba42419e878a2f6feb193a69",
            "value": "100%"
          }
        },
        "0f2cc680cc764d648a5ee25a06e94ee8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_71f32b135ac746779fdc512dcc9396d7",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_90b1259a390d48dab3a4e6859bd31cf6",
            "value": 1
          }
        },
        "a4e5413db12f4b31b373829680ee5072": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5fa91cf42e684c21a77df765bb8be1bf",
            "placeholder": "​",
            "style": "IPY_MODEL_754e18889f08400ea6c1bfcd7f8a9bd5",
            "value": " 1/1 [00:00&lt;00:00,  7.08it/s]"
          }
        },
        "f8f3a7a9c236442c96a8d4f61efb4f9f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0b4eafdcded44e579596e97b5c8569fd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "69e72020ba42419e878a2f6feb193a69": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "71f32b135ac746779fdc512dcc9396d7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "90b1259a390d48dab3a4e6859bd31cf6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "5fa91cf42e684c21a77df765bb8be1bf": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "754e18889f08400ea6c1bfcd7f8a9bd5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "1fcc5253576d4a83aa64463f01304dde": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_68ba3b6d444742cc899a5a2ff07aedd2",
              "IPY_MODEL_2c595ac389e947a6a4f3754d5babfba2",
              "IPY_MODEL_ecd8f06a4ed54c42afde7ed0d77da2fa"
            ],
            "layout": "IPY_MODEL_243b258f0b0f41f7bce55530be576401"
          }
        },
        "68ba3b6d444742cc899a5a2ff07aedd2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_1236e9fb43f8493b89b81cb89bb4bd11",
            "placeholder": "​",
            "style": "IPY_MODEL_743be657b0684f7ca993133fc4cf200b",
            "value": "Downloading pytorch_model.bin:  50%"
          }
        },
        "2c595ac389e947a6a4f3754d5babfba2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_607eea92e5284a9f96955a2a3063236d",
            "max": 2063600078,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_52a42ec0ab0145f0b584e25fd0ad84c4",
            "value": 1048576000
          }
        },
        "ecd8f06a4ed54c42afde7ed0d77da2fa": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b063f920aef44bfe9faa1011a96bb7e1",
            "placeholder": "​",
            "style": "IPY_MODEL_af1c65ded00248fc88325fe78aec5900",
            "value": " 1.04G/2.06G [00:28&lt;00:30, 33.1MB/s]"
          }
        },
        "243b258f0b0f41f7bce55530be576401": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1236e9fb43f8493b89b81cb89bb4bd11": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "743be657b0684f7ca993133fc4cf200b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "607eea92e5284a9f96955a2a3063236d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "52a42ec0ab0145f0b584e25fd0ad84c4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "b063f920aef44bfe9faa1011a96bb7e1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "af1c65ded00248fc88325fe78aec5900": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}